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Abstract
Start2quit: a randomised clinical controlled trial to evaluate
the effectiveness and cost-effectiveness of using personal
tailored risk information and taster sessions to increase the
uptake of the NHS Stop Smoking Services
Hazel Gilbert,1* Stephen Sutton,2 Richard Morris,1 Irene Petersen,1
Qi Wu,3 Steve Parrott,3 Simon Galton,4 Dimitra Kale,1
Molly Sweeney Magee,1 Leanne Gardner1 and Irwin Nazareth1
1Research Department of Primary Care and Population Health, University College London,
London, UK
2Institute of Public Health, University of Cambridge, Cambridge, UK
3Department of Health Sciences, University of York, York, UK
4Smokefree Camden (Public Health), NHS Camden, London, UK
*Corresponding author hazel.gilbert@ucl.ac.uk
Background: The NHS Stop Smoking Services (SSSs) offer help to smokers who want to quit. However,
the proportion of smokers attending the SSSs is low and current figures show a continuing downward
trend. This research addressed the problem of how to motivate more smokers to accept help to quit.
Objectives: To assess the relative effectiveness, and cost-effectiveness, of an intervention consisting of
proactive recruitment by a brief computer-tailored personal risk letter and an invitation to a ‘Come
and Try it’ taster session to provide information about the SSSs, compared with a standard generic letter
advertising the service, in terms of attendance at the SSSs of at least one session and validated 7-day point
prevalent abstinence at the 6-month follow-up.
Design: Randomised controlled trial of a complex intervention with follow-up 6 months after the date
of randomisation.
Setting: SSSs and general practices in England.
Participants: All smokers aged ≥ 16 years identified from medical records in participating practices who
were motivated to quit and who had not attended the SSS in the previous 12 months. Participants were
randomised in the ratio 3 : 2 (intervention to control) by a computer program.
Interventions: Intervention – brief personalised and tailored letter sent from the general practitioner using
information obtained from the screening questionnaire and from medical records, and an invitation to
attend a taster session, run by the local SSS. Control – standard generic letter from the general practice
advertising the local SSS and the therapies available, and asking the smoker to contact the service to make
an appointment.
Main outcome measures: (1) Proportion of people attending the first session of a 6-week course over a
period of 6 months from the receipt of the invitation letter, measured by records of attendance at the
SSSs; (2) 7-day point prevalent abstinence at the 6-month follow-up, validated by salivary cotinine analysis;
and (3) cost-effectiveness of the intervention.
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Results: Eighteen SSSs and 99 practices within the SSS areas participated; 4384 participants were
randomised to the intervention (n = 2636) or control (n = 1748). One participant withdrew and 4383 were
analysed. The proportion of people attending the first session of a SSS course was significantly higher in
the intervention group than in the control group [17.4% vs. 9.0%; unadjusted odds ratio (OR) 2.12, 95%
confidence interval (CI) 1.75 to 2.57; p < 0.001]. The validated 7-day point prevalent abstinence at the
6-month follow-up was significantly higher in the intervention group than in the control group (9.0% vs.
5.6%; unadjusted OR 1.68, 95% CI 1.32 to 2.15; p < 0.001), as was the validated 3-month prolonged
abstinence and all other periods of abstinence measured by self-report. Using the National Institute for
Health and Care Excellence decision-making threshold range of £20,000–30,000 per quality-adjusted
life-year gained, the probability that the intervention was more cost-effective than the control was up to
27% at 6 months and > 86% over a lifetime horizon.
Limitations: Participating SSSs may not be representative of all SSSs in England. Recruitment was low,
at 4%.
Conclusions: The Start2quit trial added to evidence that a proactive approach with an intensive
intervention to deliver personalised risk information and offer a no-commitment introductory session
can be successful in reaching more smokers and increasing the uptake of the SSS and quit rates. The
intervention appears less likely to be cost-effective in the short term, but is highly likely to be cost-effective
over a lifetime horizon.
Future work: Further research could assess the separate effects of these components.
Trial registration: Current Controlled Trials ISRCTN76561916.
Funding details: This project was funded by the National Institute for Health Research (NIHR) Health
Technology Assessment programme and will be published in full in Health Technology Assessment;
Vol. 21, No. 3. See the NIHR Journals Library website for further project information.
ABSTRACT
NIHR Journals Library www.journalslibrary.nihr.ac.uk
vi
Contents
List of tables xi
List of figures xiii
List of abbreviations xv
Plain English summary xvii
Scientific summary xix
Chapter 1 Introduction 1
The problem 1
Rationale for intervention 2
Mass mailing and proactive strategy 2
Individual computer-tailoring and risk information 3
Opportunity to experience a support service without commitment 4
Aims and objectives 4
Principal research question 4
Primary objective 4
Secondary objectives 5
Chapter 2 Methods 7
Study design and setting 7
Trial management and conduct 7
Participants 7
Target population 7
Inclusion/exclusion criteria 7
Recruitment procedure 8
Stop Smoking Service and practice recruitment 8
Participant recruitment 8
Interventions 8
Control group 8
Intervention group 8
Development of the tailored intervention letter 9
Development of the taster session and training 9
Procedure and baseline data management 11
Procedure 11
Security and baseline data management 12
Randomisation and blinding 12
Follow-up data collection and evaluation procedure 14
Measures 15
Baseline measures 15
Outcome measures 15
Sample size and power calculations 16
Interim analyses and stopping guidelines 17
DOI: 10.3310/hta21030 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 3
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Gilbert et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
vii
Statistical methods 17
Levels of significance 18
Subgroup analyses 18
Subsidiary analyses 18
Patient and public involvement 19
Chapter 3 Results 21
Recruitment and participant flow 21
Practice recruitment 21
Participant recruitment 21
Follow-up 24
Biochemical validation of 7-day abstinence 26
Characteristics of participants 26
Baseline 26
Characteristics associated with study attrition 31
External validity 31
Outcomes 31
Primary outcome 31
Secondary outcomes 31
Subgroup analyses 35
Subgroups 35
Effect of repeat reminders 35
Seasonal variation 35
Variation in outcome by Stop Smoking Service 35
Chapter 4 Process evaluation and subsidiary analysis 41
Conduct of and adherence to the intervention, association with outcomes and
self-reported attendance 41
Background 41
Methods 42
Results 43
Summary 45
Perception of the intervention 46
Background 46
Methods 46
Results 48
Summary 52
Assessment of the fidelity of the delivery of the taster sessions 52
Background 52
Method 53
Results 57
Discussion 60
An exploration of the reasons for non-attendance and barriers to attendance at the Stop
Smoking Service 62
Background 62
Method 62
Results 63
Discussion 65
CONTENTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
viii
Chapter 5 Health economics 69
Introduction 69
Methods 69
Assessment of costs 69
Measurement of resource use 69
Unit costs for resource use 71
Health outcome measures 71
Cost-effectiveness analysis 73
Uncertainty assessment 73
Handling missing data 74
Sensitivity analysis 74
Long-term costs and outcomes predictions 74
Results 74
Costs 74
Outcomes: utility and quality-adjusted life-years 76
Cost-effectiveness analysis and uncertainty 77
Sensitivity analysis (complete-case analysis) 79
Sensitivity analysis (intervention components) 83
Long-term costs and outcomes predictions 84
Summary/conclusion 87
Chapter 6 Discussion 89
Main outcome and effectiveness 89
Recruitment, retention and generalisability of the trial findings 89
Interpretation, acceptance and feasibility 90
Cost-effectiveness 94
Strengths and limitations 94
Chapter 7 Conclusions 97
Main conclusion 97
Recommendations for research 97
Implications for health care 98
Intellectual property and adoption of positive elements of the approach in the NHS 98
Acknowledgements 99
References 101
Appendix 1 Changes to protocol 111
Appendix 2 Pilot assessment report 115
Appendix 3 Recruitment materials 127
Appendix 4 Questionnaires and data collection forms 135
Appendix 5 Intervention materials 177
Appendix 6 Taster session training manual and protocol 185
DOI: 10.3310/hta21030 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 3
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Gilbert et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
ix

List of tables
TABLE 1 Letter structure 10
TABLE 2 Participating SSSs 23
TABLE 3 Response within SSS 26
TABLE 4 Participant characteristics at baseline 27
TABLE 5 Participant characteristics associated with study attrition 32
TABLE 6 Comparison of demographic characteristics of participants and
non-participants 33
TABLE 7 Attendance at SSS and various abstinence rates recorded at 6 months
after randomisation 34
TABLE 8 Self-reported changes in daily cigarette consumption, quit attempts,
and changes in motivation and intention to quit in continuing smokers 35
TABLE 9 Interactions in outcomes 6 months after date of randomisation 36
TABLE 10 Attendance at the SSS by season of recruitment 38
TABLE 11 Number of participants completing the follow-up questionnaire 42
TABLE 12 Self-reported attendance in participants completing the 6-month
follow-up 45
TABLE 13 Agreement and disagreement between self-reported and validated
attendance at a taster session in participants who completed the 6-month
follow-up and remembered receiving an invitation to the taster session
(intervention group only, n= 1387) 45
TABLE 14 Agreement and disagreement between self-reported and validated
attendance at the SSS in participants completing the 6-month follow-up in
intervention and control groups 45
TABLE 15 Perceptions of the personal risk letter by treatment group 48
TABLE 16 Perception of the taster session (number answering very or extremely
on a scale of 1 to 5) 49
TABLE 17 Decision to attend the SSS and decisions to quit by treatment group 51
TABLE 18 Protocol-specified behaviours classified into BCTs 54
TABLE 19 Characteristics of lead advisors in analysed taster sessions (n= 41) 58
TABLE 20 Demographic and smoking characteristics of respondents 64
DOI: 10.3310/hta21030 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 3
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Gilbert et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
xi
TABLE 21 Treatment Barriers Questionnaire: scales, items and factor loadings 66
TABLE 22 Correlations among TBQ scales interscale correlations 67
TABLE 23 Cost components of the trial interventions 70
TABLE 24 Unit costs (and sources) employed to estimate total costs (in 2012–13
prices) 72
TABLE 25 Intervention costs by allocated treatment (prices in £ in 2012–13) 75
TABLE 26 Average cost by category and treatment allocation (prices in £ in
2012–13) 75
TABLE 27 EQ-5D scores and QALYs by treatment and by time 76
TABLE 28 Cost per additional attendee to the SSS (multiple imputation analysis) 77
TABLE 29 Cost per additional quitter (multiple imputation analysis) 77
TABLE 30 Cost per additional QALY (multiple imputation analysis) 78
TABLE 31 Average cost by category and treatment allocation (complete-case
analysis) 80
TABLE 32 Cost per additional attendee to the SSS (complete-case analysis) 80
TABLE 33 Cost per additional quitter (complete-case analysis) 81
TABLE 34 Cost per additional QALY (complete-case analysis) 81
TABLE 35 Summary of cost-effectiveness results from the multiple imputation
analysis vs. complete-case analysis 82
TABLE 36 Breakdown of the intervention components 83
TABLE 37 Cumulative lifetime QALY gains by gender and age group 84
TABLE 38 Discounted cumulative lifetime QALY gains by gender and age group 85
TABLE 39 Lifetime health-care costs due to myocardial infarction, stroke, lung
cancer, COPD and other causes of death 85
TABLE 40 Long-term cost-effectiveness results 86
TABLE 41 Recruitment of participants 122
TABLE 42 Differences in attendance at SSSs between the intervention and
control groups 124
LIST OF TABLES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
xii
List of figures
FIGURE 1 Study schedule showing the duration and timing of the procedure,
intervention and follow-up 13
FIGURE 2 Map showing level of socioeconomic deprivation in England and SSSs
participating in Start2quit 22
FIGURE 3 Percentage of practices (%) within each IMD quintile 23
FIGURE 4 The IMD scores of practices compared with the mean IMD scores of all
smokers living in the practice catchment area 24
FIGURE 5 The IMD scores of practices and the proportion of smokers identified
in the practice 24
FIGURE 6 The CONSORT diagram of recruitment and flow of participants
through the trial 25
FIGURE 7 Percentage male participants and non-participants by SSS area 33
FIGURE 8 The IMD scores of participants and non-participants by SSS area 33
FIGURE 9 Time from randomisation to attendance at the SSS in the (a) intervention
group (n= 445) and (b) the control group n= 147 37
FIGURE 10 Percentage of participants attending SSSs by treatment group and by SSS 38
FIGURE 11 Percentage of all participants with validated 7-day abstinence by
treatment group and by SSS 39
FIGURE 12 Flow chart showing numbers attending a taster session, the SSS and
achieving a validated 7-day point prevalent abstinence in the intervention and
the control groups 44
FIGURE 13 Percentage adherence to manual-specified content in each analysed
taster session 59
FIGURE 14 Median fidelity to BCTs across sessions 61
FIGURE 15 Cost difference between two intervention groups 76
FIGURE 16 Cost-effectiveness plane (multiple imputation analysis) 79
FIGURE 17 Cost-effectiveness acceptability curve (multiple imputation analysis) 79
FIGURE 18 Cost-effectiveness plane (complete-case analysis) 82
FIGURE 19 Cost-effectiveness acceptability curve (complete-case analysis) 83
FIGURE 20 Lifetime CEAC (before discounting) 86
DOI: 10.3310/hta21030 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 3
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Gilbert et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
xiii
FIGURE 21 Lifetime CEAC (discounted) 87
FIGURE 22 Flow diagram of the progress of the pilot phase of the Start2quit trial 121
FIGURE 23 Response rates for practices in the pilot phase 123
FIGURE 24 Taster session attendance rates 123
FIGURE 25 Actual recruitment vs. target recruitment for Start2quit 125
FIGURE 26 Timetable for Start2quit 126
LIST OF FIGURES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
xiv
List of abbreviations
BCT behaviour change technique
CEA cost-effectiveness analysis
CEAC cost-effectiveness acceptability
curve
CEP cost-effectiveness plane
CI confidence interval
CO carbon monoxide
CONSORT Consolidated Standards of
Reporting Trials
COPD chronic obstructive pulmonary
disease
EQ-5D European Quality of Life-5
Dimensions
GP general practitioner
HTA Health Technology Assessment
ICC intracluster correlation coefficient
ICER incremental cost-effectiveness ratio
IMD Index of Multiple Deprivation
NICE National Institute for Health and
Care Excellence
NRT nicotine replacement therapy
OR odds ratio
PCA principal components analysis
PCRN Primary Care Research Network
QALY quality-adjusted life-year
QOF Quality and Outcomes Framework
SD standard deviation
SSS Stop Smoking Service
TBQ Treatment Barriers Questionnaire
UCL University College London
DOI: 10.3310/hta21030 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 3
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Gilbert et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
xv

Plain English summary
The NHS Stop Smoking Services (SSSs) offer help to stop smoking, but < 5% of smokers use theseservices, and recently there has been a large decrease in uptake. We developed an intervention to
persuade more smokers to get help to try to quit. We wrote to them directly with a letter about their
personal health risks and invited them to a ‘Come and Try it’ taster session to find out more about the
SSS. At the end of a 6-month period we compared the number of people who had attended the SSS after
receiving this letter and invitation with the number of people who attended after receiving a standard
letter advertising the service. We also measured the number of people in each group who had quit.
Eighteen SSSs and 99 practices within the SSS areas took part in the trial. We identified smokers from records
in participating practices and wrote to them inviting them to take part in the research; 4384 smokers agreed
and were randomised to the intervention group (n = 2636) or to the control group (n = 1748).
More people who received the personal letter and invitation attended at least one session of a 6-week SSS
course than people who received the standard letter (17.4% vs. 9.0%). At 6 months more people had quit
(stopped smoking for at least 7 days) in the intervention group than in the control group (9.0% vs. 5.6%).
Although the intervention is not likely to be cost-effective in the short term, it is likely to be over a
lifetime horizon.
This programme of recruitment offers an alternative method for promoting the service and could be used
to raise awareness of the SSS.
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Scientific summary
Background
Smoking is the leading cause of ill health and mortality, and remains a major public health problem.
Government-funded specialist smoking cessation services, now known as the NHS Stop Smoking Services
(SSSs), were established by Primary Care Trusts throughout England in 2000. However, the proportion of
smokers in England using the SSSs in 2011 was only 4.1%. Furthermore, figures since 2012 show a
continuing downward trend in the number of smokers attending the SSS; thus, these clinical interventions,
provided free of charge by the NHS, reach only a small proportion of the total population of smokers in
England. This research addressed the problem of how to persuade and motivate more smokers to seek,
or accept, help to quit.
Objectives
The primary objective of the study was to assess the relative effectiveness and cost-effectiveness of a
complex intervention, consisting of proactive recruitment by a brief computer-tailored personal risk letter
and an invitation to a ‘Come and Try it’ taster session to provide information about the SSSs compared
with a standard generic letter advertising the service, on attendance at the SSSs of at least one session.
Secondary objectives aimed to (1) assess the relative effectiveness of the intervention on biochemically validated
7-day point prevalent abstinence rates at the 6-month follow-up; (2) compare the cost-effectiveness of the
intervention; (3) assess the relative effectiveness on additional periods of abstinence measured by self-report of
not smoking for periods of 24 hours to 3 months at the 6-month follow-up; (4) assess the number of smokers
attending the taster session and the number of smokers completing the 6-week NHS smoking cessation course;
(5) assess the number of quit attempts made and any reduction in daily cigarette consumption; (6) explore
the effectiveness of the intervention by socioeconomic status and social deprivation; (7) explore reasons for
non-attendance and barriers to attendance at the SSS; and (8) determine predictors of attendance at the
services and the taster sessions (in the intervention group).
Methods
The Start2quit study was a pragmatic, randomised controlled trial of a complex intervention, utilising
general practices in England to recruit smokers into the trial. Recruitment, collection of baseline data and
delivery of the intervention took place over 4 years, between January 2011 and December 2014.
Current smokers aged ≥ 16 years, able to read English, motivated to quit and who had not attended the
SSS in the previous 12 months were eligible for inclusion in the study. For the purposes of this research,
motivation to quit was defined as answering ‘yes’ to either or both of the following questions:
1. Are you seriously thinking of quitting in the next 6 months?
2. Would you think of quitting if appropriate help was offered at a convenient time and place?
The National Institute for Health Research Primary Care Research Network recruited SSSs, and also
identified and recruited practices in the selected SSS areas. All smokers aged ≥ 16 years were identified
from medical records in participating practices and were sent an invitation from their general practitioner
(GP) to participate, together with a participant information sheet, a consent form and a screening
questionnaire. The questionnaire assessed demographics, self-reported health, nicotine dependence,
DOI: 10.3310/hta21030 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 3
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Gilbert et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
xix
smoking history, determination and confidence to quit. Participants were asked to consent to the use of
information from their medical records and given in the screening questionnaire to send them information
about quitting, and for the researchers to access relevant data from their attendance at the SSSs. Non-
responders were sent a reminder and duplicate questionnaire after 3 weeks. All smokers returning the
questionnaire and signed consent form, and who were eligible to participate, were randomised to the
intervention group or the control group. Patients had the opportunity to decline to participate but to
return the questionnaire with basic information to update their smoking status in their medical records.
Interventions
Participants allocated to the control group were sent a standard generic letter from the GP practice
advertising the local SSS and the therapies available, and asking the smoker to contact the service to make
an appointment to see an advisor.
Participants allocated to the intervention group received:
l a brief personalised and tailored letter sent from the GP that included information specific to the
patient, using information obtained from the screening questionnaire and from their medical records
l a personal invitation and appointment to attend a ‘Come and Try it’ taster session to find out more
about the services, run by advisors from the local SSS
l a repeated personal letter with a further invitation 3 months after the original if they failed to attend a
taster session following the first letter and invitation.
The overall objectives of the letter were to communicate personal risk level if they continued to smoke,
using individualised information on the risk of serious illness, and to encourage attendance at the SSS.
The goal of the taster session was to offer information, to promote the SSS, to address any concerns or
queries smokers may have and to encourage sign-up to a course. It was not intended to replicate the first
session of a course.
Data management
The patient-level data collected comprised information downloaded from practice records and information
provided by participants on the consent form and baseline questionnaire. The information from the
practice record was used to generate letters inviting patients to participate in the trial. It was also used,
along with baseline questionnaire information, to generate the tailored letters.
Randomisation, at the level of the study participant, was embedded into the computer program using
permuted blocks. Participants were randomised in the ratio 3 : 2 (intervention to control) within practice,
stratified by gender, and using a block size of five. It was not possible to blind participants to the receipt
of a personally tailored letter and invitation to a taster session. Although the personal letter was generated
in the practice by a research assistant, the remainder of the research team, in all cases, were blind to the
allocation of the participant, which was enforced by the data management. In follow-up interviews, the
interviewer was blinded to the allocation of the respondent.
At the end of the 6-month follow-up period in each SSS, valid data of attendance were collected from the
SSSs using NHS monitoring data collected by smoking cessation advisors. In addition, a computer-assisted
telephone interview was conducted 6 months after the date of randomisation by research interviewers,
independent from the service providers, to assess self-reported SSS attendance, current smoking status and
other outcome data. Participants claiming 7-day abstinence were asked to provide a salivary cotinine
sample by post, using a saliva sample kit, to biochemically validate 7-day point prevalent smoking cessation
at a 6-month follow-up.
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Outcome measures
The primary outcome measure was the proportion of people entering the smoking cessation service
(i.e. attending the first session of a 6-week course) over a period of 6 months from the receipt of the
invitation letter, as measured by records of attendance at the SSSs.
Secondary outcome measures were:
l 7-day point prevalent abstinence at the 6-month follow-up, validated by salivary cotinine analysis
l additional periods of abstinence measured by self-report: 24-hour and 7-day point prevalent, 1- and
3-month prolonged abstinence
l validated 3-month prolonged abstinence
l self-reported changes in daily cigarette consumption, quit attempts, and changes in motivation and
intention to quit in continuing smokers
l the number completing the 6-week NHS course.
Process measures included:
l the number of smokers attending the taster session (intervention group only)
l self-reported attendance data
l perception of the personal risk letters and taster session
l reasons for non-attendance at the taster session and barriers to attendance at the NHS services.
The economic component estimated the cost of providing the interventions using primary cost data from
a NHS and Personal Social Services perspective. We also measured patients’ use of health and social
care services using comprehensive service use questionnaires. Quality-adjusted life-years (QALYs) were
calculated from the European Quality of Life-5 Dimensions questionnaire using the area-under-the-curve
method. A cost-effectiveness analysis compared the tailored letter plus the taster session with the
generic letter.
Sample and analysis
To detect an increase in SSS attendance of 4.6% [from 8.9% to 13.5%; odds ratio (OR) 1.65] at 90%
power at the 5% significance level required a sample of 1029 participants, 2058 in total. Allowing for a
therapist intracluster correlation coefficient (ICC) of 0.005 and a therapist cluster size of 103 required
inflation of our sample size by a factor of 1.51 in the intervention group to 1554 participants. Thus, we
originally aimed to recruit 2583 participants in total. An extension to the trial, funded to permit evaluation
of 7-day point prevalent abstinence at the 6-month follow-up, required an 80% increase in the sample
size, to 4500 (1793 in the control group and 2707 in the intervention group) to detect a doubling of the
quit rate from 2.2% to 4.4%, with 95% power.
A comparison of proportions was carried out for binary outcomes between the intervention and control
groups. Univariable logistic regression analysis was carried out to take into account clustering at the SSS
level and multivariable logistic regression was also carried out to take into account any imbalance in
important baseline characteristics known to predict smoking cessation outcomes, nominated prior to
examination of the trial data, between the groups.
Results
Eighteen SSSs and 99 practices within the SSS areas agreed to participate in the trial. Current cigarette
smokers aged ≥ 16 years were identified from computer records in participating practices (n = 141,488;
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14.7% of the total list size); 4384 gave consent and were eligible, a response rate of 4.1%, and were
randomised to the intervention group (n = 2636) or to the control group (n = 1748). One participant from
the intervention group withdrew from the study and 4383 were analysed.
Validated SSS attendance data were obtained for each participant from SSSs at the end of the 6-month
follow-up period. Additional data were obtained by telephone interview or postal questionnaire from
3372 (76.9%) participants. Of those claiming abstinence, 595 (94.4%) agreed to send a saliva sample for
biochemical validation of 7-day abstinence, 443 (70.3%) returned a sample and 44 had resumed smoking;
399 (63.3%) samples were sent for analysis.
The study sample was 50.9% male with a mean age of 49.3 years. A total of 50.7% were living in areas
of high deprivation, defined as Index of Multiple Deprivation (IMD) quintiles 4 and 5, and 32% of the
sample were living in a household with another smoker. One-quarter (26.5%) were highly nicotine
dependent. Although 55.1% were not planning to quit in the next 30 days, motivation and determination
to quit were relatively high (means 3.76 and 3.74, respectively, scored on a 1 to 5 scale) but confidence in
the ability to quit was lower (mean 2.71).
Anonymised data of smokers who were invited to participate in the study, but did not accept, showed that
males were under-represented in the study sample (50.9% vs. 54.3%) and participants were significantly
older than non-participants (mean age 49.31 vs. 43.29 years). The IMD score was significantly different
between participants and non-participants, but the difference (1.18) was small.
The proportion of people attending the first session of a 6-week SSS course was significantly higher in the
intervention group than in the control group [17.4% vs. 9.0%; unadjusted OR 2.12, 95% confidence
interval (CI) 1.75 to 2.57; p < 0.001]. Validated 7-day point prevalent abstinence at the 6-month follow-up
was significantly higher in the intervention group than in the control group (9.0% vs. 5.6%; unadjusted
OR 1.68, 95% CI 1.32 to 2.15; p < 0.001), as were all other periods of abstinence measured by self-report.
The number completing the 6-week SSS course was also significantly higher in the intervention group than
in the control group (14.5% vs. 7.0%; unadjusted OR 2.24, 95% CI 1.81 to 2.78; p < 0.001).
There was a slight reduction in the consumption of cigarettes per day in those continuing to smoke
(of 2.6 cigarettes), and 23.7% had made a quit attempt. Intention and motivation to quit changed little in
continuing smokers. There was no difference between the groups.
The effect of the intervention on attendance at the SSS was significantly greater for males (19% vs. 8%;
OR 2.70, 95% CI 2.04 to 3.57) than for females (15.7% vs. 10.1%; OR 1.67, 95% CI 1.28 to 2.19), and
also for validated 7-day point prevalent abstinence (males: OR 2.37, 95% CI 1.63 to 3.42; females: OR
1.23, 95% CI 0.88 to 1.72). Attendance at the SSS was lower in the control group for participants in IMD
quintiles 2–4 (medium deprivation) than for those in quintiles 1 or 5. Overall attendance varied between
SSSs from 2.1% to 23.1% (ICC 0.031, 95% CI 0.01 to 0.09) and validated 7-day abstinence from 2.1%
to 13.4% (ICC 0.034, 95% CI 0.011 to 0.096), suggesting that around 3% of participants’ tendency to
attend and to quit smoking was explained by the SSS in which they were located.
The mean intervention cost per participant was £54 [standard deviation (SD) £12] and £0.87 (SD £2) in the
intervention and control groups, respectively. Considering the wider health resource use, the estimated
total mean costs over the 6-month period were £777 (SD £2176) in the intervention group and £679
(SD £1860) in the control group. Comparing the intervention with the control group, incremental
cost-effectiveness ratios were estimated at £627 per additional attendee to the SSS, £2689 per additional
quitter and £59,401 per QALY gained after 6 months. Using the National Institute for Health and Care
Excellence decision-making threshold range of £20,000–30,000 per QALY gained, the probability that the
intervention was more cost-effective was 20–27% in the short term and > 86% in the long term.
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Conclusion
The Start2quit trial has added to the evidence that a proactive approach can be successful in reaching
more smokers and informing them of the SSSs and consequently increasing the service uptake. An
intensive intervention to deliver personalised risk information and provide a no-commitment introductory
session, designed to inform smokers about the service and what it offers, more than doubled attendance
at the SSSs. We also demonstrated that the increased attendance can translate to increased quit rates.
The acceptability of both parts of the intervention was established.
Although the costs of the personal risk information and taster sessions compared with a standard generic
letter suggest that it is less likely to be a cost-effective option in short term, the long-term results indicate
that, over a lifetime horizon, the intervention has an 86% probability of being more cost-effective than the
generic letter. Some adaptation to the method of recruitment could reduce costs without reducing the
impact and, thus, increasing the viability of the strategy as a means to increase uptake of the SSSs and
also reduce smoking prevalence.
Recommendations for research
l Further research to dismantle the components of the intervention in a factorial study to assess their
separate effects and to identify the mechanisms of action.
l Further investigation into the long-term abstinence of smokers proactively recruited compared with
those who self-refer.
l More exploration into the barriers to seeking help and to attendance at support services, and into
possible changes to the format, content and timing of the introductory sessions.
l Qualitative work to break down the components of the personal risk letter and to investigate which
type of smoker is likely to be prompted by the contents to attend.
l Experimentation with reactive and opportunistic recruitment to suggest ways in which initial
recruitment to the research could be improved.
Implications for health care
Recent data have shown a significant decrease in the number of smokers accessing SSSs in the past few
years. Efforts to reverse this trend should be a priority, as services offer smokers a significantly higher
chance of stopping smoking than trying to quit without support.
The evidence suggests that a programme of proactive recruitment can be effective in raising awareness of
the SSSs, and personal invitations, with or without additional risk information, may also offer the services
an opportunity to promote the service in the form of introductory sessions to emphasise its approachability
and empathy.
Trial registration
This trial is registered as Current Controlled Trials ISRCTN76561916.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National Institute
for Health Research.
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Chapter 1 Introduction
The problem
Smoking is the leading cause of ill health and mortality, and remains a major public health problem.
Approximately 80,000 deaths in England in 2009 were caused by smoking1 and around 5% of all hospital
admissions for those aged ≥ 35 years in 2011/12 were attributable to the habit.2 Although the prevalence
of smoking in the adult population in Great Britain has fallen by more than half since 1974, from 46% to
19% in 2013, the fall in prevalence has slowed and has changed little since 2007.2 Furthermore, the gap
in smoking prevalence between those in professional and managerial occupations and those in routine and
manual workers shows no sign of diminishing; those living in the most deprived areas are more than twice
as likely to smoke as those living in the least deprived areas.3
A key objective of every UK government over the last two decades has been to reduce the prevalence of
smoking,1,4 and various initiatives have been introduced aimed at reducing tobacco use. One of the key
strategies to help current smokers quit was to implement government-funded specialist smoking cessation
services in Health Action Zones in 1999, which were then rolled out throughout England in 2000.5
These specialist services were established by Primary Care Trusts, operating predominantly in primary care
settings, and offered intensive advice and support to smokers motivated to quit, in group or one-to-one
sessions. Early evaluations suggested that the services were effective in their aim of supporting smokers
to quit6,7 and were reaching smokers from more-deprived groups.8 Since their introduction, the services,
now known as the NHS Stop Smoking Services (SSSs), have continued to evolve. The most significant
change took place during the course of this research in April 2013, when commissioning of local SSSs
was transferred from the NHS to the local authority. The result of this was the tendering out of previously
in-house services, leading to some SSSs being run by private and voluntary sector companies.
According to the latest figures available, 61% of smokers indicated more than ‘a little’ inclination to give
up, and 26% of all smokers had made an attempt to quit in the previous year.9 This figure has changed
little over the years, but along with this evidence that the majority of smokers want to quit, there is a
large literature suggesting that, despite this desire, programmes of support are consistently underused.
The majority of smokers do not want to participate in formal cessation programmes but prefer to quit on
their own.10–13 More recent surveys and reviews have confirmed that this has changed little; although the
trend for unassisted quit attempts may be decreasing, effective treatments remain widely underused and
the majority of quit attempts are still unassisted.14–16 The proportion of smokers in England using the SSSs
is similarly low. Estimates in 2001–2 suggest that 2% of the adult smoking population in England set a
quit date using SSSs.8 In 2009, although 43% of smokers had sought some kind of advice or help to quit,
the majority of these used self-help leaflets and books, and only 15% had asked a health professional for
help. Just 8% were referred or self-referred to a stop smoking group.9 West and Brown17 report that, of all
quit attempts reported in 2011, 46.5% were unaided and only 4.1% reported using the SSS. Furthermore,
figures from the Health and Social Care Information Centre show that since 2012 the number of smokers
attending the SSS has a continuing downward trend.18 Thus, these clinical interventions, provided free of
charge by the NHS, reach relatively few self-selected smokers and only a small proportion of the total
population of smokers in England.
Recruitment methods to cessation services generally employ a reactive approach, in which smokers are
expected to seek out help and approach the service themselves.11 General practitioners (GPs) and health
professionals are encouraged to offer brief advice and to provide referral to services, but in 2008–9 only
55% of smokers reported being given advice, and only 8% were referred to the services.9 Moreover, these
smokers were generally expected to follow up their referral and contact the service themselves to make
the appointment. There is a wide range of factors that will deter smokers from seeking help, these include
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a lack of time, lack of availability and accessibility of times and locations, perceived inappropriateness of
the service, a perception that help is not necessary, a sense of a lack of empathy from health professionals
and not wanting the social stigma associated with participation in formal programmes, as well as a lack of
readiness to quit.13,19,20
The problem to be addressed then is, given that the majority of smokers say they want to quit, how can
more smokers be persuaded and motivated to take the plunge and seek, or accept, help to quit, which
would lead to more successful quit attempts.
Rationale for intervention
Mass mailing and proactive strategy
Studies suggest that the direct marketing approach has potential as a population-based strategy for
recruiting smokers into support services, and could provide treatment access to individuals who might not
otherwise seek cessation care. Paul et al.20 explored the acceptability of direct marketing and proactive
contact offering cessation services to smokers. The authors reported that 92.8% of the sample found it
acceptable for the health service to contact people to offer assistance and 55.7% said they were likely to
take up the offer of individual counselling. This could be an overestimation of actual take-up of the service,
but suggests that proactive contact is acceptable and that smokers are open to the idea of intensive counselling.
The importance of proactively encouraging smokers to quit has also been demonstrated in studies exploring
recruitment to telephone quit lines, lending support to the ‘cold call’ telephone approach. These studies
suggested that demand and interest in using services or receiving information about quitting may be greater
than is reflected in current usage rates, and that proactively offering services could result in an increase in
uptake.21–24 A recent systematic review of recruitment methods for smoking cessation programmes suggested
that personal tailored messages and proactive and intensive recruitment strategies can enhance recruitment.25
This review confirmed the conclusion reached by McDonald26 that interpersonal strategies have a positive
effect on recruitment into smoking cessation programmes.
Lichtenstein and Hollis27 employed a more proactive recruitment method. They invited smokers attending
a medical appointment to an immediate intervention where they were offered information about what
attendance at the service would involve, and a strong referral message to the service. Attendance at the
first session of the cessation programme increased to 11.3%, compared with 0.006% in a control group
who received brief advice only. Fiore et al.28 also showed that many primary care patients identified as
smokers will accept treatment ‘if it is free, appropriately incorporated into the health-care delivery system
to ensure convenience, and encouraged through proactive recruitment’.
In line with these findings, a major UK study used a proactive strategy to identify individual smokers and
inform them about available cessation services. In a cluster randomised controlled trial, Murray et al.29
identified all patients in general practices recorded as current smokers or with no status recorded. These
patients were proactively informed by letter about the SSSs and given the option of being contacted by an
advisor. Smokers in practices allocated to the intervention group indicating that they would like to speak
to an advisor were contacted within 8 weeks by a researcher trained as an advisor and offered advice and
an appointment. Smokers in control group practices received no further contact. Overall, the proportion of
current smokers expressing interest was 13.8%, suggesting that more than the current 5% of the smoking
population setting quit dates within the NHS were interested in receiving help. Furthermore, Murray et al.29
reported a 7.7% absolute increase in smokers using the SSSs in the intervention group over the control
group at the 6-month follow-up, and an increase of 1.8% in validated abstinence in those smokers
requesting contact over the control group (4% vs. 2.2%).
This study by Murray et al.29 was the first in the UK to assess a proactive method of recruitment to attract
smokers into the SSSs. It demonstrated the potential to increase attendance, and also indicated that novel
methods of marketing are needed in order to engage interested smokers to encourage use of the SSSs.
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Individual computer-tailoring and risk information
One possible way of enhancing recruitment is to use individual characteristics to personalise and tailor
communications. Computer-based systems can generate highly tailored materials, defined as ‘any
combination of information or change strategies intended to reach one specific person and based on
characteristics unique to that person’.30 This technology offers a method for personalisation of
communications to patients and can include an individualised risk communication element based on an
individual’s own risk factors, more personally relevant to the consumer than information about population
‘average’ risks.31
The use of fear in health promotion has been the subject of debate and is somewhat controversial,
with claims that ‘shock tactics’ do not work, are too frightening, or can backfire and prove to be
counterproductive by prompting a maladaptive behavioural response. There is also a general notion that
healthy lifestyle campaigns and anti-smoking messages should be positive and reflect non-smoking role
models rather than dealing with the ‘scary’ health consequences of smoking.32 However, in a review
of studies on fear appeals, Sutton33 concluded that increases in fear in communications are associated with
increases in acceptance of the recommended action, in a linear relationship. Providing recipients with a
reassuring message that adopting the recommended action would be effective, together with clear advice
on how to go about it strengthens intentions to follow the advised course of action.34
Fear messages about smoking can indeed push people to attempt to quit. The fear induced by such
messages can be dealt with adaptively by a behavioural response that removes the reason to be fearful,
such as quitting smoking, or maladaptively by, for example, denying the truth or personal relevance of the
threat.32 The likelihood of eliciting the desired response can be maximised by empowering the recipient
and giving reassurance that it is possible, and also providing a ‘helping relationship’ that is needed to
succeed.35 This has been demonstrated to good effect in mass media campaigns, particularly that of the
Australian national anti-smoking advertising campaign, which used graphic fear-based messages as a
dominant part of the communication strategy, but tagged with the national quit helpline number and an
additional advertisement encouraging calls to that number.36 This strategy is also consistent with social
cognitive models such as the health belief model, which posits that a greater perceived risk of a disease
and perceived efficacy of the action in preventing it is associated with increased participation in a
recommended behaviour. The health belief model also highlights the importance of providing a specific
cue to action, which can act as a trigger and increase compliance with the recommended behaviour.37,38
Additional justification for this approach lies in the evidence that smokers do not fully acknowledge their
own personal vulnerability. Data show unequivocally that smokers acknowledge that their risks of health
problems are higher than those of non-smokers. However, studies indicate that they substantially
underestimate their own personal risk and tend to conclude that they are less likely to suffer health effects
than other smokers.39 A large literature demonstrates this ‘optimistic bias’ or ‘unrealistic optimism’.
Weinstein et al.40 provided further clear evidence that smokers engage in risk minimisation by convincing
themselves that they are not as much at risk as other smokers. Moreover, smokers do not perceive the
relationship between the amount smoked and their perceived risk. Thus, even if people are aware of
the well-publicised risks, they resist the idea that the risks apply to them, and a key factor is getting
participants to acknowledge that these risks are personally relevant.
Computer-tailoring can be used to customise an individual’s risk factors, enhancing perceived personal
relevance and helping to overcome the tendency to deny that the information in the tailored messages
applies to the recipient. These personal communications can both inform the smoker of their own personal
risk, while at the same time promoting confidence and providing the helping relationship that is essential
to encouraging acceptance of the advice and following the recommended course of action. These basic
tenets were put together in the 3Ts (Tension, Trigger, Treatment) model proposed by West and Sohal.41
They proposed that triggers can lead to sudden changes and that creating motivational tension can trigger
action in smokers who are predisposed, or motivated, to change. The immediate availability of treatment
can then prompt action.
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Research has shown that individually tailored self-help materials have a small but useful effect over generic
materials on smoking cessation.42 The addition of personalised risk communication that is more personally
relevant to the consumer has also been found to increase uptake of screening.31 Computer technology can
be used to produce a communication that combines the tenets of this model, and can also be combined
with proactive recruitment methods with the potential to engage with and recruit a larger proportion of
the smoking population in a relatively inexpensive way.
Opportunity to experience a support service without commitment
In addition to the factors noted as barriers to the use of support services, the literature also suggests
that many smokers are unaware of, or have insufficient knowledge of or inadequate information about,
the services available.20,43 This lack of knowledge can also lead to the belief that ‘it wouldn’t help me
anyway’.20 The combination of ‘why quit’ messages, hard-hitting messages about the consequences of
tobacco use and ‘how to quit’ messages, supportive and positive and emphasising quitting resources, was
recommended in the Global Dialogue for Effective Stop Smoking Campaigns,44 an international review of
the literature. This report also recommended that promotional efforts need to both build awareness that
getting help will increase the chances of success and build awareness of and comfort with the quitting
services.
Lichtenstein and Hollis27 demonstrated how a proactive and personal approach can be combined with
an opportunity to gain more information about the service and what it involves at a no-commitment
introductory session. Their intervention included an assessment, measurement of expired-air carbon
monoxide (CO) level with an interpretation, video testimonials and the opportunity to ask questions, a
voucher fee waiver and immediate scheduling of the smoker for the group. Thus, including a personal
invitation with an appointment to a no-commitment introductory session offers the opportunity to gain an
insight into what the service can offer, and also has the potential to increase service use.
This research study brings together evidence on proactive and direct mail recruitment, on personalised
computer-tailoring and risk information, and on offering the opportunity to experience a support service
without commitment, to evaluate a complex intervention comprising all of these elements, in encouraging
and increasing attendance at the English SSSs.
The intervention is further enhanced by the addition of a repeated personal letter, with a further invitation
sent 3 months after the original to all participants who fail to attend a taster session. This is consistent with
recommendations made by Lichtenstein and Hollis27 who proposed that, with repeated advice over time,
a greater proportion will be likely to respond.
Aims and objectives
Principal research question
We hypothesised that smokers, identified from general practice records, sent brief personal tailored
letters based on characteristics available in their primary care medical records and on a short screening
questionnaire, and invited to a ‘Come and Try it’ taster session designed to inform them about the SSSs,
were more likely to attend the services than those who received a standard generic letter advertising
the service.
Primary objective
The primary objective of the study was to assess the relative effectiveness and cost-effectiveness of a
complex intervention, consisting of proactive recruitment by a brief personal letter tailored to individual
characteristics available in medical records, and an invitation to a ‘Come and Try it’ taster session to
provide information about the SSSs, over a standard generic letter advertising the service, on attendance at
the SSSs of at least one session.
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Secondary objectives
The secondary objectives were to (1) assess the relative effectiveness of the intervention on biochemically
validated 7-day point prevalent abstinence rates at the 6-month follow-up; (2) compare the cost-effectiveness
of the intervention; (3) assess the relative effectiveness on additional periods of abstinence measured by
self-report of not smoking for periods of 24 hours to 3 months at the 6-month follow-up; (4) assess the
number of smokers attending the taster session and the number of smokers completing the 6-week NHS
smoking cessation course; (5) assess the number of quit attempts made and any reduction in daily cigarette
consumption; (6) explore the effectiveness of the intervention by socioeconomic status and social deprivation;
(7) explore reasons for non-attendance and barriers to attendance at the SSS; and (8) determine predictors of
attendance at the services and at the taster sessions (in the intervention group).
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Chapter 2 Methods
Study design and setting
The Start2quit study was a pragmatic two-arm randomised controlled trial of a complex intervention,
utilising general practices in England to recruit smokers into the trial.
Trial management and conduct
The trial was conducted in two stages. A pilot phase was conducted in seven practices covered by two
SSSs between January and December 2011. The aims of the pilot phase were to assess the feasibility of
the procedure, to ascertain recruitment rates and assess the uptake of the taster sessions, and to establish
that the uptake of smoking cessation services in the intervention group was at least as good as that in the
control group (i.e. the difference in proportions of intervention minus control was greater than zero).
The methodology of the pilot phase was essentially the same as the full trial, to enable combination of the
data from both phases for analysis. However, lessons learnt on recruitment strategies from the pilot phase
were applied to the main trial.
The trial was originally funded for 48 months. Additional funding, approved in July 2012 to carry out
additional work, increased the size of the sample and extended the trial by 12 months.
Amendments to the final protocol including the trial extension are presented in Appendix 1. The report of the
pilot phase submitted to the Health Technology Assessment (HTA) programme in January 2012 is in Appendix 2.
The study was approved by the London–Surrey Borders Research Ethics Committee and received approval
from the local NHS trusts.
Participants
Target population
The target group was smokers motivated to quit who had not attended SSSs in the previous 12 months.
We aimed to target smokers in areas of high deprivation and ethnic minorities, where smoking prevalence
is high.
Inclusion/exclusion criteria
All current smokers willing to participate and returning the signed consent form, aged ≥ 16 years, able to
read English, motivated to quit and who had not attended SSSs in the previous 12 months were eligible
for inclusion in the study. For the purposes of this research, motivation to quit was defined as answering
‘yes’ to either or both of the following questions:
1. Are you seriously thinking of quitting in the next 6 months?
2. Would you think of quitting if appropriate help was offered at a convenient time and place?
Exclusion criteria were minimal because the aim was to recruit all smokers into the services. However,
smokers aged < 16 years were excluded because of the need for parental consent to participate for this
age group, and any patients identified considered by the GP to be unsuitable for the project, for example
the severely or terminally ill, were excluded.
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Recruitment procedure
Stop Smoking Service and practice recruitment
We worked with the National Institute for Health Research Primary Care Research Network (PCRN) to
identify SSSs willing to participate in the trial, and to then identify and recruit practices in the selected SSS
areas. We aimed to select more practices in areas of high deprivation and of large ethnic communities to
ensure full representation of smokers most in need of help, and to maximise the generalisability of the
results. The SSSs and PCRNs assisted in identifying sufficient practices serving these populations.
The trial was originally planned to cover 10 different areas served by a SSS, and we initially recruited
Camden (North London) and Oxfordshire SSSs and practices in those areas for the pilot phase of the trial.
The extension of the trial and the increase in the size of the sample meant that the number of SSSs was
increased to 18 in areas representative of the English SSS.
Participant recruitment
All smokers aged ≥ 16 years were identified from their medical records in participating practices. GPs
screened the list to exclude anyone they deemed to be unsuitable for the research, for example severely or
terminally ill, and the list was also screened to ensure that only one person from the same address was
selected. All remaining persons on the list were sent a letter from their GP inviting them to participate in
the trial, together with a participant information sheet describing the research, a consent form and a
screening questionnaire. Participants were asked to consent to the use of information from their medical
records and information given in the screening questionnaire to send them information about quitting,
and for the researchers to access relevant data from their attendance at the SSSs. Data generated from
the screening questionnaire were used both to assess the criteria for inclusion in the trial, to provide
information for the computer-generated tailored intervention letter and to provide baseline characteristics.
Participants returned these questionnaires to the practice using a Freepost envelope. Non-responders were
sent a reminder and duplicate questionnaire after 3 weeks. All smokers returning the signed consent form
and who were eligible to participate were randomised to the intervention or the control group. Patients
had the opportunity to decline to participate but to return the questionnaire with basic information to
update their smoking status in their GP practice records.
All recruitment materials can be found in Appendix 3. The baseline questionnaire is included in
Appendix 4.
Interventions
Control group
Participants allocated to the control group were sent a standard generic letter from the GP practice
advertising the local SSS and the therapies available, and asking the smoker to contact the service to make
an appointment to see an advisor.
Intervention group
Participants allocated to the intervention group received the following:
l a brief personalised and tailored letter sent from the GP that included information specific to the
patient, using information obtained from the screening questionnaire and from their medical records
l a personal invitation and appointment to attend a ‘Come and Try it’ taster session to find out more
about the services, run by advisors from the local SSS
l a repeated personal letter with a further invitation sent 3 months after the original to all participants
who failed to attend a taster session following the first letter and invitation.
Each of these components is described in the following sections in detail.
METHODS
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Development of the tailored intervention letter
The overall objectives of the letter were to communicate personal risk level if the person continues to
smoke, using individualised information on the risk of serious illness, and to encourage attendance at
the SSS.
Letter content
The letter was tailored to the individual using characteristics from practice records (gender and age) and
confirmed by the baseline screening questionnaire, information obtained from the screening questionnaire
(number of cigarettes per day and previous quit attempts) and information from medical records about
diagnosed conditions on the Quality and Outcomes Framework (QOF) register. The final list of diseases
consisted of all cancers (excluding lung because of its terminal nature); myocardial infarction; coronary
heart disease and heart failure (combined because of terminology and the difficulty of telling someone
they have a ‘weak heart’); lone atrial fibrillation; stroke and transient ischaemic attack; diabetes; epilepsy;
hypertension; hypothyroidism; asthma; chronic obstructive pulmonary disease (COPD); dementia (if the
patient was able to consent); depression and severe mental illnesses (schizophrenia and bipolar disorders);
and obesity. Possibilities around co-occurrence of diseases were considered and messages created for the
following: COPD and heart failure; COPD and asthma; coronary heart disease and hypertension, stroke,
dementia, severe mental illnesses, diabetes, obesity; and for multiple conditions. Because of additional
risks associated with smoking for women who are pregnant or taking the contraceptive pill or hormone
replacement therapy, personal risk information was also included for these smokers.
Personal risk information can be presented as an absolute or relative risk score, categorised, or as a list of
the individual’s risk factors. As it was felt not appropriate to provide specific probability figures without the
opportunity to discuss them with a health professional, risk was classified as high, very high or extremely
high compared with non- or ex-smokers, as recommended by Edwards et al.31
The offer of help was tailored to previous quit experience, and the letter was accompanied by a personal
invitation to the taster session with details of time and place.
The content of the letter was developed in collaboration with GPs and primary care experts with
knowledge of medical information available in records. Two service users also contributed.
Letter structure
The letter was headed ‘Personal Health Risk Report and Taster Session Invitation’. It consisted of four
sections (Table 1). The amount of tailoring was maximised within the constraints of the short screening
questionnaire and a brief letter, so that the final communication consisted of two pages. The section
headings were coloured as a traffic light system, using red for the risks, orange to encourage the person to
prepare to stop and green for the invitation to the taster session.
The letter was generated by a computer program, signed by the GP and sent from the practice. The first
letter was posted to the participant within 3 weeks of returning the completed questionnaire. A second
identical letter and invitation was sent 3 months later to every participant who had not attended one of
the earlier taster sessions.
Examples of the personal letter are included in Appendix 5.
Development of the taster session and training
The goal of the taster session was to offer information about the SSS, promote the service, address any
concerns or queries smokers may have about the service provided and encourage sign-up to a course.
It was not intended to replicate the first session of a course.
A draft of the content of the taster sessions was prepared by one of the co-investigators (SG), and was
developed into a standard protocol in consultation with the research team. The final standardised protocol
DOI: 10.3310/hta21030 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 3
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Gilbert et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
9
also included items from the NHS Centre for Smoking Cessation and Training’s Standard Treatment
Programme46 to ensure conformity with national guidelines, and a detailed manual was produced.
The standard protocol for the taster session included:
l a motivational element, congratulating attendees on coming to the session
l an introduction to the SSS, emphasising that it is a free service and based on well-researched evidence
l emphasising the importance of stopping smoking and outlining the benefits of quitting, both health
and financial/lifestyle
l information about the services offered, outlining the structure the treatment programme in one-to-one
or group sessions, the length of sessions and of the course
l information about what to expect when they attend and the content of advice, for example
emphasising that no-one will be forced to quit, but will be helped to explore the reasons for and
against wanting to give up smoking, and helped to develop strategies to resist smoking after their
quit date
l interaction between attendees, discussing, among other things, reasons for stopping
l discussion about withdrawal symptoms, with information about the available medications and range of
nicotine replacement therapy (NRT) products available
l the opportunity to have a measurement of CO level taken, with an interpretation
l a 5-minute digital versatile disk showing group and one-to-one sessions in progress, and testimonials
from previous successful attendees, produced by University College London (UCL) Media Services in
collaboration with Camden SSS
l the opportunity to ask questions about the service
l details of how to contact the service and a clear and persuasive invitation to sign up for a group or
individual session.
TABLE 1 Letter structure
Section Objectives
Information
included Source
1. Introduction To explain the purpose of letter, so that the individual will
know that it is a personalised letter based on their
assessment
2. Personal risk in terms
of dependence and
general health
To tell the individual his or her dependence in the context of
norms
Dependence Questionnaire
To indicate a category of risk according to dependency in
terms of the number of cigarettes smoked per day, the
number of QOF-registered conditions and age
Age Medical
records
Number of
QOF diseases
3. Disease-specific
health risks and the
benefits of quitting
To make the individual aware of the personal health
consequences of continuing to smoke, and their own
individual risk of serious illness in relation to dependence
and own health status
Dependence Questionnaire
To make the individual anxious because of perception of
their own personal risk
Age
To change the individual’s balance of perceived ‘benefits’
against their understanding of the harm caused by smoking
Gender Medical
records
QOF disease
4. Invitation to taster
session
To remind the individual that help and support is
immediately available
Previous quit
attempts
Questionnaire
To encourage them to seek out support and use the
resources available
Source: reproduced from Gilbert et al.45 © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the
CC BY license.
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Between two and seven advisors in each SSS, already trained to give smoking cessation advice in group
and one-to-one sessions, attended a 2-hour training session to enable them to facilitate the taster sessions
according to the standardised protocol and manual. The training sessions took place within each SSS and
were led by two members of the team (either HG or SG), and included an explanation and clarification of
the study protocol and procedures, and specified the exact information to be delivered in the session. Only
trained advisors led the taster sessions, and each session was run either by one advisor with additional
administrative support provided by one other, or the presentation was divided between two advisors.
They were encouraged to introduce themselves and describe their background and expertise to reassure
attendees of their credibility and expertise.
It was intended that each SSS should run between 4 and 12 taster sessions, depending on the number of
participants recruited and the area covered by the SSS, and that up to 50 participants were invited to each
session, which lasted approximately 1 hour. Sessions were held in the early evening normally beginning
between 18.00 and 19.00. On arrival attendees were asked to sign an attendance sheet provided by the
research team. An evaluation form was developed for immediate assessment of attendees views of the
session, the form included space to indicate interest in signing up to the SSS. Advisors encouraged
attendees to complete these evaluation forms before leaving the session and, when possible, participants
were given a date and time of a group or one-to-one session before they left. The taster session protocol
in included in Appendix 6.
Fidelity
The training session included a basic introduction to the methodology of randomised controlled trials and of
uniformity of an intervention. Thus, training emphasised the importance of standardising taster sessions, and
of delivering all protocol-specified content, while allowing for differences in the organisation of the individual
SSSs and also allowing for advisors to deliver the information naturally, as they would in their smoking
cessation clinics. To assess fidelity to the protocol, the taster sessions were, with the consent of the attendees,
audio-recorded. Advisors also completed a personal details form, gathering data on gender, age, highest
educational qualification, type of smoking cessation training, time since smoking cessation training, number
of patients seen in the previous 6 months and job title to account for differences in ‘therapist effects’.
Procedure and baseline data management
Procedure
Recruitment, collection of baseline data and delivery of the intervention took place over 4 years, between
January 2011 to June 2011 for the pilot phase, and between January 2012 and December 2014 for the
main trial. The procedure in each practice took 12 weeks to complete, during which time the research
assistants visited the practice on four occasions, assisting practice staff with mailing invitation letters and
questionnaires to patients, processing returned questionnaires, and generating tailored and generic
intervention letters. A series of purpose-written computer programs written in Visual Basic for Applications
(1997–2003, Microsoft Corporation, Redmond, WA, USA) that read and write Microsoft Excel® (Microsoft
Corporation, Redmond, WA, USA) and Microsoft Word® (Microsoft Corporation, Redmond, WA, USA) files
facilitated these processes, and were installed on laptops for use in the practices.
The practice staff initially ran a search using the practice computer system to identify all patients recorded as
smokers. The GPs then screened the list for exclusions. Research assistants visited the practice to first run the
‘Check for Duplicates’ computer program, which randomly selected one smoker from each address on the list,
and then using the ‘Invite’ program-generated letters inviting smokers to participate, which were then mailed.
Research assistants visited the practice a second time to process returns, using a third computer program
‘Risk’ which allocated identification numbers and randomised participants to the control or intervention
group. This computer program also combined the data from the baseline questionnaire and medical records
with the correct messages from a message library, written using Microsoft Word, to generate tailored letters
and invitations to the taster session for those participants randomised to the intervention, and the generic
letters for control participants. These were then mailed to the participants. The first taster session was held
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approximately 2 weeks after this mailing. Research assistants visited the practice on two further occasions to
process responses from patients in the same manner as previously described. Further taster sessions were
timed accordingly.
Three months later, all participants in the intervention group who had previously been invited to attend
a taster session but had not attended were sent a second intervention letter (identical to the first) and a
further invitation to a taster session (Figure 1).
Patients who returned the questionnaire with written consent but who were not eligible to take part in the
study were sent a letter thanking them for responding and informing them that they did not fit the study
criteria, and patients who returned questionnaires outside the time frame for processing were sent a
similar letter informing them that the recruitment period had ended. Both of these letters were sent from
the general practice and contained information about the local SSS, advising the smoker to contact the
service for more information or to speak to an advisor.
Security and baseline data management
The patient-level data collected in this trial comprised information downloaded from practice records and
information provided by participants on the consent form and baseline questionnaire. The information
from the practice record was used to generate letters inviting patients to participate in the trial. It was also
used, along with baseline questionnaire information, to generate the tailored and generic letters.
All data files and backup media remained in the practice until all eligible participants had been randomised
and the tailored and generic letters generated. At this point data files were transferred to the study centre at
UCL using proprietary encryption software (TrueCrypt, V61.1; TrueCrypt Foundation, Henderson, NV, USA).
At the end of recruitment in each practice anonymised average data on patients who were invited to
participate in the study but did not respond were collected to establish the external validity of our results.
These anonymised data comprised gender, date of birth and postcode. Date of birth was converted to age
at the time of the invitation and the postcode converted to an Index of Multiple Deprivation (IMD) score
via GeoConvert (2011, UK Data Service Census Support, University of Essex, University of Manchester).
IMD is the government’s official measure of multiple deprivation at the small-area level, which provides a
relative ranking of areas across England according to their level of deprivation. Names and all other
identifying data were removed.
Randomisation and blinding
Randomisation, at the level of the study participant, was embedded into the computer program using
permuted blocks. Participants were randomised in the ratio 3 : 2 (intervention to control) within the
practice, stratified by gender and using a block size of five. For each practice, a computer program was run
to create two randomisation tables, one for men and one for women. Each table consisted of 500 rows.
In one column, there was a sequence of 2s and 1s in blocks of five (e.g. 1, 1, 2, 2, 1, where 1 and 2 were
intervention and control, respectively). This sequence was created by listing all possible permutations of
three 1s and two 2s (10 in all), then repeatedly selecting one permutation at random (with replacement)
and adding each selection to the sequence. This procedure used the random number generating function
rnd in Microsoft Visual Basic for Applications. For each table, the randomise statement was used to initialise
the random number generator with a seed based on the system timer. Having created the tables for a given
practice, another computer program was used to allocate participants from that practice to an intervention
group by selecting the first unused code (1 or 2) from the table for men or the table for women, depending
on the participant’s gender, and then marking that code as used. If the information about gender was
missing for a participant, the randomisation table to be used was selected at random. Any imbalances were
controlled for in the statistical analysis using covariates that were identified prior to examining the trial data.
The use of a computer program that enforced randomisation after consent and baseline data entry ensured
that concealment was preserved and differential entry prevented.
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Taster
session 1
Taster
session 2
Taster
session 3
Taster
session 4
Week 1/2
Reminder letters and questionnaires 
mailed to non-respondersRAs check returned
questionnaires 
for eligibility
RAs check returned
questionnaires 
for eligibility
RAs check returned
questionnaires 
for eligibility
Week 3
Week 32/38
Week 37/49
Week 6
Week 9
Week 8
Week 12
Week 11
Week 14
Week 21
Week 23
Control
 group sent 
generic 
letter
Intervention group 
sent tailored letter 
and invitation 
to taster session
Practices search computer records for all
smokers aged > 16 years. GPs screen list
Invitation letters mailed with questionnaire
and patient information sheet
Follow-up of participants
 by telephone
Collection of attendance 
data from SSSs
Collection of saliva samples 
to validate smoking status
Consenting patients randomised 
to control or intervention group
Reminder tailored 
letter and second 
invitation sent to 
all non-attenders
FIGURE 1 Study schedule showing the duration and timing of the procedure, intervention and follow-up.
RA, research assisstant. Reproduced from Gilbert et al.45 © The Author(s). Published by Elsevier Ltd. This is an
Open Access article under the CC BY license.
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It was not possible to blind participants to the receipt of a personally tailored letter and invitation to a
taster session. Although the personal letter was generated in the practice by a research assistant, the
remainder of the research team in all cases were blind to the allocation of the participant, which was
enforced by the data management. GPs and practice staff were not aware of their patients’ allocation. In
follow-up interviews, the interviewer was blinded to the allocation of the respondent in order to avoid bias
in outcome assessment. The interviewers could become unblinded during the course of the interview when
participants were asked about the receipt of the letter and attendance at the taster session; however, the
main outcome questions were asked at the start of the interview.
By randomising at the level of participant rather than by practice, there was a slight risk of contamination
by communication between patients at the same practice allocated to different intervention groups. To
reduce this risk we (1) ensured that only one person from the same household received a screening
questionnaire; (2) monitored attendance at the taster sessions, to ensure that anyone attending who had
not received an invitation was recorded and checked against participants in the control group; (3) kept a
record of attendance at the taster sessions; and (4) measured the amount of contamination at follow-up
by asking participants whether or not they had attended a taster session and, if not, whether or not they
personally knew or had spoken to anyone else who had been invited to a taster session.
Follow-up data collection and evaluation procedure
At the end of the 6-month follow-up period in each SSS, valid data of attendance were collected from the
SSSs using NHS monitoring data collected by smoking cessation advisors. A list of participants recruited
from the particular SSS was sent to the local collaborator, who searched their user database for each
participant named. For each participant whose name was present in the database, and had attended the
service between the study entry date and the 6-month follow-up date, a case report form was completed.
Data were collected on dates of attendance, agreed quit date, 4-week follow-up date, total number of
sessions attended and treatment outcome. We also collected data on the type of advisor, the type and
setting of support received, and pharmacological support used.
Research interviewers, independent from the service providers, conducted a computer-assisted telephone
interview 6 months after the date of randomisation to assess self-reported SSS attendance, current
smoking status, daily cigarette consumption, reasons for non-attendance and barriers to attendance in
all participants.
Procedures were applied to maximise retention of participants at the 6-month follow-up. Interviewers
made a maximum of 10 attempts to contact a participant by telephone. If, after 10 attempts, the
interviewers had been unable to speak to a participant in person, they sent a text message prompting a
response back to the mobile phone from which it was sent. The participant was sent the same message a
second time if no response was received after 3 days, and, if no response was received after a further
3 days, the participant was sent a paper version of the follow-up questionnaire to complete and return by
post. The paper questionnaire was also sent to participants unable to complete the telephone interview
but willing to complete and return a postal questionnaire. A decision was taken late on in the trial to send
a reminder for this postal questionnaire. If a participant did not fully complete or did not wish to complete
the telephone interview, the interviewer attempted to ask the participant four basic questions most
relevant to the primary and main secondary outcome.
Participants claiming 7-day abstinence at the 6-month follow-up were asked to provide a salivary cotinine
sample to biochemically validate 7-day point prevalent smoking cessation.47 Samples were obtained by
post using a saliva sample kit.48 Use of NRT at the time the sample was taken was assessed by questionnaire,
as the cotinine content can be affected by continued use, and taken into account when the results of the
analysis were received. To maximise return of samples, a £5 Marks and Spencer voucher was included with
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each kit, and a further £5 voucher was sent on return of the sample. Participants were contacted by a
research interviewer to remind them to return their kit if saliva samples were not returned within 7 days,
and after 10 unsuccessful attempts to contact the participant, they were sent a reminder text message.
If the interviewer was successful in contacting the participant but their sample was still not returned after
7 days, the participant was sent the same reminder text message.
Figure 1 shows detail of the timing of assessments, intervention and follow-up.
Measures
Baseline measures
Inclusion criteria (age, intention and motivation to quit, and previous SSS attendance), demographics
(gender, marital status, qualifications, employment and ethnicity), self-reported health, dependence on
nicotine (number of cigarettes per day and time from waking to first cigarette), smoking history (age
started and previous quit attempts), determination and confidence to quit were assessed in the baseline
screening questionnaire.
Outcome measures
Primary outcome
The proportion of people entering the smoking cessation service (i.e. attending the first session of a
6-week course) over a period of 6 months from the receipt of the invitation letter, as measured by the NHS
records of attendance at the SSSs.
Secondary outcomes
1. Seven-day point prevalent abstinence at the 6-month follow-up, validated by salivary cotinine for all
participants reporting abstinence in both the intervention and control groups.
2. Additional periods of abstinence measured by self-report only: 24-hour and 7-day point prevalent,
1- and 3-month prolonged abstinence.
3. Three-month prolonged abstinence, measured by self-report and validated.
4. Self-reported changes in daily cigarette consumption, quit attempts, and changes in motivation and
intention to quit in continuing smokers.
5. The number completing the 6-week NHS course.
Process measures
1. The number of smokers attending the taster session (intervention group only).
2. Self-reported attendance data.
3. Perception of the taster session.
4. Perception of the personal invitation letters.
5. Reasons for non-attendance at the taster session and barriers to attendance at the NHS services.
The number attending the taster sessions was taken from records, all other process measures were
included in the follow-up interview 6 months after the date of randomisation. Perception of the taster
session was also assessed by an evaluation form immediately after each session.
Reasons for non-attendance at the taster session and barriers to attendance at the NHS services were
assessed using open questions. In addition, all participants who reported not attending the SSS were asked
to complete the 40-item Treatment Barriers Questionnaire (TBQ), validated on a US population,49 to assess
in more depth reasons and barriers to the use of the SSS.
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Health economic measures
The economic component estimated the cost of providing the interventions, using primary cost data from
a NHS and Personal Social Services perspective, as recommended by National Institute for Health and Care
Excellence (NICE) guidance.50 We also measured patients’ use of health and social care services using a
comprehensive service use questionnaires. Quality-adjusted life-years (QALYs) were calculated from the
European Quality of Life-5 Dimensions (EQ-5D) questionnaire using the area-under-the-curve method.51
A cost-effectiveness analysis (CEA) was undertaken to compare the tailored letter plus the taster session
and the generic letter. In addition to the within-trial CEA, lifetime health-care cost savings and QALY gains
associated with the two interventions were estimated based on a decision-analytic model.52
Sample size and power calculations
Evidence from the study by Murray et al.29 suggested that attendance at NHS services could be increased
by 7.7% (from 8.9% to 16.6%) using a proactive intervention. To detect an effect of this size at 90%
power and an alpha of 0.05 required a sample of 420 participants per group. However, in the absence
of other similar trials, we conservatively assumed that the uptake of services in those who received the
tailored letter and the taster session could be lower than that reported by Murray et al.29 Therefore,
we assumed an estimated increase of 4.6% [from 8.9% to 13.5%, odds ratio (OR) 1.65] requiring 1029
participants per group, 2058 in all, to detect this difference as statistically significant at the 5% level with
90% power.
We originally planned to recruit practices from 10 different SSSs. The taster sessions in each SSS were to
be run by the same four advisors comprising 10 therapist clusters. Thus, before adjusting for clustering we
would expect 103 patients per cluster. Although the intervention was manualised and structured training
run to reduce the variability between the interventions delivered in each SSS, we decided to account for
any persistent therapist effects that might apply to those randomised to receive a taster session. The
literature reporting intracluster correlations is scarce; however, Adams et al.53 found a single study54 of
smoking cessation delivered in pharmacies, which reported an intracluster correlation coefficient (ICC) of
0.007: this shrank to 0 after adjustment. We therefore assumed an ICC of 0.005 for our study. Allowing
for this ICC, coupled with a therapist cluster size of 103, required our existing sample size to be inflated by
a factor of 1.51 only in the intervention group, where the effects would occur. Thus, 1554 would receive
the tailored letter and taster session, with 2583 participants in total.
The study by Murray et al.29 also found validated quit rates at 6 months of 4% in the intervention
group, compared with 2.2% in the control group (a difference of 1.8%). With our planned sample size
of 2583 participants, we had < 80% power to detect a difference of 1.8%. However, if the quit rate
were to double from 2.2% to 4.4% (a difference of 2.2%), we still had 80% power to detect such
a difference.
An extension to the trial was funded to permit evaluation with adequate power of the intervention effect
on 7-day point prevalent abstinence at the 6-month follow-up. This required an 80% increase in the
sample size to 1793 in the control group and 2707 in the intervention group (assuming the same therapist
effect as the original protocol), giving a total of 4500. This would give 85.4% power to detect a difference
of 1.8% at the 5% significance level, assuming quit rates of 4% compared with 2.2% in the intervention
and control groups, respectively. The same sample size would have 95% power to detect the difference
between quit rates of 4.4% and 2.2% (doubling of quit rate), respectively.
Practices generally identify 13–22% of their patients as smokers,55 depending on the characteristics of the
patient population and the accuracy and completeness of the records. We initially estimated that six
practices in each of 10 SSSs, with a list size of > 4000, would give approximately 240,000 patients and,
assuming a conservative smoking prevalence of 15% in patients aged ≥ 16 years, 36,000 smokers.
Based on previous studies,29,56 we estimated a response rate from two mailings of 7% from smokers
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motivated to quit, securing 2520 participants and meeting the requirements of the original sample size
calculation. The extension to the trial required an additional 2000 participants and, based on recruitment
figures at the time the extension was funded, we estimated that an additional eight SSSs (48 practices)
would recruit 2060 participants, giving a total of 4580 and meeting the requirement of the new power
calculation.
Interim analyses and stopping guidelines
The study was initiated with a pilot phase conducted in seven practices recruited from two SSSs. This was
intended to be approximately 20% of the original total sample. The criteria for judging the success of the
pilot phase and proceeding to full trial was based on:
1. achieving a 7% response rate (i.e. a mean of 42 participants per practice giving consent and agreeing
to randomisation) in the first seven practices
2. a preliminary analysis that suggested that the uptake of smoking cessation services in the intervention
group was greater than in the control group (i.e. the difference in proportions, intervention minus
control, was greater than zero).
No other stopping rules were applied.
Statistical methods
All main analysis comparing groups for primary and secondary outcomes, and additional subgroup and
adjusted analyses was conducted using Stata version 13 (StataCorp LP, College Station, TX, USA).
Baseline characteristics of participants were summarised in terms of the mean, standard deviation (SD),
median, minimum, maximum and number of observations and categorical data in terms of frequency
counts and percentages. No formal statistical tests were performed.
Comparison of proportions was carried out for binary outcomes between the intervention and the control
groups (entry to smoking cessation service, point prevalent and prolonged abstinence, number completing
the 6-week SSS course). Univariable logistic regression analysis was carried out to take into account
clustering at the SSS level, and multivariable logistic regression was also carried out to take into account
any imbalance in important baseline characteristics known to predict smoking cessation outcomes,
nominated prior to examination of the trial data, between the groups. Both unadjusted and adjusted
estimates are reported. The unadjusted analysis is considered to be the primary analysis. The size of the
difference between treatments is expressed as an OR including 95% confidence interval (CI) from logistic
regression, with appropriate allowance for clustering.
The therapists were SSS based rather than practice based, and we initially intended that the therapist
effect be accounted for by allowing greater variance between SSSs in the intervention group than in
the control group, so that the difference in variance would represent the therapist effect. In fact, we
discovered that the estimated variance for the primary outcome was slightly lower in the intervention
group, rendering it impossible to fit a model including a special clustering effect for participants only
assigned to the intervention. Hence, we allowed only for variance between SSSs, assuming it to be the
same in the two groups, and thus fitted a random intercepts model.
Self-reported changes in daily cigarette consumption (the difference between cigarette consumption at
baseline and at the 6-month follow-up) is a continuous variable and was compared with the two-sample
t-test and with multiple linear regression to account for important baseline characteristics. ORs for the
difference in means is quoted together with the 95% CI.
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Furthermore, we estimated the ICC for our primary outcome and for the validated 7-day abstinent
outcome. The ICC for a binary outcome can be estimated as:
ρ =
σ2u
σ2u +
π2
3
. (1)
The term σ2u can be interpreted as the component of outcome variance because of differences between
SSSs, the denominator as the total variance and ρ as the proportion of the total outcome variance that is
due to between-cluster variation.57
Loss to follow-up after randomisation is reported. Analysis is based on intention to treat; that is, we
assume that all randomised participants received the treatment that they were randomised to, and all
those lost to follow-up are assumed to be still smoking.
Levels of significance
During the course of running the trial but prior to locking the database, based on further expert statistical
advice, we devised an analysis plan for interpreting significance levels for analysis on multiple outcomes of
interest. Hence, the interpretation of the results of the trial for the primary outcome, (1) engagement with
SSS, and the main secondary outcome, (2) 7-day point prevalent abstinence, was governed by an alpha
spending plan that preserved the study-wise alpha for (1) and (2). We hypothesised that these outcomes
fall naturally into a hierarchy with (1) as a step prior to (2). We employed a hierarchical monitoring plan in
which alpha was spent first on (1) and the remaining alpha was available for (2). The simple formula below
describes alpha allocation in the hierarchy:
α2c = 1 ½(1 α2s)=(1 α2e), (2)
where subscript 2 = two sided; s = study-level critical alpha (0.05); e = engagement with SSS; and
c = 7-day point prevalent abstinence. Thus, if the p-value for attendance at SSS was 0.02, there
remains a p-value of 0.031 to spend on the second outcome of 7-day point prevalent abstinence and
a p-value for that outcome of < 0.031 would be considered significant. If the p-value for the primary
outcome (difference in smoking cessation service attendance) was > 0.05, then the overall study
would be considered neutral and any finding on the second outcome considered exploratory with a
nominal p-value.
Likewise, if there was a significant decrease in attendance within the intervention arm over the control
arm, the second outcome would be considered exploratory with a nominal p-value.
Subgroup analyses
In order to assess whether or not the intervention was any more effective for any particular subgroup of
smokers, we explored interactions between intervention and deprivation (defined in fifths), intervention
and gender, and intervention and age (defined by categories 16–39 years, 40–64 years and ≥ 65 years),
for the primary outcome (attendance) and 7-day point prevalent abstinence at the 6-month follow-up.
We had planned at an early stage to analyse the interaction with deprivation,58 and with gender and age
when drawing up our analysis plan,59 prior to the end of data collection.
Subsidiary analyses
We also explored any delayed effect of sending repeat reminders to smokers on the uptake of service, and
any differences in attendance due to seasonal variations.
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Patient and public involvement
This trial was embedded in the NHS through the inclusion of a SSS manager as a coapplicant, who was
involved in all stages of the research, from design and conduct to analysis. In addition, a past successful
user of the Camden SSS was invited onto the Trial Management Group and has been involved in the study
from the design stage onwards. The service user contributed to the design of both parts of the intervention
and to the conduct of the trial and collection of data.
Another past user of the Camden SSS also contributed to the development of the intervention; thus, two
service users were involved in the development of both parts of the intervention. They were consulted on
the content of the brief personal letter at all stages of development, and were also consulted on the
protocol for the taster sessions. Both service users also narrated their own experiences of quitting and
these were used to create the video that formed a part of the taster session.
The Trial Management Group member was fully involved at all management meetings. Considerable effort
was put into increasing response rate to the follow-up, and the service user was particularly helpful with
suggestions of how to maximise this response, using her perception as a user to propose the use of text
messaging and how the texts should be phrased. She also added greatly to the discussion of the results
and of the practical implications of this method of recruitment to the SSSs.
Thus, the interests of all parties and the views of the public have been fully represented in the conduct of
the study.
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Chapter 3 Results
Recruitment and participant flow
Practice recruitment
Eighteen SSSs spread across England, located in both high and low areas of deprivation and representing
both large and small organisations, agreed to participate in the trial (Figure 2). Ninety-nine practices within
the participating SSS areas, identified and approached by PCRNs, agreed to participate. The number of
practices per SSS ranged from 3 to 10, and the practice list size ranged from 2205 to 26,000 (mean,
9723; median, 9725). Cumulative list sizes, shown in Table 2, ranged from 17,617 in Medway to
106,424 in Durham and Darlington. Current cigarette smokers aged 16–99 years were identified from
computer records in participating practices (n = 141,488; 14.7% of the total list size). The proportion
of smokers identified in each practice ranged between 4.8% and 39.7%, and within each SSS from
9.7% to 20.81%.
The study targeted higher-risk groups; therefore, practices in areas of high deprivation were preferentially
selected as determined by the practice postcode converted to an IMD score (the government’s official
measure of multiple deprivation at the small-area level). A majority (54.6%) of practices were located in
areas of high deprivation (i.e. within the two highest quintiles of IMD scores, a score > 21.34) (Figure 3).
This suggests that the catchment area for these practices were within areas of high deprivation or that a
higher number of participants were living in highly deprived areas; however, the postcode of the practice
does not always indicate the deprivation status of the catchment area. Nevertheless, a comparison of the
mean IMD scores of all smokers identified for each practice with the IMD of the practice indicated a similar
trend, and there was good correlation between smokers’ IMD scores and those of the practices (r = 0.80)
(Figure 4).
One would also expect to find a high proportion of smokers identified in areas of high deprivation,
indicated by a high IMD score, and in many cases there appears to be a close match. However, in some
areas the percentage was lower than would be expected, and this may be accounted for by a high ethnic
population, in which smoking prevalence may be lower in women, for example in Derby and Brent
(Figure 5).
Participant recruitment
The recruitment of participants for the pilot phase of the trial was conducted between January and
March 2011. Recruitment for the main phase began in January 2012 and was completed in October 2013.
General practitioners excluded 4186 patients considered to be unsuitable to take part in the study.
Reasons for exclusion included patients unable to understand English sufficiently, serious pre-existing
condition or terminal illness, and severe cognitive, mental or psychological impairment. However, most
practices did not give the reasons for exclusion and we are unable to estimate numbers in each category.
A further 25,086 patients were excluded because of duplicate addresses, ensuring that only one person
from the same address was selected. All remaining persons on the list (n = 112,216) were invited to
participate in the trial. Of these, 21,971 (19.6%) replied. However, 5333 replied to say they were
non-smokers and 420 were returned to the practices unopened as a result of incorrect addresses or
deceased. Records are not always accurate, and those returned from non-smokers are likely to represent
only a portion of those recorded as smokers but are actually non-smokers. Thus, our best estimate of total
potentially eligible is 106,463 (see Figure 6).
The total number of questionnaires returned from potentially eligible participants was 16,638 and, of
these, 10,380 declined to take part in the study but returned the questionnaire with basic information only
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to update their smoking status in their practice records. A further 1874 were willing to take part in the
study but did not fit the inclusion criteria, leaving 4384 participants enrolled in the trial, representing a
response rate of 4.1%. Of these, 2636 were allocated to the intervention group and 1748 to the control
1 Camden
2 Oxfordshire
3 Medway
4 Eastern and Coastal Kent
5 Lincolnshire
6 Essex
7 Cornwall
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10 Plymouth
11 Swindon
12 Durham and Darlington
13 Hampshire
14 Portsmouth
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16 Barnsley
17 Buckinghamshire    
18 Coventry  
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FIGURE 2 Map showing level of socioeconomic deprivation in England and SSSs participating in Start2quit.
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group. One participant from the intervention group withdrew from the study before follow-up commenced
and 4383 were analysed. See the Consolidated Standards of Reporting Trials (CONSORT) flow chart
(Figure 6) for details.
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FIGURE 3 Percentage of practices (%) within each IMD quintile.
TABLE 2 Participating SSSs
ID SSS
Number of
practices
Cumulative
list size
Mean %
smokers
Mean % smokers range
between practices
Mean practice
IMD score
1 Camden 3 19,791 20.81 7.03–39.73 22.98
2 Oxfordshire 4 42,394 17.88 16.48–20.21 19.24
3 Medway 4 17,617 18.01 15.69–24.04 22.29
4 Eastern and Coastal
Kent
4 43,814 14.43 13.31–15.23 16.14
5 Lincolnshire 6 47,000 12.40 6.83–21.91 12.30
6 Essex 3 46,916 12.11 6.65–19.65 24.27
7 Cornwall 7 65,528 17.42 13.27–22.20 29.06
8 Derby 4 47,307 14.47 8.17–18.62 49.67
9 Brent 4 21,905 11.74 8.38–14.78 41.86
10 Plymouth 6 55,344 19.11 10.79–24.72 32.41
11 Swindon 8 68,583 13.48 8.25–19.15 22.73
12 Durham and Darlington 10 106,424 16.11 7.27–25.11 28.63
13 Hampshire 9 99,829 11.15 5.98–16.53 20.68
14 Portsmouth 6 55,367 12.94 8.75–16.53 22.73
15 Staffordshire 7 65,239 19.29 16.27–23.87 21.74
16 Barnsley 4 46,488 19.96 15.22–30.54 29.75
17 Buckinghamshire 4 65,580 9.70 5.40–15.47 6.86
18 Coventry 6 47,422 13.34 4.79–19.80 24.98
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Follow-up
Follow-up data collection took place 6 months post randomisation and was conducted between August
and November 2011 for the pilot phase and between August 2012 and July 2014 for the main study.
Complete validation data of attendance at the SSS were obtained for each participant from SSSs at the end of
the quarter following the end of the 6-month follow-up period in each area. Additional data were obtained by
telephone interview or postal questionnaire. In total, 2910 (66.4%) completed the full telephone interview,
302 (6.9%) completed a shorter paper version of the follow-up questionnaire returned by post and an
additional 160 (3.7%) completed the four basic questions related to the primary outcome, giving a total
response rate of 3372 (76.9%). There was no difference in follow-up response between the treatment groups:
76.7% and 77.3% in the intervention and control groups, respectively. The reasons for loss to follow-up were
declined to complete the interview (n= 150), not able to be contacted (n= 857), and died within the 6-month
follow-up period (n= 4) (see Figure 6). The timing of completing the follow-up ranged from 20 days prior to
the due date (180 days after randomisation) to 194 days after the due date (mean, 27.53 days; median,
22 days). This was not statistically different between the intervention and the control groups.
0
10
20
30
40
0 10 20 30 40 50 60
Pe
rc
en
ta
g
e 
sm
o
ke
rs
Practice IMD scores
FIGURE 5 The IMD scores of practices and the proportion of smokers identified in the practice. Derby and Brent
are highlighted in blue.
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FIGURE 4 The IMD scores of practices compared with the mean IMD scores of all smokers living in the practice
catchment area.
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SSSs 
(n = 18)
Total practices recruited 
(n = 99)
List size (range 2205–26,000)
Total list size 962,548
Total smokers identified
(n = 141,488) (14.7%)a
Gave consent but did not 
fit criteria (N = 1874)
• Not ready to quit, n = 457
• Attended SSS in last year, n = 457
• Recently quit, n = 776
• Pipe/cigar smoker, n = 118
• Non-smoker, n = 57
• Other, n = 9
Wrong address/deceased (n = 420)
Non-smoker (n = 5333)
Did not reply 
(n = 89,825)
Declined to participate 
(n = 10,380)
Total sent invitation to participate and questionnaire
(n = 112,216; 11.7%)a
Total potentially eligible smokers sent invitation and questionnaire 
(n = 106,463;b 11.1%)a
Smokers enrolled in trial
 (n = 4384) (4.1%)c
N analysed (n = 4383)
Randomised to intervention group
(n = 2636)
Sent personalised letter with risk 
information and invitation and 
appointment to taster session
Withdrawn from study
(n = 1)
Randomised to control group 
(n = 1748)
Sent standard generic letter 
advertising the services 
Completed 6-month follow-up 
(N = 1352; 77.3%)   
  • Telephone interview, n = 1170 (66.9%)
  • Postal questionnaire, n = 127 (7.3%)
  • Basic, n = 55 (3.1%) 
Not completed (N = 396; 22.7%)
  • Declined to complete, n = 43 (2.5%)
  • No contact, n = 350 (20%)
  • Deceased, n = 3 (0.2%)
Excluded before invitations sent
 (N = 29,272)
• By GP, n = 4186
• Duplicate address, n = 25,086
Completed 6-month follow-up 
(N = 2020; 76.7%)
  • Telephone interview, n = 1740 (66%)
  • Postal questionnaire, n = 175 (6.6%)
  • Basic, n = 105 (4%) 
Not completed (N = 615; 23.3%)
  • Declined to complete, n = 107 (4.1%)
  • No contact, n = 507 (19.2%)
  • Deceased, n = 1 (0 .04%)
FIGURE 6 The CONSORT diagram of recruitment and flow of participants through the trial. a, Percentage of total
list size; b, total invitations sent minus non-smokers and wrong address/deceased; c, of total potentially eligible.
Adapted from Gilbert et al.45 © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the
CC BY license.
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There were large differences in recruitment between SSSs, ranging from 2.3% in Brent to 6.7% in
Oxfordshire, and also in follow-up response. There were also large variations between practices within
SSSs. We deliberately included some practices in areas with high ethnic minority populations, for example
in Derby and Brent, but in these practices recruitment was especially low (Table 3).
Biochemical validation of 7-day abstinence
Of the 630 participants who answered ‘not at all’ in response to the question ‘How often do you currently
smoke cigarettes or rollups?’ at the follow-up, and who were asked to provide a salivary cotinine sample
to validate abstinence, 595 (94.4%) agreed to send a saliva sample for analysis and 443 (70.3%) returned
a sample; 399 (63.3%) samples were sent for analysis. Samples from 44 participants who reported that
they had resumed smoking between follow-up and returning the sample were not analysed.
Of the samples analysed, 345 (54.8%) were validated (249 had a cotinine content of < 12 ng/ml, 36 were
from participants using NRT and 60 from participants were using e-cigarettes). Of the 54 samples not
validated, 30 had a cotinine content of > 12 ng/ml and were from participants not using NRT or e-cigarettes,
five samples came from participants who had smoked in the previous 6 days and 19 samples were of
insufficient volume to be analysed. There was no difference between the intervention and control groups.
Characteristics of participants
Baseline
Table 4 shows the demographic and smoking characteristics by intervention and control group.
TABLE 3 Response within SSS
ID SSS
Recruitment
rate (%)
Recruitment rate
range between
practices (%)
6-month follow-up
response (%)
6-month follow-up
response range
between practices (%)
1 Camden 3.2 2.7–5.8 65.6 61.0–78.6
2 Oxfordshire 6.7 5.5–9.2 72.1 69.7–74.1
3 Medway 5.1 1.8–5.9 72.2 68.2–80.0
4 Eastern and Coastal Kent 5.5 3.5–8.2 80.4 72.3–85.7
5 Lincolnshire 3.1 2.0–3.6 82.8 82.6–83.3
6 Essex 5.0 3.0–6.1 75.3 57.1–87.0
7 Cornwall 5.3 4.3–6.5 76.9 74.6–80.0
8 Derby 3.4 1.7–4.1 67.0 60.0–72.5
9 Brent 2.3 1.4–3.9 79.2 68.4–100
10 Plymouth 3.3 1.6–5.1 70.2 64.3–75.5
11 Swindon 4.7 3.8–6.1 74.9 68.3–79.3
12 Durham and Darlington 4.0 2.3–5.7 76.5 61.5–82.6
13 Hampshire 4.6 2.7–5.6 79.6 72.3–86.7
14 Portsmouth 3.0 1.3–5.1 82.9 74.3–96.8
15 Staffordshire 3.8 2.0–6.1 81.1 75.0–84.3
16 Barnsley 3.2 2.7–4.4 76.8 72.3–79.7
17 Buckinghamshire 4.5 3.7–5.4 85.3 82.0–93.3
18 Coventry 2.7 1.9–4.9 87.0 77.8–100
Source: reproduced from Gilbert et al.45 © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the
CC BY license.
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TABLE 4 Participant characteristics at baseline
Characteristic
Group
Total (N= 4383)
Intervention
(N= 2635; 60.1%)
Control
(N= 1748; 39.9%)
Demographics
Gender, n (%)
Male 1345 (51.0) 886 (50.7) 2231 (50.9)
Female 1290 (49.0) 862 (49.3) 2152 (49.1)
Age (years)
Mean (SD) 49.2 (14.3) 49.5 (14.3) 49.3 (14.3)
Range 16–88 16–89 16–89
Marital status, n (%)
Single 664 (25.2) 444 (25.4) 1108 (25.3)
Living with a spouse 1429 (54.2) 961 (55.0) 2390 (54.5)
Separated/divorced 392 (14.9) 252 (14.4) 644 (14.7)
Widowed 134 (5.1) 83 (4.8) 217 (5.0)
Missing 16 (0.6) 8 (0.5) 24 (0.6)
Employment status, n (%)
Unemployed 287 (10.9) 190 (10.9) 477 (10.9)
Paid employment 1422 (53.9) 903 (51.7) 2325 (53.1)
Full-time student 44 (1.7) 32 (1.8) 76 (1.7)
Home maker 104 (4.0) 89 (5.1) 193 (4.4)
Retired 495 (18.8) 344 (19.7) 839 (19.1)
Disabled/too ill to work 254 (9.6) 171 (9.8) 425 (9.7)
Missing 29 (1.1) 19 (1.1) 48 (1.1)
Highest qualification, n (%)
None 672 (25.5) 460 (26.3) 1132 (25.8)
GCSE/CSE/O Level 1042 (39.5) 655 (37.5) 1697 (38.7)
A Level 306 (11.6) 232 (13.3) 538 (12.3)
Degree/equivalent 454 (17.2) 301 (17.2) 755 (17.2)
Postgraduate 82 (3.1) 34 (2.0) 116 (2.7)
Missing 79 (3.0) 66 (3.8) 145 (3.3)
Ethnic background, n (%)
White 2522 (95.7) 1669 (95.5) 4191 (95.6)
Black 29 (1.1) 22 (1.3) 51 (1.2)
Asian 36 (1.4) 29 (1.7) 65 (1.5)
Other 27 (1.0) 23 (1.3) 50 (1.1)
Missing 21 (0.8) 5 (0.3) 26 (0.6)
continued
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TABLE 4 Participant characteristics at baseline (continued )
Characteristic
Group
Total (N= 4383)
Intervention
(N= 2635; 60.1%)
Control
(N= 1748; 39.9%)
Deprivation (IMD score), n (%)
Quintile 1 334 (12.7) 215 (12.3) 549 (12.5)
Quintile 2 378 (14.4) 244 (14.0) 622 (14.2)
Quintile 3 574 (21.8) 392 (22.4) 966 (22.0)
Quintile 4 677 (25.7) 453 (25.9) 1130 (25.8)
Quintile 5 653 (24.8) 436 (24.9) 1089 (24.9)
Missing 19 (0.7) 8 (0.5) 27 (0.6)
Live with smokers, n (%)
No 1791 (68.0) 1177 (67.3) 2968 (67.7)
Yes 835 (31.7) 567 (32.4) 1402 (32.0)
Missing 9 (0.3) 4 (0.2) 13 (0.3)
Smoking characteristics
Daily smokers, n (%) 2401 (91.1) 1616 (92.5) 4017 (91.6)
Non-daily smokers, n (%) 214 (8.1) 126 (7.2) 340 (7.8)
Missing, n (%) 20 (0.8) 6 (0.3) 26 (0.6)
Cigarettes per day
Mean (SD) 16.1 (8.6) 16.8 (9.9) 16.4 (9.2)
Range 0.1–80 0.3–99 0.1–99
Missing, n (%) 10 (0.4) 9 (0.5) 19 (0.4)
Time from waking to first cigarette, n (%)
< 5 minutes 568 (21.6) 414 (23.7) 982 (22.4)
6–30 minutes 1186 (45.0) 802 (45.9) 1988 (45.4)
31–60 minutes 436 (16.6) 246 (14.1) 682 (15.6)
1–2 hours 222 (8.4) 152 (8.7) 374 (8.5)
> 2 hours 215 (8.2) 132 (7.6) 347 (7.9)
Missing 8 (0.3) 2 (0.1) 10 (0.2)
Nicotine dependence score (0–6)a
Mean (SD) 2.57 (1.49) 2.67 (1.52) 2.61 (1.51)
Low (score 0–2), n (%) 1094 (41.5) 669 (38.3) 1763 (40.2)
Medium (score 3), n (%) 850 (32.3) 581 (33.2) 1431 (32.7)
High (score 4–6), n (%) 673 (25.5) 487 (27.9) 1160 (26.5)
Missing, n (%) 18 (0.7) 11 (0.6) 29 (0.7)
Age started smoking (years)
Mean (SD) 16.5 (4.5) 16.5 (4.6) 16.5 (4.5)
Range 6–55 1–51 1–55
Missing (%) 12 7 19
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TABLE 4 Participant characteristics at baseline (continued )
Characteristic
Group
Total (N= 4383)
Intervention
(N= 2635; 60.1%)
Control
(N= 1748; 39.9%)
Intention and motivation to quit
When planning to quit, n (%)
In next 2 weeks 481 (18.3) 315 (18.0) 796 (18.2)
Next 30 days 606 (23.0) 380 (21.7) 986 (22.5)
Next 6 months 1103 (41.9) 759 (43.4) 1862 (42.5)
Not in the next 6 months 333 (12.6) 218 (12.5) 551 (12.6)
Missing 112 (4.3) 76. (4.4) 188 (4.3)
Longest previous quit attempt, n (%)
< 24 hours 243 (9.2) 172 (9.8) 415 (9.5)
1–6 days 474 (17.9) 286 (16.4) 760 (17.3)
1–4 weeks 436 (16.6) 282 (16.2) 718 (16.4)
> 1 month 1454 (55.2) 986 (56.4) 2440 (55.7)
Missing 28 (1.1) 22 (1.3) 50 (1.1)
Previously attended SSS, n (%)
No 1763 (66.9) 1135 (64.9) 2898 (66.1)
Yes 872 (33.1) 613 (35.1) 1485 (33.9)
‘How much do you want to quit?’ (1 = not at all, 5 = extremely)
Mean score (SD) 3.74 (0.91) 3.79 (0.90) 3.76 (0.91)
Not at all, n (%) 14 (0.5) 7 (0.4) 21 (0.5)
A little, n (%) 235 (8.9) 152 (8.7) 387 (8.8)
Moderately, n (%) 714 (27.1) 429 (24.5) 1143 (26.1)
Very much, n (%) 1117 (42.4) 759 (43.4) 1876 (42.8)
Extremely, n (%) 549 (20.8) 393 (22.5) 942 (21.5)
Missing, n (%) 6 (0.2) 8 (0.5) 14 (0.3)
‘How determined are you to quit?’ (1 = not at all, 5= extremely)
Mean score (SD) 3.74 (0.93) 3.75 (0.93) 3.74 (0.93)
Not at all, n (%) 26 (1.0) 19 (1.1) 45 (1.0)
A little, n (%) 228 (8.7) 160 (9.2) 388 (8.9)
Moderately, n (%) 739 (28.1) 435 (24.9) 1174 (26.8)
Very much, n (%) 1047 (39.7) 736 (42.1) 1783 (40.7)
Extremely, n (%) 588 (22.3) 383 (21.9) 971 (22.2)
Missing, n (%) 7 (0.3) 15 (0.9) 22 (0.5)
‘How confident are you that you can quit?’ (1= not at all, 5= extremely)
Mean score (SD) 2.73 (1.07) 2.69 (1.06) 2.71 (1.07)
Not at all, n (%) 362 (13.7) 248 (14.2) 610 (13.9)
A little, n (%) 704 (26.7) 480 (27.5) 1184 (27.0)
continued
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The sample was 50.9% male and had a mean age of 49.3 years; 54.5% lived with a spouse or partner
and 95.6% were of a white ethnic background. Half of the sample (50.7%) were living in areas of high
deprivation, defined as IMD quintiles 4 and 5, and 32% of the sample were living in a household with
another smoker. In terms of nicotine dependence, approximately one-quarter were highly dependent;
however, a high proportion fell into the low-dependence category, probably accounted for by the
non-daily smokers (7.8%), who were not excluded from this study. The mean age at which participants
started to smoke was 16.5 years. Regarding intention to quit and motivation, 42.5% were planning to quit
some time in the next 6 months, 55.7% had previously quit for > 1 month and 33.9% had previously
attended the SSS (but not in the previous 12 months). Motivation and determination to quit were relatively
high (mean 3.76 and 3.74, respectively, scored on a 1–5 scale), but confidence in this ability to quit was
lower (mean 2.71). Although 74.1% reported having no health problems linked to smoking, 45.7% were
recorded as having at least one QOF disease.
TABLE 4 Participant characteristics at baseline (continued )
Characteristic
Group
Total (N= 4383)
Intervention
(N= 2635; 60.1%)
Control
(N= 1748; 39.9%)
Moderately, n (%) 1024 (38.9) 680 (38.9) 1704 (38.9)
Very much, n (%) 372 (14.1) 229 (13.1) 601 (13.7)
Extremely, n (%) 169 (6.4) 105 (6.0) 274 (6.3)
Missing, n (%) 4 (0.2) 6 (0.3) 10 (0.2)
Health
Health problems (self-reported), n (%)
No 1969 (74.7) 1280 (73.2) 3249 (74.1)
Yes 592 (22.5) 424 (24.3) 1016 (23.2)
Missing 74 (2.8) 44 (2.5) 118 (2.7)
Health problems (number of QOF diseases recorded), n (%)
0 1422 (54.0) 957 (54.8) 2379 (54.3)
1 758 (28.8) 459 (26.3) 1217 (27.8)
2 313 (11.9) 222 (12.7) 535 (12.2)
3 106 (4.0) 75 (4.3) 181 (4.1)
4 29 (1.1) 25 (1.4) 54 (1.2)
5 5 (0.2) 7 (0.4) 12 (0.3)
6 1 (0.04) 3 (0.2) 4 (0.1)
7 1 (0.04) 0 (0.0) 1 (0.02)
Pregnant 2 (0.1) 9 (0.5) 11 (0.3)
HRT 35 (1.3) 19 (1.1) 54 (1.2)
Contraceptive pill 124 (4.7) 76 (4.4) 200 (4.6)
A Level, Advanced Level; CSE, Certificate of Secondary Education; GSCE, General Certificate of Secondary Education;
HRT, hormone replacement therapy; O Level, Ordinary Level.
a Dependence score was computed from the number of cigarettes per day and time from waking to first cigarette, and is
a score between 0 and 6, categorised as low (0–2), medium (3) and high (4–6).
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Characteristics associated with study attrition
There were differences between those who completed the follow-up interview, either by telephone or by
post, and those who did not complete. Participants who did not complete were younger (mean age 45.2
years vs. 50.5 years; p < 0.001), more likely to be living in a highly deprived area [IMD quintile 5 (27.7%)
vs. IMD quintile 1 (16.4%); p < 0.001] and were more likely to be single (30.1% vs. 20.6%; p < 0.001).
Non-completers had a higher dependence score (mean score 2.73 vs. 2.57; p = 0.004), were more likely to
have not previously quit for > 24 hours [longest quit attempt < 24 hours (29.6%) vs. > 1 month (21.7%);
p = 0.003] and were more likely to intend to quit in the next 2 weeks than to intend to quit in the next
6 months (28% vs. 19.2%, respectively; p = 0.001). Non-completers also scored higher on wanting and
determination to quit (3.86 vs. 3.73 and 3.85 vs. 3.71, respectively; both p < 0.001) and were more
confident in their ability to quit (2.79 vs. 2.69; p = 0.005). Participants who completed the follow-up were
more likely to have previously attended the SSS (20% vs. 24.6%; p = 0.001). Completion was not related
to self-reported or recorded health status (Table 5).
External validity
Anonymised data of patients who were invited to participate in the study but did not accept were
compared with the data of the participants to explore whether or not the sample was representative of
the whole population of smokers. Numbers in the anonymised data set are higher than those stated in
Figure 6 because of errors in the initial search identifying smokers, leading to a difference in the electronic
anonymised data retrieved from practices.
Overall, differences were found between participants and non-participants in gender, age and deprivation
(Table 6). Males were under represented in the sample (50.9% vs. 54.3%); however, the difference was
small, and may only be significant as a result of the large sample size. The difference was more pronounced
in some SSSs than others (Figure 7). Participants were significantly older than non-participants (mean age
49.3 years vs. 43.3 years) and this was reproduced consistently in each SSS. The IMD score was significantly
different between participants and non-participants, but the difference was small (1.18); however, there was
large variation in IMD scores between individual SSSs. In areas where the population had higher IMD scores,
for example Derby SSS and Durham and Darlington SSS, the mean IMD score of participants was lower than
that of non-participants, whereas in areas of lower deprivation (Buckinghamshire and Swindon SSSs) the
sample recruited tended to be more deprived than the average (Figure 8).
Overall, although the sample is consistently older than the average smoker in all areas, in terms of gender
and IMD score the differences are small; therefore, we can probably consider the sample to be
representative and have reasonable external validity.
Outcomes
Primary outcome
The proportion of people entering the smoking cessation service (i.e. attending the first session of a 6-week
course) over a period of 6 months from the receipt of the invitation letter, as measured by records of
attendance at the SSSs, was significantly higher in the intervention group than in the control group
(17.4% vs. 9.0%; unadjusted OR 2.12, 95% CI 1.75 to 2.57; p < 0.001) (Table 7).
Secondary outcomes
The main secondary outcome of 7-day point prevalent abstinence at the 6-month follow-up, validated by
salivary cotinine, was significantly higher in the intervention than in the control group (9.0% vs. 5.6%;
unadjusted OR 1.68, 95% CI 1.32 to 2.15; p < 0.001). All other periods of abstinence measured by
self-report (24-hour and 7-day point prevalent abstinence, 1- and 3-month prolonged abstinence),
3-month-validated prolonged abstinence and the number completing the 6-week SSS course were
significantly higher in the intervention group than in the control group (see Table 7).
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There was a slight reduction in daily cigarette consumption in those continuing to smoke in both the
intervention and the control groups, and the proportion of these who had made a quit attempt
(approximately one-quarter) was similar in both groups. Intention and motivation to quit changed little
in these continuing smokers, and there was no difference between the groups (Table 8).
TABLE 5 Participant characteristics associated with study attrition
Characteristic
Follow-up
p-value
Completed
(N= 3354; 76.9%)
Not completed
(N= 1005; 23.1%)
Age (years)
Mean (SD) 50.51 (13.75) 45.28 (15.29) < 0.001
Deprivation (IMD score), n (%)
Quintile 1 459 (83.6) 90 (16.4) < 0.001
Quintile 2 493 (79.3) 129 (20.7)
Quintile 3 742 (76.8) 224 (23.2)
Quintile 4 872 (77.2) 258 (22.8)
Quintile 5 787 (72.3) 302 (27.7)
Marital status, n (%)
Single 774 (69.9) 334 (30.1) < 0.001
Not single 2580 (79.4) 671 (20.6)
Mean nicotine dependence score (0–6)
Mean (SD) 2.57(1.49) 2.73 (1.54) 0.004
Longest previous quit attempt, n (%)
< 24 hours 292 (70.4) 123 (29.6) 0.003
1–6 days 572 (75.3) 188 (24.7)
1–4 weeks 557 (77.6) 161 (22.4)
> 1 month 1911 (78.3) 529 (21.7)
When planning to quit, n (%)
In next 2 weeks 573 (72) 223 (28) 0.001
Next 30 days 755 (76.6) 231 (23.4)
Next 6 months 414 (77.8) 1448 (22.2)
Not in next 6 months 445 (80.8) 106 (19.2)
Previously attended SSS, n (%)
No 2184 (75.4) 714 (24.6) 0.001
Yes 1188 (80.0) 297 (20.0)
‘How much do you want to quit?’ (1–5)
Mean (SD) 3.73 (0.9) 3.86 (0.91) < 0.001
‘How determined are you to quit?’ (1–5)
Mean (SD) 3.71 (0.94) 3.85 (0.93) < 0.001
‘How confident are you that you can quit?’ (1–5)
Mean (SD) 2.69 (1.06) 2.79 (1.09) 0.005
Source: reproduced from Gilbert et al.45 © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the
CC BY license.
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FIGURE 7 Percentage male participants and non-participants by SSS area.
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FIGURE 8 The IMD scores of participants and non-participants by SSS area.
TABLE 6 Comparison of demographic characteristics of participants and non-participants
Characteristic
Participants
(n= 4383)
Non-participants
(n= 106,451)
Absolute difference
(95% CI) p-value
Male, n (%) 2231 (50.9) 56,046 (52.65) 1.7 (–3.3 to –0.2) < 0.001
Missing 0 (0) 3212 (3.0)
Mean age (years), mean (SD) 49.31 (14.29) 43.29 (15.92) 6.01 (5.53 to 6.49) < 0.001
Missing 0 983 (0.9)
IMD score, mean (SD) 24.28 (14.21) 25.46 (14.63) –1.18 (–1.63 to –0.74) < 0.001
Missing 27 (0.03) 3561 (3.4)
Source: adapted from Gilbert et al.45 © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the
CC BY license.
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Subgroup analyses
Subgroups
Table 9 shows subgroup interactions in outcomes.
The effect of the intervention on attendance at the SSS was greater for males (19% vs. 8%; OR 2.70,
95% CI 2.04 to 3.57) than for females (15.7 vs. 10.1%; OR 1.67, 95% CI 1.28 to 2.19), and the
interaction term was significant (p-for-interaction = 0.01). There was also a differential effect for males and
females for validated 7-day point prevalent abstinence (p-for-interaction = 0.01). The intervention was
more effective for males (OR 2.37, 95% CI 1.63 to 3.42) than for females (OR 1.23, 95% CI 0.88 to 1.72).
Although attendance at the SSS in the intervention group was similar in all IMD quintiles, it was lower in
the control group for participants in quintiles 2–4 (medium deprivation) than for those in quintiles 1 or 5,
thus the differential was significantly greater (p-for-interaction = 0.001). Abstinence was lower overall in
the higher-deprivation groups, but with no significant interaction. There were no significant interactions by
age category. Both attendance and abstinence increased with age in both groups.
Effect of repeat reminders
We also explored any effect on the uptake of service of sending repeat reminders to smokers approximately
9–15 weeks (63–105 days) after randomisation. Mean time in days from randomisation to attendance in valid
cases (i.e. dates reported by SSSs falling within the 6-month time frame) was 47.35 days (SD 37.91 days) in
the intervention group and 55.99 days (SD 49.01 days) in the control group. The most frequent time for
attendance in the intervention group was between 19 and 29 days (mode 21 days), with no noticeable
increase between 63 and 105 days. In the control group, multiple modes were 15, 40 and 62 days, but there
was no clear pattern in the peaks (Figure 9).
Seasonal variation
To assess any seasonal variation in attendance and any differences between the groups, we examined
attendance by quarter and by group. Attendance was significantly higher overall in earlier months (17.4%
in January to March vs. 11.4% in October to December; p < 0.001), but the relative effect between groups
was not significantly different (Table 10).
Variation in outcome by Stop Smoking Service
To assess any variation in the outcome by SSS we examined attendance and 7-day-validated abstinence in
each SSS area by treatment group. Overall attendance at the SSSs varied from 2.1% to 23.1%, and
attendance varied from 3.3% to 28.3% in the intervention group and from 0% to 16.7% in the control
group. In all SSSs, the number attending was higher in the intervention group than in the control group
TABLE 8 Self-reported changes in daily cigarette consumption, quit attempts, and changes in motivation and
intention to quit in continuing smokers
Self-reported change
Group
Total (N= 3737)Intervention (N= 2190) Control (N= 1547)
Mean change in daily cigarette consumption (SD) –2.6 (6.4) –2.7 (6.7) –2.6 (6.5)
Made a quit attempt, n (%) 528 (24.1) 359 (23.2) 887 (23.7)
Changes in motivation and intention, mean (SD)
Mean change in intention to quit (3 to –3) –0.28 (1.11) –0.28 (1.07) –0.28 (1.1)
Mean change in ‘want to quit’ (4 to –4) 0.05 (1.11) 0.04 (1.08) 0.05 (1.08)
Mean change in ‘determined to quit’ (4 to –4) –0.01 (1.24) 0.04 (1.25) 0.01 (1.24)
Mean change in ‘confident can quit’ (4 to –4) 0.10 (1.31) –0.02 (1.22) 0.05 (1.27)
Source: adapted from Gilbert et al.45 © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the
CC BY license.
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(Figure 10). The ICC for the overall attendance was 0.031 (95% CI 0.01 to 0.09), suggesting that around
3% of participants’ tendency to attend the SSS was explained by the SSS in which they were located.
The proportion of participants achieving validated 7-day abstinence varied from 2.1% to 13.4% overall, and
from 3.3% to 16% and from 0% to 10.5% in the intervention and control groups, respectively (Figure 11).
The ICC for 7-day abstinence was 0.034 (95% CI 0.011 to 0.096), again suggesting that around 3% of
participants’ tendency to quit smoking was explained by the SSS in which they were located.
TABLE 9 Interactions in outcomes 6 months after date of randomisation
Outcome
Group, n (%)
OR (95% CI)
p-for-
interaction
Number of
participants
in stratum
Intervention
(N= 2635)
Control
(N= 1748)
Attendance at SSS
Interaction with gender (stratified analysis) 0.01 4383
Male 255 (19.0) 71 (8.0) 2.70 (2.04 to 3.57) 2231
Female 203 (15.7) 87 (10.1) 1.67 (1.28 to 2.19) 2152
Interaction with age (years) (stratified
analysis)
0.65 4383
16–40 77 (11.6) 31 (7.2) 1.69 (1.09 to 2.63) 1095
40–64 283 (18.0) 92 (8.9) 2.28 (1.78 to 2.94) 2616
≥ 65 98 (24.8) 35 (12.6) 2.33 (1.52 to 3.57) 672
Interaction with deprivation (stratified
analysis)
0.001 4383
IMD quintile 1 58 (17.4) 22 (10.2) 1.85 (1.09 to 3.14) 549
IMD quintile 2 70 (18.5) 19 (7.8) 2.65 (1.55 to 4.54) 622
IMD quintile 3 106 (18.5) 17 (4.3) 5.00 (2.94 to 8.49) 966
IMD quintile 4 113 (16.7) 47 (10.4) 1.76 (1.22 to 2.54) 1130
IMD quintile 5 109 (16.7) 53 (12.2) 1.46 (1.02 to 2.07) 1089
7-day point prevalent abstinence (validated)
Interaction with gender (stratified analysis) 0.01 4383
Male 131(9.7) 39 (4.4) 2.37 (1.63 to 3.42) 2231
Female 105 (8.1) 58 (6.7) 1.23 (0.88 to 1.72) 2152
Interaction with age (years) (stratified
analysis)
0.72 4383
16–40 years 46 (6.9) 21 (4.9) 1.47 (0.86 to 2.50) 1095
40–64 years 150 (9.5) 57 (5.5) 1.83 (1.33 to 2.51) 2616
≥ 65 years 40 (10.1) 19 (6.9) 1.53 (0.87 to 2.70) 672
Interaction with deprivation (stratified
analysis)
0.68 4383
IMD quintile 1 34 (10.2) 15 (7.0) 1.51 (0.80 to 2.85) 549
IMD quintile 2 44 (11.6) 18 (7.4) 1.63 (0.91 to 2.90) 622
IMD quintile 3 60 (10.5) 23 (5.9) 1.92 (1.16 to 3.18) 966
IMD quintile 4 58 (8.6) 19 (4.2) 2.14 (1.26 to 3.64) 1130
IMD quintile 5 39 (6.0) 22 (5.0) 1.18 (0.69 to 2.03) 1089
Source: adapted from Gilbert et al.45 © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the
CC BY license.
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FIGURE 10 Percentage of participants attending SSSs by treatment group and by SSS.
TABLE 10 Attendance at the SSS by season of recruitment
Season of recruitment
Group, n (%)
Total, n (%)Intervention Control
January–March 159 (21) 61 (12.1) 220 (17.4)
April–June 133 (16.9) 41 (7.7) 174 (13.2)
July–September 79 (17.9) 21 (7.3) 100 (13.7)
October–December 87 (13.4) 35 (8.3) 122 (11.4)
Total 458 (17.4) 158 (9) 616 (14.1)
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FIGURE 11 Percentage of all participants with validated 7-day abstinence by treatment group and by SSS.
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Chapter 4 Process evaluation and subsidiary
analysis
The intervention developed and employed in the Start2quit study was a complex one consisting ofa personal risk letter and an invitation to a taster session provided by the local SSS. In complex
interventions such as this, the elements act both on their own and in conjunction with each other. It is
therefore important to try to understand the range of effects and to examine the data to determine the
active components, and identify the causal mechanisms through which treatment operates.60 Process data
are the sum of all data collected to document the conduct of the study61 and can be used to explore the
way in which the intervention was implemented and the acceptability and feasibility of the intervention,
and can also provide insight into the way the ingredients of the intervention facilitate the outcome.
In this chapter we report on process evaluations that were embedded into the trial, including a descriptive
analysis of adherence to the intervention and its association with outcomes, data collected to evaluate and
assess how acceptable and appropriate participants found the intervention, and an assessment of the
fidelity to the protocol of delivery of the taster sessions. We also report on reasons for non-attendance in
an additional study exploring barriers to attendance at the SSS.
A more detailed analysis is planned to examine the moderators and mediators of the intervention effect,
and the relationships between the various components of the intervention and the outcome in an attempt
to explore the active ingredients of the intervention and how they exert their effect. However, it is not
possible to report a full assessment of intervention processes within the constraints of the HTA-funded
research. These will be examined in more detail in future outputs.
Conduct of and adherence to the intervention, association with
outcomes and self-reported attendance
Background
Adherence can be defined as the degree to which behaviour coincides with the recommendations of
health-care providers.62 In trials this can be applied to the intervention as a recommended strategy and
accurate measurement of adherence behaviour is necessary to be able to assess whether or not the
outcomes can be attributed to the recommended strategy. Any decisions or recommendations based on
the outcome depend on valid and reliable measurement of adherence to the treatment,63 and inadequate
adherence can adversely impact the effectiveness of an intervention.
One component of this intervention consisted of the opportunity to gain more information about the SSS
and what it involves at a no-commitment taster session. This session was part of the strategy to encourage
attendance at SSSs and, therefore, attendance at the session was hypothesised to be a major influence on
the decision to attend the SSS. Not all participants took up the offer of a taster session. In order to assess
the impact of the taster sessions on the primary outcome of the study, details of the provision and
attendance at the taster sessions are reported. In addition to the original primary outcome (attendance at
the SSS), the trial was powered to assess 7-day point prevalent abstinence at the 6-month follow-up,
validated by salivary cotinine analysis. This allowed assessment of whether or not this intervention, and
subsequent attendance at the SSS, also translated to increased quit rates. Thus, the first aim of this part of
the analysis was to examine the flow of participants from attendance at the taster session, through
attendance at the SSS, to achieving validated 7-day abstinence, and the associations between attendance
and abstinence.
One approach to measuring adherence behaviour is to ask participants for their subjective ratings of
attendance. However, literature on adherence to both medical and behavioural regimes has shown that
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the subjective reports of patients are problematic. Inaccuracies can result and adherence can be either
over- or underestimated.63 More reliable objective strategies were used in this study to measure attendance
both at the taster session and at the SSS. However, self-reported adherence can be revealing, and the
second aim of this section was to describe the self-reported attendance, and the amount of agreement
and disagreement with the objective measures of attendance.
Methods
Measures
Full details of taster sessions held in each area were documented. Local advisors delivering the session
were provided with a list of participants invited to each session, and participants were asked to sign in
on arrival. The number attending the taster sessions was taken from these records. Attendance at the
SSS was the primary outcome measure and was the valid data of attendance collected from the SSSs.
The main secondary outcome of 7-day biochemically validated abstinence was used to define abstinence.
Self-reported attendance at the taster sessions and at the SSS were included in the follow-up interview
6 months after the date of randomisation.
Respondents were asked ‘Do you remember receiving an invitation from your GP to attend a “Come and
Try it” taster session to introduce you to the Stop Smoking Service?’. If they did remember, they were asked
‘Did you attend a “Come and Try it” taster session?’. Regarding attendance at the SSS, all respondents
were asked ‘In the last 6 months have you tried to make an appointment with the NHS Stop Smoking
Service?’. Respondents answering ‘yes’ to this question were then asked ‘Were you successful in making
an appointment with the Stop Smoking Service?’, and if they answered ‘yes’ to this they were asked ‘How
many times in the last 6 months have you attended any appointments with the Stop Smoking Service?’.
Respondents who reported attending were also asked ‘How helpful was attending the Stop Smoking
Service to you in quitting or attempting to quit smoking?’. Respondents who completed the basic questions
were asked only one question ‘Have you attended any appointments with the NHS Stop Smoking Service in
the last 6 months?’. (See Appendix 4 for full follow-up questionnaires.)
Participants
Data from records of attendance include data from all participants. Analysis of the self-reported data
includes data from those participants who completed the follow-up in any form (i.e. by telephone, post or
by answering the basic questions) (Table 11).
Analysis
Frequencies and proportions of participants attending the taster sessions, attending the SSS and achieving
validated 7-day point prevalent abstinence were calculated. A rudimentary analysis using a series of
chi-squared tests examined the differences in abstinence between the groups according to their
attendance at the taster session and at the SSS.
TABLE 11 Number of participants completing the follow-up questionnaire
Method of Completion
Group, n (%)
Total, n (%)Intervention Control
Telephone interview 1740 (66.0) 1170 (66.9) 2910 (66.4)
Postal questionnaire 175 (6.6) 127 (7.3) 302 (6.9)
Basic questions 105 (4.0) 55 (3.1) 160 (3.7)
Total 2020 (76.7) 1352 (77.3) 3372 (76.9)
Source: reproduced from Gilbert et al.45 © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the
CC BY license.
PROCESS EVALUATION AND SUBSIDIARY ANALYSIS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
42
Results
Taster session organisation
A total of 146 taster sessions were organised across the 18 SSS areas, between 4 and 12 in each
area depending on the number of participants recruited and the area covered by the SSS. Of these,
106 sessions were first sessions, offered immediately after the first intervention mailing, and 40 were
follow-up sessions to which all participants who had not attended one of the first sessions were invited.
Of the 146 planned sessions, 131 went ahead, but 15 were cancelled because of low or no attendance.
The mean number of participants invited to an initial session was 24.4 (range 2–78) and to the follow-up
session was 49.62 (range 7–168) participants. The numbers varied according to the area covered and the
number recruited. Because this varied widely, and some areas were widespread, few people were invited to
some sessions. Higher numbers were invited to the follow-up sessions because it was found in the pilot
phase that numbers attending the follow-up session were low. Attendance at sessions that went ahead was
between 1 and 19 (mean 5.64) participants.
Taster session and Stop Smoking Service attendance and smoking status outcome
Of the 2635 participants in the intervention group invited to attend a taster session, 739 (28%) attended.
In the intervention group more participants who had attended a taster session attended the SSS than those
who had not (45.7% vs. 6.3%), and more participants who attended a taster session and the SSS achieved
7-day abstinence (28.7%) than those who only attended the taster session (10%) or only attended the
SSS (17.5%). Participants who did not attend a taster session nor the SSS had the lowest rates of validated
7-day abstinence (4.4% and 4.7% in the intervention and control groups, respectively) (Figure 12).
Self-reported attendance data
In the intervention group, 1387 (68.6%) participants said that they remembered receiving an invitation to a
taster session and 468 (23.2%) reported attending. In addition, 259 (19.2%) participants from the control
group also said that they remembered receiving an invitation and 16 (1.2%) said that they attended.
Overall, 1067 (31.6%) respondents reported that they had tried to make an appointment with the SSS:
773 (38.3%) in the intervention group and 294 (21.8%) in the control group. One-quarter of participants
(881, 26.1%) reported that they were successful in making an appointment [643 (31.8%) and 238
(17.6%) in the intervention and control groups, respectively] and 820 reported attending the SSS at least
once [592 (29.3%) and 228 (16.9%) in the intervention and control groups, respectively] (Table 12). The
largest proportion (22.6%) said they attended only once, but one person reported attending up to
48 times.
Self-reported attendance at taster sessions or at the SSS did not correspond to the recorded attendance
and validated attendance data from the records of the participating SSSs.
Of the 468 intervention participants who reported attending a taster session, 16 were not recorded as
attending, whereas 12 were recorded as attending but did not recall attendance (Table 13). Furthermore,
16 participants in the control group said that they had attended a taster session. Of all participants who
completed the follow-up and reported attending the SSS, 429 (intervention, n = 328; control, n = 101)
were validated by SSS records, 89 (intervention, n = 66; control, n = 23) did not report attending but
according to SSS records did attend and a further 391 (intervention, n = 264; control, n = 127) said that
they attended but their attendance was not validated by records (Table 14). Agreement on taster session
attendance was much higher at 98% than for attendance at the SSS. Agreement on attendance at the SSS
was slightly higher in the control group than in the intervention group (88.9% vs. 83.6%).
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Respondents who reported attending were asked ‘How helpful was attending the Stop Smoking Service
to you in quitting or attempting to quit smoking?’ and 309 (73.9% of those whose attendance was
validated) rated attending the service as very or extremely helpful on a scale of 1 to 5 (mean 4.09).
Summary
The opportunity to find out more about the SSS by attending a taster session was taken up by less
than one-third of participants. The large difference of 40% in SSS attendance between attendees and
non-attendees at taster sessions suggests that the session was successful in encouraging uptake of the
service, although it is possible that the more motivated smokers were more likely to attend the taster
session and also more likely to attend the SSS.
TABLE 13 Agreement and disagreement between self-reported and validated attendance at a taster session in
participants who completed the 6-month follow-up and remembered receiving an invitation to the taster session
(intervention group only n= 1387)
Recorded attendance n (%)
Attended Did not attend
Self-reported attendance n (%) Reported attending 452 (32.6) 16 (1.2)
Did not report attending 12 (0.8) 907 (65.4)
TABLE 12 Self-reported attendance in participants completing the 6-month follow-up
Self-reported attendance
Group, n (%)
Total, n (%) (N= 3372)Intervention (n= 2020) Control (n= 1352)
Remembered invitation to taster session 1387 (68.6) 259 (19.2)
Attended a taster session 468 (23.2) 16 (1.2)
Tried to make appointment with SSS 773 (38.3) 294 (21.8) 1067 (31.6)
Successfully made appointment with SSS 643 (31.8) 238 (17.6) 881 (26.1)
Attended SSS at least once 592 (29.3) 228 (16.9) 820 (24.3)
TABLE 14 Agreement and disagreement between self-reported and validated attendance at the SSS in participants
completing the 6-month follow-up in intervention and control groups
Intervention group (N= 2020) Attendance validated by records n (%)
Attended Did not attend
Self-reported attendance n (%) Reported attending at least once 328 (16.2) 264 (13.1)
Did not report attending 66 (3.3) 1362 (67.4)
Control group (N= 1352) Attendance validated by records n (%)
Attended Did not attend
Self-reported attendance n (%) Reported attending at least once 101 (7.5) 127 (9.4)
DOI: 10.3310/hta21030 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 3
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Gilbert et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
45
Participants in both the intervention and control groups were more likely to be abstinent if they had
attended the SSS. This increase in the proportion abstinent suggests that attending the SSS is more likely
to result in abstinence than quitting alone, and confirms the consistent evidence that individual counselling
increases the likelihood of cessation.64,65 Participants who received the intervention and attended the SSS
were most likely to be abstinent, whereas participants who received the intervention but did not attend
the SSS were not more likely to quit than those in the control group who had not attended the SSS.
Attending either the taster session or the SSS (i.e. having some contact with the support services or an
advisor) was beneficial, although clearly attending the SSS was most beneficial, and the abstinence figures
for the intervention group suggest a possible added benefit of receiving a personal risk letter.
The self-reported SSS attendance figures reflect the effectiveness of the intervention. However, the
discrepancy between self-reported attendance at the SSS and the objective measures confirmed the
inadequacy of subjective measurement data. Recall or retrospective bias can account for some of this
discrepancy, but there is also an issue of interpretation or misunderstanding. Although every effort was
made to word the questions clearly, there may have been a lack of differentiation in the minds of the
respondents between the taster session and the SSS course, which could account for the slightly better
agreement in the control group than in the intervention group. Alternatively, participants may have
received advice from elsewhere and not have signed up to a SSS course. In addition, social desirability,
the desire to give the impression of compliance, could explain some of the discrepancy. Overall, this
demonstrates the importance of collecting objective data, when possible.
Perception of the intervention
Background
Thorough evaluation of an intervention should include an assessment of how acceptable and appropriate
participants found the intervention. Participant satisfaction is an important determinant of the potential
impact, as it is associated with adherence to the recommended advice and compliance to medical regimes
in primary health care.66,67 This is particularly important when evaluating personal health communication.
The superiority of tailored health communications depends on how well received the material was by the
target population.68 Furthermore, assessing the perception of the tailored letter used in this study is crucial
because of the use of personal information related to diseases. Issues related to health typically tend to
be anxiety-laden and associated with negative rather than positive feelings,69 and a fear-driven appeal
message presenting individuals with information about themselves can prompt a maladaptive behavioural
response by, for example, denying the truth or personal relevance of the threat.32
The focus of this section is to evaluate the perception of both the personal risk letters and of the taster
session, assessed using measures from previous trials of tailored feedback,70,71 and included in the
telephone interview at the 6-month follow–up, using both closed and open questions. Perception of the
taster session was also assessed by an evaluation form completed immediately following each session.
Methods
Measures
Respondents to the telephone interview were asked if they remembered receiving a letter from their GP
about the NHS SSSs. Those who did remember were asked if they had read the letter and if they had
discussed the letter with others. They were then asked a series of questions about their views of the letter
and how it made them feel, measured using a five-point Likert scale (1 = not at all, 5 = extremely). A series of
similar questions was asked about the taster session of those respondents who reported attending a session.
In a combination of closed and open questions, respondents who self-reported having attended the SSS
or having quit were asked to what they attributed their decision to attend the SSS and to what they
attributed their decision to quit.
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Respondents who said they remembered a letter were asked ‘Did you make the appointment with the
Stop Smoking Service as a result of receiving this letter or was it something else?’. Participants who
remembered the letter and said they attended a taster session were also asked the question ‘Did you
make the appointment with the Stop Smoking Service as a result of attending this “Come and Try it”
taster session or was it something else?’. Regarding the decision to quit, all respondents replying ‘not at
all’ to the question ‘(How often) do you currently smoke cigarettes or rollups?’ were asked if they had quit
as a result of receiving a letter (personal or generic, depending on the group allocation). Respondents who
self-reported having quit and also reported attending a taster session were also asked ‘Have you quit
smoking as a result of attending the taster session?’. In all of these questions, if respondents reported that
making an appointment with the SSS was not as a result of the letter but a result of something else,
interviewers probed for their reason for making the appointment.
Respondents who reported attending a taster session were also asked whether attending the taster session
or receiving the letter was more important in their decision to attend the SSS and, if they reported having
quit, were asked whether attending the taster session or receiving the letter was more important in their
decision to quit smoking. (See Appendix 4 for full follow-up questionnaires.)
The questions also incorporated reasons for attendance and non-attendance at the taster session using
open questions. Respondents who reported attending the taster session were asked in an open question
their reasons for deciding to attend, and respondents who remembered the invitation but did not attend
were asked for their reasons for not attending the taster session.
Participants who said they remembered the invitation but did not attend were asked if they would have
attended the taster session if they had received a text or telephone reminder. A control measure was
included to see whether or not any of the participants had spoken to a taster session attendee.
All taster session attendees were asked to complete an evaluation form immediately following the taster
session. Questions matched those of the follow-up interview and also allowed space for free-text comments.
Participants
The data included in this analysis on the perception of the intervention were from those participants who
completed the telephone interview [total, n = 2910 (66.4%); intervention, n = 1740 (66.0%); control,
n = 1170 (66.9%)].
For the assessment of the taster session and decision to attend the SSS, the analysis includes only those who
were validated as attending the SSS or the taster session. However, for the decision to quit, the self-reported
smoking status was used. This referred to their perceived state at the time of the follow-up, not to their
validated smoking status and, therefore, probably reflects a truer perception of their decision to quit.
Analysis
Proportions and means were calculated to describe the perception of the personal risk letter. Chi-squared
and t-tests were used to compare the perception of the risk letter with that of the generic letter. However,
these results should be interpreted with caution because of the number of comparisons made. For the
perception of the taster session, the proportions endorsing each statement at the 6-month follow-up were
calculated and were compared descriptively with the proportions endorsing each statement on the
evaluation form immediately following each session. The free-text comments in the evaluation forms were
analysed by two of the authors, both thematically and also for content to classify the comments into
positive, negative and neutral categories.
The decision to take action as a result of the intervention and the attribution for these decisions are
described using frequencies and proportions, and comments from probes were content analysed.
Chi-squared tests were used to compare the intervention and control groups on their decisions concerning
the letter. However, these are self-selected subgroups and the results should be interpreted with caution.
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Results
Perception of the personal risk letter
Of those who completed the telephone follow-up, 2605 (89.5%) remembered receiving a letter. The
numbers responding to individual questions on the perception of the letter ranged from 2327 to 2453.
The results are shown in Table 15.
Participants in the intervention group were not more likely than those in the control group to remember
receiving a letter (90.2% vs. 88.5%), but were more likely to read the letter (87.2% vs. 83.5%; p = 0.004)
and to discuss the letter with others (37.6% vs. 29.7%; p = 0.001) (see Table 15). Participants in the
intervention group who received the tailored letter found it to be more personally relevant to them [3.43
vs. 3.22 (on a 1–5 scale); p < 0.001] and reported that it made them feel more confident towards quitting
(3.18 vs. 2.95; p < 0.001), more determined towards quitting (3.36 vs. 3.10; p < 0.001) and made them
feel more optimistic (2.99 vs. 2.83; p = 0.003) than those in the control group who received the standard
letter. They also said that they liked the tone of the letter more than those who had received the standard
letter (3.68 vs. 3.54; p = 0.003).
The personal risk letter was considered to be highly acceptable, with the majority of respondents rating it
very or extremely easy to read [1421 (95.8%)], and very or extremely easy to understand [1440 (96.8%)],
and approximately two-thirds finding it interesting [888 (61.2%)] and useful [960 (66%)]. Very few
respondents reported feeling very or extremely angry [60 (4.1%)], anxious [122 (8.2%)] or depressed
[67 (4.5%)]. The majority reported low ratings of ‘not at all’ or ‘a little’ on these measures, whereas
565 (67%) rated the letter as making them feel at least moderately optimistic.
TABLE 15 Perceptions of the personal risk letter by treatment group
Perception
Group
p-valueIntervention (N= 1740) Control group (N= 1170)
Remembered letter, n (%) 1570 (90.2) 1035 (88.5) 0.138
Read letter, n (%) 1517 (87.2) 977 (83.5) 0.004
Discussed letter, n (%) 654 (37.6) 348 (29.7) < 0.001
Easy to read,a mean (SD) 4.75 (0.57) 4.73 (0.65) 0.255
Easy to understand,a mean (SD) 4.78 (0.53) 4.75 (0.60) 0.196
Written for me,a mean (SD) 3.43 (1.38) 3.22 (1.37) < 0.001
Contained new information,a
mean (SD)
3.12 (1.37) 3.11 (1.36) 0.966
Interesting,a mean (SD) 3.73 (1.17) 3.67 (1.20) 0.227
Useful,a mean (SD) 3.83 (1.28) 3.72 (1.23) 0.038
Felt more confident,a mean (SD) 3.18 (1.42) 2.95 (1.42) < 0.001
Felt more determined,a mean (SD) 3.36 (1.41) 3.10 (1.40) < 0.001
Liked the tone,a mean (SD) 3.68 (1.10) 3.54 (1.14) 0.003
Liked the appearance,a mean (SD) 3.59 (1.12) 3.51 (1.16) 0.075
Angry,a mean (SD) 1.27 (0.81) 1.22 (0.71) 0.147
Anxious,a mean (SD) 1.54 (1.06) 1.46 (0.96) 0.054
Depressed,a mean (SD) 1.31 (0.83) 1.30 (0.82) 0.695
Optimistic,a mean (SD) 2.99 (1.34) 2.83 (1.31) 0.003
a Scored on a scale of 1 to 5.
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Perception of the taster session in the intervention group
Of 1740 participants in the intervention group who completed the telephone interview, 1387 said that they
remembered receiving an invitation to a taster session and 468 reported attending a taster session, although
16 of these were not validated by records. Thus, 452 respondents in the intervention group reported
attending a taster session, were validated by records of attendance and gave their views on the session in
the telephone interview. This analysis is based on these 452 participants. A further 12 participants in the
control group also said that they remembered attending a taster session, but were excluded from the
analysis. The evaluation form was completed by 637 attendees. Some of the respondents completed only
the follow-up or only the evaluation form; approximately two-thirds completed both.
The taster sessions were viewed positively by the majority of attendees. Over 90% of respondents found
the session very or extremely easy to understand, and > 70% found it interesting and useful. Although
91.5% expressed the intention to sign up immediately following the session, at the 6-month follow-up
69.9% reported that the session made them more inclined to make an appointment with the SSS. As
previously noted, validated records show that 338 (45.7%) attended the SSS following attendance at the
taster session. In general, the taster session was rated more highly immediately following the session than
at the 6-month follow-up (Table 16).
Of the 637 attendees who completed the evaluation forms, 528 left comments. The content analysis
overwhelmingly confirmed that the taster sessions were seen as helpful and encouraging, with 91.7%
of the comments being positive, 3% negative and 5.3% neutral. The most common words used to
describe the session were ‘informative’ (used by 99 attendees), ‘interesting’ (by 70 attendees), ‘friendly’
(by 31 attendees) and ‘encouraging’ (by 21 attendees).
Comments suggested that the advisors did not exert any pressure on the attendees to sign up, and the
attendees felt relaxed. For example:
. . . well organised and informative and the first time I have tried ‘group therapy’. I was anxious about
group therapy as giving up but it was all cool and helpful.
Male, 54 years
. . . very welcoming and informal and friendly informative and non-judgmental.
Male, 61 years
TABLE 16 Perception of the taster session (number answering very or extremely on a scale of 1 to 5)
Perception
Evaluation, n (%)
6 months after
taster session (N= 452)
Immediately after
taster session (N= 637)
Taster session was easy to understand 417 (92.3) 610 (95.7)
Taster session contained new information 254 (56.2) 415 (65.2)
Taster session was interesting 334 (73.9) 534 (83.8)
Taster session was useful 329 (72.8) 559 (87.8)
Taster session made me more inclined to make an
appointment (follow-up)
316 (69.9)
Intend to make an appointment (evaluation form) 583 (91.5)
Taster session made me feel more confident 318 (70.4) 410/556 (73.7)
Taster session made me feel more determined 326 (72.1) 441/556 (79.3)
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. . . very good. Without trying to ‘preach’ or exert undue pressure.
Male, 70 years
. . . relaxed atmosphere and ‘no lectures’.
Female, 68 years
Comments also confirmed that some smokers are not aware of the service and what is offered, or how to
go about quitting, illustrated by:
. . . informative and knowing I can discuss my problems with someone has made my decision to try to
quit easier.
Female, 64 years
. . . nice to know that such a service exists.
Male 50 years
. . . quite enlightening.
Female, 68 years
. . . an interesting concept.
Male, 62 years
Other comments suggest that the taster session gave people new information and encouraged them to
look at things in a different way, for example:
. . . puts things into perspective
Male, 52 years
and that the sessions are motivating and encouraging.
. . . time well spent – increasing my determination to quit.
Male, 61 years
Actions as a result of the intervention
Decision to attend the Stop Smoking Service
Three hundred and fifty-three respondents (intervention, n = 273; control, n = 80) who answered the
question ‘Did you make the appointment with the Stop Smoking Service as a result of receiving this letter
or was it something else?’ said that they attended the SSS and were validated by SSS records. Of these,
277 (78.5%) said that they attended because of the letter [224 (82.1%) vs. 53 (66.3%) in the intervention
and control groups, respectively; p = 0.002].
In the intervention group, 258 respondents also said that they attended a taster session and were asked
the question ‘Did you make the appointment with the Stop Smoking Service as a result of attending this
“Come and Try it” taster session or was it something else?’. Of these, 193 (74.8%) said that they made
the appointment because of the letter, 170 (65.9%) because of the taster session and 151 (58.5%)
answered yes to both questions. These participants were also asked whether attending the taster session
or receiving the letter was more important in their decision to attend the SSS: 141 (54.7%) said both
equally, 19 said the taster contributed more and 20 said the letter contributed more (Table 17).
Decision to quit
Six hundred and thirty respondents self-reported having quit and, of the 504 participants who answered
the question ‘Have you quit smoking as a result of receiving this letter?’, 283 (56.2%) replied that they
had [intervention, n = 220 (63%); control, n = 63 (40.7%); p < 0.001].
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Two hundred and twenty-six self-reported having quit, attended a taster session (validated by records) and
were asked ‘Have you quit smoking as a result of attending the taster session?’. Of these, 158 (69.9%)
said that they quit smoking as a result of the letter, 153 (67.7%) said they quit smoking as a result of the
taster session and 131 (58%) answered ‘yes’ to both questions. These participants were also asked
whether attending the taster session or receiving the letter was more important in their decision to quit
smoking: 112 (49.6%) said both were equally important, 32 said the taster session was more important
and 17 said the letter was more important (see Table 17).
Open questions
Interviewers probed the 75 respondents who reported that making an appointment with the SSS was not
as a result of the letter but because of something else, for a reason for making the appointment. The most
frequently given reason concerned health (n = 23, 30.7%). Other frequently given reasons suggested the
respondent wanted to stop anyway and the letter came at the right time to prompt them to make an
appointment (n = 21, 28%), for example ‘I’ve been thinking about it so this was a nudge’ or ‘I was going
to do it anyway’.
Reasons for attendance and non-attendance at the taster session
Comments analysed were limited to those from validated attendees (n = 451). A majority (239, 53%) said
that they attended the taster session because they wanted to quit and saw this as a way of getting help,
although a substantial minority (n = 77, 17.1%) said that they attended out of curiosity and ‘wanted to
see what it was about’.
Of intervention group participants, 907 gave a reason for not attending the taster session. Many said that
they were too busy and had other commitments (n = 367, 40.5%), or that the taster sessions were held at
inconvenient times or locations (n = 221, 24.4%). Some reported that they ‘didn’t really want to quit’ or
that they were ‘not ready for it’, and a small number wanted to quit on their own or ‘do it my way’.
TABLE 17 Decision to attend the SSS and decisions to quit by treatment group
Decision
Group, n (%)
p-valueIntervention Control
Decision to attend the SSS
Completed interview and attendance valid (n = 353)
Made appointment as result of letter 224/273 (82.1) 53/80 (66.3) 0.002
Attended the SSS and taster session (n = 258)
Made appointment as result of letter 193 (74.8)
Made appointment as result of taster 170 (65.9)
Made appointment as result of letter and taster 151 (58.5)
Decision to attend SSS equal letter and taster 141 (54.7)
Decision to quit smoking
Completed interview, said quit smoking and answered the question ‘Have you quit smoking as a result of receiving
this letter?’ (n = 504)
Quit smoking as result of letter 220/349 (63.0) 63/155 (40.7) < 0.001
Quit smoking and attended taster session (n = 226)
Quit smoking as result of letter 158 (69.9)
Quit smoking as result of taster 153 (67.7)
Quit smoking as result of letter and taster 131 (58.0)
Decision to quit equal letter and taster 112 (49.6)
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Some respondents in the control group (n = 243) reported that they remembered getting an invitation and
were therefore also asked this question. Most cited other commitments (n = 72, 29.6%), no desire to quit
(n = 33, 13.6%) or wanting to quit alone (n = 35, 14.4%). However, as these participants did not receive
an invitation to a taster session they would be referring to the service itself not to the taster session.
Supplementary questions
The majority of respondents who said that they remembered the invitation but did not attend (n = 633/902,
70.2%) suggested that a text or telephone reminder would not influence their decision not to attend.
The control measure showed that 14 participants in the intervention group and 30 in the control group
had spoken to a taster session attendee.
Summary
This analysis of the perception of the intervention suggested that both parts were well received by the
target population. The personal letter was well accepted, and participants who received this personal letter
as opposed to the generic letter were more likely to read it and to discuss it with others. They saw it as
personally relevant and it appeared to increase their confidence and determination to quit. With regard to
whether or not the intervention group found that the letter may have caused upset, few respondents
reported feeling very or extremely angry, anxious or depressed.
The taster sessions were also viewed positively by the majority of attendees. However, actual attendance at
the SSS resulting from the session was lower than the stated intention to sign up immediately following
attendance at the taster session. The comments left by attendees immediately after the session also
endorsed the positive view of the sessions, suggested that the taster sessions were reassuring and built the
intended awareness and comfort with the services. They also offered some insight into the reasons smokers
might not attend, such as the fear of criticism and victimisation.
Questions asking respondents to attribute their decision to attend the SSS or to quit might suggest that,
for many smokers, both the letter and the taster session worked in synergy to encourage attendance and
attempting to quit. However, in view of the response rate to these questions and possible problems of
interpretation and recall, there is insufficient evidence to corroborate this conjecture and further research
is necessary.
Additional reasons given for making an appointment with the SSS and for attending the taster session
indicated that smokers who attended were thinking of quitting and were prompted by the communication
to act on their plans. Similarly, reasons for not attending the taster session suggested that quitting was not
a priority and other commitments were more important at this time.
Finally, the additional question included to assess whether or not reminders would encourage attendance
suggested that it would not be worthwhile. The control question did not suggest contamination bias as a
result of a large number of control participants having access to information from the taster sessions.
Assessment of the fidelity of the delivery of the taster sessions
Background
Treatment fidelity refers to the extent to which an intervention that is delivered matches that described in
the intervention manual. Knowing the fidelity compared with the manual is important for interpretation of
results, as without this knowledge it is impossible to determine how much the intervention in question is
the primary mechanism in any changes observed.72
Assessment of the fidelity of delivery in complex behavioural interventions requires authors to report the
content of the intervention, the characteristics of those delivering the intervention, the setting, the length
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and adherence of the delivery to the protocol. However, many studies fail to report the content of the
intervention or the content and duration of training, and a recent systematic review found that few studies
of psychosocial treatments evaluated treatment fidelity.73 For behavioural interventions, in particular,
variation in delivery quality can strongly mediate intervention effectiveness. This failure to account for
fidelity may lead to underestimation of the intervention effects and faulty conclusions that interventions
are not effective, when in reality they were not implemented as intended, or to the acceptance of
statistically effective interventions, which differ greatly from their initial design.72
The use of present/absent checklists has been identified as the most reliable method to monitor the fidelity
of delivery of study interventions.72,74,75 Key to this method is the prespecified intervention content or
‘treatment manual’, a manual containing explicit guidelines about the content and method of delivery of
an intervention to ensure that all providers receive the same training and information. In addition to
identifying the extent of fidelity of delivery, it is also important to understand the ‘essential’ components of
an intervention.76,77 A taxonomy of behaviour change techniques (BCTs) has been developed and modified
to apply to behavioural support for smoking cessation.78
Procedures to assess the fidelity of delivery of the taster sessions were embedded into the trial. We aimed
to answer the following research questions:
(a) To what extent did advisors adhere to protocol-specified content and BCTs?
(b) Were advisor or session characteristics related to adherence to protocol-specified content?
(c) Was adherence to protocol-specified content related to participants’ attendance at the SSS or to
validated 7-day point prevalent abstinence?
Method
Sampling frame
A total of 146 taster sessions were organised across the 18 SSS areas. Of these, 131 went ahead as
planned and 15 were cancelled because of lower than expected attendance rates. Only trained advisors
led the taster sessions, and each session was either run by one advisor with additional administrative
support provided by one other, or the presentation was divided between the two advisors, with one
advisor leading and the other supplementing some of the content. To assess fidelity to the protocol, the
taster sessions were, with the consent of the attendees, audio-recorded.
Of the 131 sessions delivered, 93 (71%) were recorded. The remainder were not recorded because of
forgotten recording equipment, equipment failure or because one or more participants attending the
session declined to consent to the recording. Owing to the quantity and length of the recordings one
session by each lead advisor (when available) was randomly selected (n = 41, 31.3% of sessions delivered)
for transcription and analysis.
To ensure that those selected were representative of the total taster sessions, analysed sessions were
compared with those not analysed for session characteristics and outcome variables. There were no
significant differences in length of sessions, number of attendees or in outcomes (SSS attendance or 7-day
point prevalent abstinence at the 6-month follow-up).
Measures
Adherence measures
The taster session protocol contained 73 specified behaviours (Table 18), all of which were either specific
information that the advisors should communicate (e.g. that the first SSS session involves discussion of
reasons for and against smoking) or instructions that they should follow (e.g. ask attendees how many of
them enjoy smoking). A coding frame was developed by one of the authors based on this protocol, and
this was verified by two additional researchers.
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TABLE 18 Protocol-specified behaviours classified into BCTs
BCTa Description
Component behaviours in taster session manual
(n= 73)
Give information on stop
smoking medication
Explain the benefits of medication,
safety, potential side effects,
contraindications, how to use them
most effectively and how to get
them; advise on the most
appropriate medication for the
smoker and promote effective use
1. Use of medication as important part of quitting
2. Nicotine deprivation may lead to withdrawal
symptoms
3. Medication available to reduce cravings while
adjusting to not smoking
4. How NRT works
5. Types of NRT available
6. Bupropion (Zyban®, GlaxoSmithKline, London, UK)
and varenicline (Champix®, Pfizer, New York, NY,
USA) and how they can help reduce desire to smoke
Boost motivation and
self-efficacy
Give encouragement and bolster
confidence in ability to stop
1. Congratulate attendees on coming to the session
2. Attending session suggests motivation to quit
3. This an important step in process of quitting
4. Positives of this, being something to prepare for
5. Good way of proving that attendees are doing
something good for their health
Build general rapport/
emphasise empathy of SSS
advisors
Establish a positive, friendly and
professional relationship with the
smoker and foster a sense that
the smoker’s experiences are
understood
1. Introduce self and describes personal background
2. Explain understanding of SSS advisors that
smoking is something attendees enjoy
3. Support in event of ‘slip up’
4. SSS can help work out cause of slip up and work
out strategies for avoiding future occurrences
5. Recap: thank attendees for attending
Elicit and answer questions Prompt questions from the smoker
and answer clearly and accurately
1. Ask for questions
Elicit client views Prompt the client to give views on
smoking, smoking cessation and
any aspects of the behavioural
support programme
1. Encourage participation
2. Encourage attendee participation
3. Encourage participation on withdrawal symptoms
Emphasise choice Emphasise client choice within the
bounds of evidence-based practice
1. Making decision in first session after weighing up
pros and cons
2. Emphasise that they will not be told to quit
Explain expectations
regarding treatment
Explain to the smoker the
treatment programme, what it
involves, the active ingredients and
what it requires of the smoker
1. NHS SSS supports smokers to stop smoking
completely, not to cut down
2. First session as preparation for stopping smoking
3. First session involves discussion of reasons for and
against smoking
4. Setting of quit date will be encouraged during first
few sessions
5. Emphasise that weekly contact is extremely
important
6. Explain that this is why weekly contact is so
important
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TABLE 18 Protocol-specified behaviours classified into BCTs (continued )
BCTa Description
Component behaviours in taster session manual
(n= 73)
Explain purpose of CO
monitoring
Explain to the smoker the reasons
for measuring CO at different time
points (e.g. before and after the
quit date)
1. Introduce test for CO present in body
2. Explain its use in NHS courses
3. Mention that it will be possible to compare this
reading with one they have later at NHS SSS after
they quit
Explain the importance of
abrupt cessation
Explain why it is better to stop
abruptly rather than cut down
gradually if at all possible
1. Not a single puff rule and its effectiveness
Give options for support
with the SSS
Give information about options for
additional support when these are
available (e.g. websites, self-help
groups, telephone helpline)
1. How many sessions in a course
2. Courses can be run by Stop Smoking advisor or
practice nurse
3. Minimum number of sessions following quit date
4. Give detail on length of sessions
Identify reasons for
wanting and not wanting
to stop smoking
Help the smoker to arrive at a clear
understanding of his or her feelings
about stopping smoking, why
it is important to stop and any
conflicting motivations
1. Ask attendees how many of them enjoy smoking
2. Identify reasons for wanting and not wanting to
stop smoking
3. Ask attendees why they are considering quitting
smoking
Measure CO Measure CO concentration 1. Offer attendees opportunity to have CO levels
read
2. Encourage all attendees to have reading taken
Provide information on
consequences of smoking
and smoking cessation
Give, or make more salient,
information about the harm caused
by smoking and the benefits of
stopping; distinguish between the
harms from smoking and nicotine;
debunk myths about low tar and
own-roll cigarettes and cutting
down
1. Short-term benefits of quitting
2. Long-term benefits of quitting
3. Explain that CO is a poisonous gas contained in
cigarette smoke
4. Explain nature of toxicity of CO
5. Good news that levels of CO drop very quickly
once they stop smoking
6. Immediately improves circulation and chance of
any related health problems
Provide information on
withdrawal symptoms
Describe to smokers what are,
and are not, nicotine withdrawal
symptoms, how common they are,
how long they typically last, what
causes them and what can be done
to alleviate them
1. Ask attendees for any common withdrawal
symptoms
2. Mention common symptoms if none is suggested
by attendees (e.g. stress/anger/lower concentration/
increased appetite)
3. Emphasise that not everyone will experience these
symptoms
Summarise information/
confirm client decisions
Provide a summary of information
exchanged and establish a clear
confirmation of decisions made and
commitments entered into
1. Recap: mention that there are benefits to quitting
in both long and short term
2. Recap: mention that attending a course will make
it four times more likely that they will have a
successful quit attempt
3. Recap: mention the courses will help develop
strategies to avoid smoking
continued
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The behaviours specified in the coding frame were independently classified by two researchers into
component BCTs using an established taxonomy of 45 smoking cessation BCTs.78 Following discussion
it was decided that most of the protocol-specified behaviours were represented by the 15 BCTs. The
remaining BCTs, detailed in the taxonomy by Michie et al.,78 were not used as they were not applicable to
the taster sessions. In addition, two novel BCTs were developed to account for the remaining behaviours
that did not fit into the existing 45 BCTs proposed by the taxonomy: ‘promote the SSS’ and ‘importance of
behaviour change’. These BCTs accounted for behaviours that were uniquely important to the aims of the
TABLE 18 Protocol-specified behaviours classified into BCTs (continued )
BCTa Description
Component behaviours in taster session manual
(n= 73)
4. Recap: mention they will also receive information
on available medications
5. Recap: remind attendees to complete an
evaluation form and return it to an advisor
6. Recap: emphasise that immediate sign up to a SSS
course is possible
Importance of behaviour
changeb
Detail the role habits play in
smoking and emphasise the help
the SSS can provide in breaking the
associations between smoking and
situational triggers
1. Explain habitual nature of smoking
2. Trigger points
3. Importance of developing strategies to break the
association between these trigger points and
smoking
4. NHS SSS support of behaviour change
5. Emphasise medication not being miracle cure and
behaviour change is also needed
Promote NHS SSSb Detail the success rates of the SSS
and explain how SSS advisors can
help smokers stop smoking and
remain quit in the long term
1. Explain NHS SSS is based on well-researched
evidence
2. Attending a NHS course has been proven to be
the best way to help people quit
3. Services are free
4. Those attending course are four times more likely
to stop and stay stopped than those who try and quit
on their own
5. Remaining sessions are for support
6. Help in developing strategies to avoid smoking is
key aspect of NHS SSS course
7. Able to find out more about NRTs at NHS SSS
8. Advisors can aid in choosing between different
forms of NRT
9. Able to find out more about these medications
from NHS SSS
10. Support available from NHS SSS advisors in this
process
11. Mention potential sign up
12. Show DVD to attendees
a From Michie et al.78
b Novel BCTs not derived from Michie et al.78
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taster sessions, encouraging a commitment to changing behaviour by quitting smoking utilising SSS
support (see Table 18).
Session characteristics
Taster session characteristics included the structure of the session (one advisor or two providing content),
the length of the session and number of attendees.
Advisor characteristics
Advisors completed a short questionnaire at the time of training. Data gathered included gender, age,
highest educational qualification, type of smoking cessation training, time since smoking cessation training,
employer, job title and number of patients seen in the previous 6 months.
Outcome variables
The outcome variables were the proportion of attendees at each session who subsequently attended the
SSS and the proportion of attendees at each session who were found to be validated 7-day point prevalent
abstinent at the 6-month follow-up.
Procedure and analysis
All transcripts were anonymised for SSS area and advisor. Every transcript was coded by two researchers,
with 25% additionally coded by a third. Average inter-rater reliability for coding was 86% (range 68–99%)
across sessions. All disagreements were resolved through discussion between researchers. The data from the
coding frames were double-entered into a spreadsheet and discrepancies were corrected.
The fidelity of each taster session was expressed as the percentage of overall protocol-specified behaviours
that were delivered; that is, the number of protocol-specified behaviours applied by the advisor divided by
the total number of behaviours (e.g. number of behaviours applied by the advisor = 50/total number of
behaviours = 73, fidelity = 68.5%). Adherence to each BCT was measured as the number of behaviours
applied by the advisor within each BCT divided by the total number classified within each.
Mean and median adherence to protocol-specified behaviours was calculated, and medians for each BCT.
t-tests and analysis of variance were used to assess differences in adherence to the protocol by advisor
characteristics and advising structure. Correlations were computed to explore associations between
adherence to protocol-specified behaviours and the length of session, and between adherence and the
main outcome measures of attendance at the SSS and 7-day point prevalent abstinence at the 6-month
follow-up.
Results
Session characteristics
Session duration ranged from 14 minutes to 1 hour 18 minutes (mean 43 hours 4 minutes). Twenty-seven
sessions (65.85%) were facilitated by one lead advisor with minimal administrative support by an additional
advisor and 14 (34.15%) were split between two advisors, with one taking the lead. The number of smokers
attending a session ranged from 1 to 17 (mean 5.41), the number of people attending in 11 of the sessions
was four.
Advisor characteristics
The majority (73.17%) of advisors were female and 51.22% were aged 45–54 years. The majority (73.17%)
were educated to degree level or higher, 41.46% had received smoking cessation training to National
Centre for Smoking Cessation and Training stage 1 and 2 certification with various additional training, and
60.98% had received training within the previous 3 years. All were employed by the SSS, and 70.73% were
employed as SSS advisors. Most (90.24%) had seen ≥ 21 patients in the last 6 months (Table 19).
DOI: 10.3310/hta21030 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 3
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Gilbert et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
57
Adherence
A median of 71.23% (mean 68.53%) of protocol-specified behaviours was delivered across sessions,
ranging from 29% to 96%. As can be seen in Figure 13, low-adherence sessions were not concentrated in
particular SSS areas.
TABLE 19 Characteristics of lead advisors in analysed taster sessions (n= 41)
Characteristic Number of participants (% of total)
Gender
Female 30 (73.17)
Male 11 (26.82)
Age (years)
18–44 12 (29.27)
45–54 21 (51.22)
≥ 55 8 (19.51)
Highest qualification
A Level or lower 11 (26.83)
Degree or higher 30 (73.17)
Smoking cessation training
NCSCT stage 1 certification/plus additional training 8 (19.51)
NCSCT stage 1 and 2 certification or SCTRP 15 (36.59)
NCSCT stage 1 and 2 certification plus additional training 17 (41.46)
Missing 1
Time since stage 2 training (years)
1–3 25 (60.98)
≥ 4 11 (26.83)
Missing 5
Employer
NHS SSS 100 (100)
Job title
SSS advisor 29 (70.73)
SSS manager 4 (9.76)
Healthy lifestyle advisor 2 (4.88)
Administrator 3 (7.32)
Other 1 (2.44)
Missing 2
Number of patients in previous 6 months
< 21 3 (7.32)
> 20 37 (9.24)
Missing 1
A Level, Advanced Level; NCSCT, National Centre for Smoking Cessation and Training; SCTRP, Smoking Cessation Training
and Research Programme.
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Median fidelity to specific BCTs across sessions varied from 50% (‘Summarise information’ and ‘Give options
for support’) to 100% in five of the BCTs. However, two of the five consisted of only one behaviour, and
another two consisted of only two behaviours. The fifth one, ‘provide information on the consequences of
smoking and smoking cessation’, consisted of six behaviours and had the highest adherence (Figure 14).
Association between adherence and session and advisor characteristics
Sessions in which the advisor was assisted by a second advisor were found to have significantly higher
adherence levels than sessions run by one advisor alone (75.73% vs. 64.79%; p= 0.044). There was a negative
correlation between session length and adherence; thus, shorter session length was associated with increased
adherence to protocol-specified content (r = –0.351, n= 41; p< 0.025). Female advisors had significantly higher
levels of adherence to protocol-specified behaviours than male advisors (72.19% vs. 58.53%; p= 0.018). Level
of adherence also varied with advisors’ age: those aged 45–54 years were significantly more adherent (75.41%)
than advisors who were younger (61.87%) or older (60.45%) (p= 0.021).
Study outcomes and association with adherence
The proportion of attendees who subsequently attended the SSS ranged from 0% to 100% (mean
44.94%), and the mean proportion of attendees who were found to be validated as 7-day point prevalent
abstinent at the 6-month follow-up was 20.21% (range 0–66.67%). No correlation was found between
adherence to protocol-specified content and the proportion of attendees attending the SSS, or between
adherence and the proportion who were 7-day point prevalent abstinent.
Discussion
The observed median of 71.2% adherence to specified behaviours is higher than that reported by many
other similar studies.79–81 The standardised training in helping smokers to quit that all advisors had received,
in addition to having previous experience of running individual or group stop smoking courses, could
account for this. However, although the adherence of many was reasonably high, one-quarter fell below
50% and one as low as 29%.
Overall, adherence was greater in sessions that were run jointly by two advisors. The second advisor possibly
acted as a safety net, delivering key items that the first advisor failed to present. In addition, presenting in
pairs could have mitigated feelings of nervousness for some advisors who had less experience of facilitating
groups. Shorter sessions were associated with higher levels of adherence, and being female and in the
mid-range age category were significantly associated with adherence to the protocol. Of the BCTs, ‘provide
information on consequences of smoking and smoking cessation’ had the highest median percentage
fidelity. Information on the consequences of smoking is likely to be a common area of focus for SSS advisors
as the health impact of smoking is the most common reason for smokers to attempt to quit.
Adherence to the protocol was not related to the main outcome of attendance at the SSS or to abstinence
from smoking. Responding to an invitation to a smoking cessation study and then attending a session to
find out more about the SSS indicates a high level of interest in both quitting smoking and getting support
to do so, and indicates generally high levels of motivation of attendees. This enthusiasm could indicate
that the presentation of protocol-specified content was less important than theorised, as attendees were
already feeling inclined to sign up for a SSS course.
The study is limited by focusing solely on adherence to the protocol and neglecting more subtle
competency-related variables and non-specific effects, such as communication characteristics (e.g.
providing examples to clarify points, and empathetic tone). In addition, a number of advisors provided
extra information, both relevant and irrelevant, which was not analysed.
The results of this evaluation indicate that the study intervention is not likely to have been significantly
impacted by issues of fidelity, and we can have greater confidence that variability in the main outcome of
the study is not a result of variability in SSS advisor adherence to the protocol of the taster sessions.
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An exploration of the reasons for non-attendance and barriers
to attendance at the Stop Smoking Service
Reasons for non-attendance at the SSS and barriers to attendance at the services were assessed using
open questions in the 6-month follow-up. In addition, all participants who completed the telephone
follow-up interview and who reported not attending the SSS were asked to complete the TBQ to assess in
more depth barriers to the use of the SSS.
Background
Until recently, little research had been devoted to identifying and removing barriers to entering stop
smoking programmes, prompting Fiore et al.65 in the US Department of Health and Human Services
guidelines to stress the importance of further investigation in order to identify and remove barriers to
treatment. Research both before and since this call has identified that major barriers include a lack of
awareness, low expectations of effectiveness, most smokers underestimating the benefits of treatment
and a belief that motivation and willpower are sufficient.10,11,16,43,82–86 The belief that ‘if you really want to
quit smoking you will succeed on your own as well as you would with help’ is prevalent.16 Concern
about lack of empathy and notions that treatments are unavailable and hard to access also permeate
the literature.43,82,83,85,86
Copeland et al.49 adopted a more structured approach to identifying the most common reasons for not
seeking treatment and developed a validated 40-item measure of reasons for not entering smoking
cessation programmes. Copeland et al.49 developed and used the TBQ, specifically with low socioeconomic
smokers in the USA, to assess barriers to entering smoking cessation programmes and to relate the barriers
to demographics, stage of readiness to quit smoking and dependence.
As part of the Start2quit study we adapted the TBQ and distributed it to a sample of English smokers in
order to explore the barriers to seeking help and support to quit in the UK, specifically to attending the
English SSSs. The aims of the study were:
1. to identify perceived factors that prevent smokers from seeking help in a UK population
2. to examine the factor structure of the adapted TBQ and investigate whether or not it shows the same
dimensions across different groups.
In a more detailed analysis, logistic regressions were conducted to determine the most important barriers
and whether or not they differ according to demographic and smoking-related characteristics. However,
this work was not within the remit of this report and a more extensive analysis and interpretation will be
reported in a future output.
Method
Participants
Participants who completed the 6-month follow-up, by telephone or by post, and reported not attending
the SSS (n = 2331) were asked for their reasons for non-attendance in an open question. Participants who
completed the follow-up by telephone were also asked to complete a further postal questionnaire, the
TBQ. Those who agreed (n = 1597) were mailed a TBQ to complete and return in a postage-paid envelope.
Participants who did not reply after 2 weeks were sent a duplicate TBQ. A total of 758 completed TBQs
were returned.
Measures
Participant characteristics were assessed at baseline: demographics (age, gender, marital status, ethnicity and
education), social deprivation (IMD score) and socioenvironmental measures (living with other smokers),
smoking history (age starting smoking, previous quit attempts), nicotine dependence (measured by number
of cigarettes smoked daily and time from waking to first cigarette), intention to quit and motivation,
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determination and confidence to quit (all rated on a five-point Likert-type scale; 1 = not all, 5 = extremely).
Previous attendance at the SSS and self-reported health problems associated with smoking were also included.
An open question asking for reasons for not trying to make an appointment with the SSS was included in
the 6-month follow-up.
The TBQ was adapted from the 40-item TBQ developed by Copeland et al.49 and previously validated in
the USA, and comprised 36 items describing possible reasons why smokers do not enter SSS programmes.
Items that did not apply to an English population (e.g. insurance coverage) were removed and British
spelling was used throughout. The TBQ was piloted with SSS managers to test for appropriateness to the
SSS. Participants responded to each item using a five-point Likert scale (1 = strongly disagree, 5 = strongly
agree) (see Appendix 4).
Analysis
Frequencies and means were calculated for baseline characteristics of the sample. The proportion of
missing data on the TBQ ranged from 0.3% to 15.6% per item (mean 3.2%). All 758 responses were
entered into the analysis. Exploratory factor analysis using principal components analysis (PCA) with
varimax rotation was conducted to investigate the underlying structure of the data. To determine the
number of factors to retain, the scree criterion87 was applied. Items with factor loadings of at least 0.40
and with no cross-loadings were retained for rotation. Interitem reliability (coefficient alpha) was
determined for each of the factors. The effect on alpha of deleting any one item was examined and any
item that did not appear to substantially improve measurement was eliminated. The mean score of the
remaining items that loaded onto each factor was calculated to construct a scale for each factor, and
Pearson’s correlations were used to examine their inter-relationships.
Results
Reasons for not making an appointment with Stop Smoking Service
Of the 2133 responses to the open question asking for reasons for not trying to make an appointment
with the SSS, 25.5% implied that they were not ready to quit or were unmotivated to do so, 20.7%
indicated that they were too busy and had conflicting commitments, and 16.6% preferred to approach the
task of quitting alone rather than use any kind of support. A further 9% were unsure of the support from
the SSS or had previously tried to quit using the SSS.
Treatment Barriers Questionnaire response
Of the 1597 participants who reported not attending the SSS and were mailed a TBQ, 758 (47.5%)
completed and returned the questionnaire. There were a number of differences overall between
responders and non-responders to TBQ. Responders were significantly older (51.6 vs. 48.49 years;
p < 0.001) and less likely to have qualifications to Advanced Level (39.2% vs. 29.7%; p < 0.001). They
were less likely to be intending to quit in the next 30 days (31% vs. 40.9%; p < 0.001), and less motivated
(3.56 vs. 3.7; p = 0.002) and less determined to quit (3.55 vs. 3.72; p < 0.001) than non-responders. They
were also more likely to have quit in the past for > 1 month (62.2% vs. 53.5%; p = 0.003).
Participant characteristics
Demographic and smoking characteristics are shown in Table 20. Although participants were randomised
2 : 1 to the intervention and control groups, fewer participants in the control group attended the SSS;
thus, respondents to the TBQ are almost equally divided between intervention and control groups
(52% vs. 48%). The mean age of respondents was 51.6 years (SD 12.75 years), and 50.4% were female.
Principal components analysis
The PCA with varimax rotation yielded seven factors as the most interpretable and explaining 53.06% of
total variance. Thirty items were retained and the scales were named for their item content: (1) work and
time constraints (five items, mean 2.65, SD 0.92); (2) smokers should quit on their own (six items, mean
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TABLE 20 Demographic and smoking characteristics of respondents
Characteristic Respondents
Intervention (%) 394 (52)
Demographics
Gender, n (%)
Male 376 (49.6)
Age (years)
Mean (SD) 51.6 (12.75)
Marital status, n (%)
Married/living with spouse 445 (58.7)
Highest qualification, n (%)
A Level or higher 288 (38)
Ethnic background, n (%)
White 735 (97)
Deprivation (IMD score), n (%)
Mean IMD score (SD)a 23.52 (14.19)
Quintile 1 102 (13.5)
Quintile 2 113 (14.9)
Quintile 3 181 (23.9)
Quintile 4 184 (24.3)
Quintile 5 174 (23.0)
Live with smokers, n (%)
Yes 236 (31.1)
Smoking characteristics
Nicotine dependence score (0–6)b
Mean (SD) 2.46 (1.53)
Low (score = 1–2), n (%) 333 (43.9)
Medium (score = 3), n (%) 234 (30.9)
High (score= 4–6), n (%) 184 (24.3)
Mean age started smoking (years), (SD)
< 14 116 (15.3)
14–16 377 (49.7)
> 16 265 (35.0)
Intention and motivation to quit
When planning to quit, n (%)
In next 2 weeks 99 (13.1)
Next 30 days 126 (16.6)
Next 6 months 352 (46.4)
Not within 6 months 149 (19.7)
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2.64, SD 0.73); (3) nothing can help in quitting smoking (five items, mean 2.91, SD 0.76); (4) lack of
interest in quitting (four items, mean 1.97, SD 0.69); (5) lack of social support to attend SSSs (four items,
mean 1.70, SD 0.65); (6) lack of privacy at SSS programmes (two items, mean 2.84, SD 1.04); and (7) lack
of information on SSS (four items, mean 2.73, SD 0.74). Coefficient alphas ranged from 0.85 to 0.63 for
the seven scales. Table 21 displays the factor structure of the TBQ, coefficient alphas and the amount of
total variance explained for each factor. Mean scores were calculated for each scale and interscale
correlations are shown in Table 22.
Discussion
Exploratory PCA to identify barriers to entering the SSS yielded a 30-item, seven-factor solution,
accounting for 53.06% of the variance. Work and time constraints accounted for the highest proportion
of variance (14.81%); the notion that smokers should quit on their own and that nothing can help in
quitting smoking were the next highest (9.93% and 8.19%, respectively). Other barriers emerging were
lack of interest in quitting, lack of social support to attend, lack of privacy at SSS programmes and a lack
of information about the SSS.
The results of the PCA were similar to those reported by the developers of the original US questionnaire.49
Both analyses extracted a seven-factor solution comprising very similar scales. ‘Work and time constraints’
and ‘smokers should quit on their own’ correspond to those found by Copeland et al.49 ‘Opinions about
professional assistance’ and ‘misinformation about professional assistance’ correspond to the combined and
renamed ‘nothing can help in quitting smoking’, and this factor is more specific in representing the belief
that support offered is ineffective. Although ‘preparedness to quit’ and ‘lack of interest in quitting’ equate
and represent smokers not ready to quit, in our study lack of interest in quitting accounted for only 6.54%.
TABLE 20 Demographic and smoking characteristics of respondents (continued )
Characteristic Respondents
Longest previous quit attempt, n (%)
< 24 hours 58 (7.7)
1–6 days 111 (14.6)
1–4 weeks 115 (15.2)
> 1 month 468 (62.2)
Previously attended SSS, n (%)
Yes 262 (34.6)
‘How much do you want to quit?’ (1 = not at all, 5 = extremely)
Mean score (SD) 3.56 (0.93)
‘How determined are you to quit?’ (1 = not at all, 5= extremely)
Mean score (SD) 3.55 (0.97)
‘How confident are you that you can quit?’ (1= not at all, 5= extremely)
Mean score (SD) 2.58 (1.06)
Health
Health problems (self-reported), n (%)
Yes 178 (23.5)
A Level, Advanced Level.
a IMD score is the government’s official measure of multiple deprivation at small-area level.
b Dependence score was computed from the number of cigarettes per day and time from waking to first cigarette and is a
score between 0 and 6, categorised as low (0–2) medium (3) and high (4–6).
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TABLE 21 Treatment Barriers Questionnaire: scales, items and factor loadings
Scale (coefficient alpha reliability, total variance explained) Loading
1. Work and time constraints (α = 0.85, 14.81% of total variance)
My work schedule would prevent me from attending a regularly scheduled programme 0.846
My work schedule is too hectic 0.843
I don’t have the time to commit to a programme 0.801
I can’t afford to spend my time that way 0.722
Those programmes are too time-consuming 0.608
2. Smokers should quit on their own (α = 0.75, 9.93% of total variance)
Any smoker can quit on his/her own if he/she puts his/her mind to it 0.724
I should be able to quit on my own 0.711
I can quit whenever I want to on my own 0.692
People shouldn’t need help in quitting smoking 0.565
Most smokers don’t need that kind of help to quit smoking 0.537
I plan to quit on my own soon 0.536
3. Nothing can help in quitting smoking (α = 0.74, 8.19% of total variance)
I’ve tried quitting smoking in the past, and just couldn’t do it 0.674
I will end up smoking again 0.619
I’ll just hear things I’ve heard over and over again about smoking 0.615
I don’t think I can quit smoking, regardless of what I do 0.595
I won’t learn anything new and helpful 0.587
4. Disinterest in quitting (α = 0.70, 6.54% of total variance)
I don’t want to give up smoking 0.744
I like smoking and don’t want to give up 0.692
I don’t think smoking is really that bad for me 0.649
I’m young and healthy and don’t need to quit right now 0.595
5. Lack of social support to attend SSSs (α = 0.63, 5.08% of total variance)
I can’t afford childcare 0.797
There is nobody who could watch my children 0.733
My health problems prevent me from getting out 0.599
My spouse/partner smokes and I wouldn’t want to quit without him/her 0.420
6. Lack of privacy at SSS programmes (α = 0.70, 4.58% of total variance)
Most programmes are conducted in groups and I am not comfortable meeting in a group 0.744
I wouldn’t want to talk about my smoking with total strangers 0.735
7. Lack of information on SSSs (α = 0.68, 3.92% of total variance)
I am not aware of any programmes in this area 0.741
There is no service near my home 0.681
I don’t know much about what programmes do to help smokers quit 0.679
I would need more information on specific programmes to make a decision whether or not I would attend 0.612
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This might be because all participants in the present study had already expressed an interest in quitting
prior to taking part in the study. The remaining three factors were also similar but were renamed to
be more appropriate for each scale. Responses to the open questions also support this interpretation.
The most frequently given answers relate to the factors accounting for most of the variance, with the
only difference being that ‘lack of interest in quitting’ has the highest frequency of responses.
The results were also consistent with previous research suggesting that time constraints, disbelief in the
efficacy of programmes, lack of childcare and transportation, and lack of knowledge about smoking
cessation and support programmes are the main perceived barriers to entering smoking cessation
programmes.16,43,82–86 Although other commitments are often put forward as a reason for not attending,
the notion that motivation is up to them and support can only help them stay abstinent88 is prevalent.
There is a need to challenge the commonly held perception that really wanting to quit is sufficient.88 A
culture change is necessary and health-care professionals need to become more proactive84 if use of
support services globally is to be increased.
The size of the sample, more than adequate to meet the requirement of a factor analysis and large
enough to allow cross-validation of the questionnaire,89 is a strength of this study. However, the smokers
that participated in the present study were recruited for the larger study and were somewhat motivated to
quit; therefore, the sample may not be fully representative of the wider population of smokers in England.
This analysis has shown the validity of the TBQ on an English population of smokers motivated to quit
smoking following an explicit invitation to attend the SSS (either with risk information and taster session
invitation or without). This validation of the TBQ will also enable the comparison of data across studies
and populations. Delineating the most common reasons for not seeking treatment could lead to changes
to the advertising of services or in information given to smokers by clinicians and could increase treatment
seeking.82
TABLE 22 Correlations among TBQ scales interscale correlations
Scale
Scale
1 2 3 4 5 6 7
1: work and time constraints – 0.15 0.16 0.08 0.22 0.22 0.23
2: smokers should quit on their own – –0.09 0.06 0.07 0.17 0.03
3. nothing can help in quitting smoking – 0.43 0.17 0.25 0.16
4: lack of interest in quitting – 0.12 0.08 0.03
5: lack of social support to attend SSSs – 0.18 0.23
6: lack of privacy at SSS programmes – 0.11
7: lack of information on SSSs –
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Chapter 5 Health economics
Introduction
A CEA was conducted alongside the Start2quit trial to establish the value for money of personal
tailored risk information and taster sessions compared with the standard generic letter advertising
the SSS.
The objectives of the CEA were:
1. to identify the resources used and costs associated with delivering the trial interventions
2. to measure the participants’ use of health and social care services
3. to compare the estimated mean cost per participant between the two treatment groups
4. to estimate the health benefits of the trial interventions using QALYs calculated from the EQ-5D
questionnaire
5. to compare the cost difference between the two treatment groups with difference in effectiveness and
generate incremental cost-effectiveness ratios (ICERs)
6. to test the uncertainty of the calculated ICERs using the bootstrapping method and to generate
cost-effectiveness acceptability curves (CEACs) to demonstrate the probability of the intervention being
cost-effective over and above the generic letter.
Methods
A full CEA was conducted following the methods of technology appraisal recommend by NICE.50
The analysis was conducted on an intention-to-treat basis, in which all participants were analysed as
randomised. The study was performed from the NHS/Personal Social Services perspective to reflect the
English NHS decision-making framework, with costs expressed in UK pounds (£) at a 2012–13 price base.
The follow-up for the analysis was 6 months from randomisation. All costs were inflated to 2012–13
price levels, when necessary, using the Hospital and Community Health Services pay and price inflation
index.90
Assessment of costs
A micro-costing approach was applied to estimate the costs of the two trial interventions. The costing
methods involved three steps: (1) identifying the relevant cost items (identification), (2) measuring the use
of the identified cost items (measurement) and (3) placing a value on these cost items (valuation).91
Measurement of resource use
Health-care utilisation was systematically collected for each participant alongside the trial. Two main
components of health-care resources were used in the trial.
First, the use of resources associated with the delivery of the trial interventions was recorded. This included
staff time, consumables (such as postage and printing) and resources required for the training of advisors
in the delivery of the taster sessions. Second, patients’ use of health and social care services was recorded
using comprehensive service-use questionnaires, as used previously in a number of trials. Table 23 lists the
resource items for the two trial interventions. Only resources directly related to the intervention in practice
were included in the costing exercise. Resources that were used solely for the purpose of research
were excluded.
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TABLE 23 Cost components of the trial interventions
Stage
Group
Intervention Control
Cost items Included Cost items Included
Before randomisation
Cost of screening
for eligible
smokers
GP time (2–5.5 hours per PCT) No GP time (2–5.5 hours per PCT) No
Other practice staff Yes Other practice staff Yes
Cost of recruiting Baseline questionnaire (printing) Yes Baseline questionnaire (printing) No
Cover letter from GP (printing) Yes Cover letter from GP (printing) No
Postage (envelope, stamps) Yes Postage (envelope, stamps) No
Staff time to prepare and post the
letter
Yes Staff time to prepare and post the
letter
No
After randomisation: intervention : control = 3 : 2
Cost of intervention
letters
Personalised tailored letter (printing) Yes Standard generic letter advertising
the SSS (printing)
Yes
Postage (envelope, stamps) Yes Postage (envelope, stamps) Yes
Staff time to prepare and post the
letter
Yes Staff time to prepare and post the
letter
Yes
Cost of taster
session
Training costs taster sessions (staff
time, material, equipment, overheads)
Yes N/A N/A
Cost of providing taster sessions (staff
time, material, equipment, overheads)
Yes N/A N/A
Cost of SSS service
taken up
Cost of SSS attendance
(sessions × unit costs)
Yes Cost of SSS attendance
(sessions × unit costs)
Yes
Cost of other
smoking cessation
aids
Non-pharmacological smoking cessation aids Non-pharmacological smoking cessation aids
GP visit Yes GP visit Yes
Practice nurse Yes Practice nurse Yes
Pharmacist Yes Pharmacist Yes
NHS Smoking Helpline Yes NHS Smoking Helpline Yes
Other smoking helpline Yes Other smoking helpline Yes
Internet Yes Internet Yes
Pharmacological smoking cessation aids Pharmacological smoking cessation aids
NRT Yes NRT Yes
Bupropion Yes Bupropion Yes
Varenicline Yes Varenicline Yes
Cost of wider
health-care
resource use
GP visit Yes GP visit Yes
Prescriptions Yes Prescriptions Yes
Day case Yes Day case Yes
Inpatient (cost per night) Yes Inpatient (cost per night) Yes
Outpatient attendance Yes Outpatient attendance Yes
A&E attendance Yes A&E attendance Yes
A&E, accident and emergency; N/A, not applicable; PCT, primary care trust.
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Smokers aged ≥ 16 years were identified from their medical records by practice staff from participating
practices. GPs from these practices then carried out further screening to exclude smokers deemed to be
unsuitable for the research, such as those who were severely or terminally ill. GPs spent approximately
2.5 hours screening each practice’s smokers list for eligibility, but GP time was spent for research purposes
and was not considered part of the intervention cost.
All eligible smokers were then sent a baseline questionnaire with a cover letter from their GP. A Freepost
envelope was included for the return of the questionnaire to the practice. For non-respondents, a reminder
and duplicate questionnaire was sent to the smoker 3 weeks after the first mailing. The cost components
of the baseline questionnaire consisted of consumables such as printing, envelopes and postage, and staff
time used to prepare and post the letters. It is noted that, although baseline questionnaires were sent to
both trial groups, the cost was included only for the intervention group because the questionnaire was
needed to gather information for generating the tailored letter. For the control group, generic letters
would be sent to smokers directly after screening if implemented in the practice. Therefore, the cost of the
baseline questionnaire was considered a research cost and excluded from the analysis.
Smokers who returned a completed baseline questionnaire, signed the consent form and were eligible to
participate were randomised in a ratio of 3 : 2 to the intervention or the control group. The control group
received a standard generic letter advertising the SSS and asking the smoker to contact the service to
make an appointment to see an advisor. The relevant resource use includes stationery, mailing and staff
time to prepare and post the letter.
In the intervention group, participants were sent a brief personalised and tailored letter based on their
medical records and information provided in the returned baseline questionnaire. The resource used for
generating the tailored letter includes consumables (printing, envelopes and postage), and staff time used
to prepare and post the letters. The intervention letter also included an invitation and an appointment to
attend a ‘Come and Try it’ taster session. Resource use associated with the taster session includes training
and time of facilitators, equipment and venue overheads.
In addition to the intervention-related resource use, data on health resource use beyond the trial
interventions were collected alongside the trial. These resources include the use of the SSSs, other smoking
cessation aids and wider health-care resource use.
Numerical information on attendance at SSSs and the intervention type for each participant was provided
by the SSS. Participants were asked at follow-up about the smoking cessation aids and other health-care
services they had used in the previous 6 months. Smoking cessation aids included pharmacological (NRT,
bupropion and varenicline) and non-pharmacological interventions (GP, nurse, pharmacist visits, smoking
helplines). Wider health resource use consisted of primary health-care services (visits to primary care
professionals) and secondary health-care services (hospital admissions and outpatient attendances).
Unit costs for resource use
The total costs of the identified resources were calculated using national unit costs from a range of
published sources. The use of national unit costs can eliminate the difference in local costs among
different sites and reflect the actual cost after generating the intervention to the real practice.50 Table 24
shows unit costs employed to calculate the total cost per participant in the trial. The main sources from
which unit costs were obtained include the Personal Social Services Research’s Unit Costs of Health and
Social Care 2013,90 the NHS Reference Costs 2012–13,95 Prescription Cost Analysis England 201396 and the
2008 Smoking Cessation Services: Costing Report.94
Health outcome measures
In addition to the clinical outcome measures used in the statistical analysis (the uptake of SSS and quit
rates), health benefits were measured in QALYs in the economic evaluation. Unlike clinical outcomes such
as quit rates, which can only be compared between smoking interventions, QALYs are a standard and
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internationally recognised method enabling comparisons across different health-care programmes. QALYs
take into account both quantity and health-related quality of life and are recommended by NICE
technology appraisal guidance.50
In this study, QALYs were calculated as the area under the curve, following the trapezium rule, using
utility scores measured by EQ-5D questionnaires at baseline and at the 6-month follow-up.51 An EQ-5D
questionnaire is a self-complete questionnaire that evaluates participants’ quality of life on five dimensions:
mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has three levels,
indicating no problem, some or a moderate problem and a major problem. Based on their combined
answers to the five questions, participants could be classified as being in 1 of 245 possible health states
(the 243 states arising from the EQ-5D, plus unconscious and deceased). A preference-based index utility
score was derived for each participant’s response to the EQ-5D questionnaire using the UK population
tariff calculated by a time trade-off method.97,98 Perfect health has a utility value of ‘1’ and death was
assigned a value of ‘0’; some health states may be considered worse than death and have negative scores.
TABLE 24 Unit costs (and sources) employed to estimate total costs (in 2012–13 prices)
Item Unit Cost (£) Source
Smoking cessation aids
Non-pharmacological smoking cessation aids
GP visit 10-minute brief advice session 40 Curtis90
Practice nurse 10-minute brief advice session 7 Curtis90
Pharmacist 10-minute brief advice session 11 Curtis90
NHS Smoking Helpline £5.90 per call at 2008–9 price 6.40 Wu et al.92
Other smoking helpline £5.90 per call at 2008–9 price 6.40 Wu et al.92
Pharmacological smoking cessation aids
NRT Per prescription item 21 Health and Social Care Information Centre93
Bupropion Per prescription item 38 Health and Social Care Information Centre93
Varenicline Per prescription item 34 Health and Social Care Information Centre93
NHS SSSs
Group session Per person per session 4.60 NICE94
Individual session Per person per session 17 NICE94
Telephone £5.90 per call at 2008–9 price 6.40 Wu et al.92
Drop-in Per person per session 17 NICE94
Couple/family Per person per session 8.50 NICE94
Wider health-care resource use
GP visit Visit (average 11.7 minutes) 37 Curtis90
Practice nurse visit Visit (average 15.5 minutes) 11 Curtis90
Day case FCE 693 Department of Health95
Inpatient (cost per night) Per bed-night 542 Department of Health95
Outpatient attendance FCE 108 Department of Health95
A&E attendance FCE 114 Department of Health95
A&E, accident and emergency; FCE, finished consultant episode.
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Cost-effectiveness analysis
To assess the relative cost-effectiveness of the two trial interventions, we employed an incremental CEA to
compare the mean difference in costs with the mean difference in health benefits. The ICER was used to
combine costs and health benefits in a single measure to which a decision rule for cost-effectiveness can
be applied:99
ICER =
ΔC
ΔE
=
CI  CC
EI  EC
, (3)
where E represents the change in effects and C represents the costs of intervention, measured in monetary
units, and subscripts ‘I’ and ‘C’ refer to intervention and control arm, respectively. In this study, three sets
of ICER were conducted using the three outcome measures using the following formulas.
1. Cost per additional attendee to the SSS:
ICER1 =
ΔC
ΔE
=
Average cost of the tailored letter þ
average cost of the taster session
 
 average cost of the generic letter
SSS attendance rateI  SSS attendance rateC . (4)
2. Cost per additional quitter at 6 months:
ICER2 =
ΔC
ΔE
=
Average cost of the tailored letter +
average cost of the taster session +
average SSS costI + health-care costI
0
@
1
A Average cost of the generic letter +
average SSS costC + health-care costC
 
Quit rate at 6 monthsI  Quit rate at 6 monthsC .
(5)
3. Cost per additional QALY gained at 6 months:
ICER3 =
ΔC
ΔE
=
Average cost of the tailored letter þ
average cost of the taster session þ
average SSS costI þhealth-care costI
0
@
1
A Average cost of the generic letter þ
average SSS costC þhealth-care costC
 
QALY gain at 6 monthsI  QALY gain at 6 monthsC .
(6)
Uncertainty assessment
A feature of CEA is the uncertainty that exists around the ICER. In this study, uncertainty around the
decision to adopt the intervention is assessed through a non-parametric bootstrap resampling technique.
Non-parametric bootstrap is a method that resamples observations from the original samples.93
Bootstrapping has been proposed as an efficient approach for calculating the confidence limits for the
ICER, as its validity does not depend on any specific form of underlying distribution.100–103 We performed
the bootstrap replications 5000 times; for each bootstrapped resample, an estimate of the differential costs
and QALYs was calculated and 95% CIs for the ICERs were constructed based on the bootstrapping
results.101,102 In addition, cost-effectiveness planes (CEPs) and CEACs were plotted based on the outcomes
of the bootstrap iterations.104
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Handling missing data
Missing data are a common and considerable problem in most economic evaluations alongside clinical
trials because of the high missing rate of the health-care resource-use questionnaires. In this study, missing
data were handled using Rubin’s multiple imputation method.99,105–107 We assumed any missing data to be
missing at random when the probability of the data being missing can depend on the observed values of
the individual but not on the missing variable values of the individual. A total of 50 imputed data sets were
generated to ensure efficient and reproducible estimates.
Sensitivity analysis
Besides the multiple imputation analysis, a sensitivity analysis was undertaken to repeat the CEA using
complete cases, whereby the results are analysed only for those participants who had both completed
cost and outcome data at the same time. Because the intervention of interest in this study was a
multicomponent intervention, the costs and effects of each intervention element were explored as the
second part of the sensitivity analysis.
Long-term costs and outcomes predictions
The within-trial analysis shows the short-term cost-effectiveness of the interventions. However, in common
with many preventative interventions, many studies on smoking cessation have demonstrated that the
majority of benefits are gained from the reduced risk of developing smoking-related diseases, such as
lung cancer, myocardial infarction, COPD and stroke, and the reduced health-care costs and improved
health-related quality of life it brings over a longer time period.108,109 These benefits may not be evident
until later in life; hence, the 6-month follow-up period of the trial is not sufficient to capture the real value
of the smoking interventions.99,107,110 Therefore, in this study, besides the within-trial analysis, we included
an estimate of lifetime health-care cost savings and QALY gains associated with the two interventions.
The method employed in this study’s long-term CEA was based on an economic model that was
developed to estimate smoking-related costs and consequences in adults in England.52 This is a Markov
model that simulated the pathway between smoking and four main smoking-related conditions (lung
cancer, myocardial infarction, COPD and stroke) and evaluated the related costs of current smokers,
ex-smokers and never-smokers. However, this study only reported the cost savings from quitting smoking.
In the absence of estimated lifetime health outcomes, we combined and utilised another English study by
Vogl et al.,111 which reported health-related quality of life by smoking status.
Both future costs and health outcomes were discounted at 3.5% per annum when necessary, in line with
the NICE guidelines for the technology appraisal methods.50 Similar to the short-term CEA, ICERs were
calculated and the uncertainty of the calculated ICERs were tested using the bootstrapping method.
Results
A total of 4384 participants were recruited to the trial. One participant withdrew from the study, leaving
4383 participants analysed in the economic evaluation: 2636 in the intervention group and 1748 in the
control group (see Figure 6). The base-case CEA was based on a multiple-imputed data set, in which all
the missing values were imputed using the multiple imputation method.
Costs
Intervention costs reflect the value of resources required to deliver the trial interventions. Table 25
summarises the average cost of each intervention component for both treatment groups. The cost of
screening was £0.30 per person recruited into the trial. For the intervention group, the cost of the baseline
questionnaire used to gather information for generating the tailored invitation letter was £32 per person.
The average costs of the tailored and generic invitation letter were £13 and £0.60 per participant,
respectively. The average cost of the taster session was £27 per person per session; this included £0.10 for
the training manual and £26 to provide the session. Four participants in the control group attended the
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taster sessions; the costs of these sessions were included in the control group according to the
intention-to-treat principle.
Table 26 and Figure 15 show the mean cost for the interventions and the subsequent use of health
services over the 6-month follow-up period. The mean intervention cost in the intervention group was
£54 (SD £12) per participant, whereas the corresponding average cost in the control group was only
£0.90 (SD £2) per participant. Costs associated with smoking cessation, including use of SSSs, and
pharmacological and non-pharmacological cessation aids, were significantly higher in the intervention
group than in the control group. The wider health resource-use cost was also higher in the intervention
group, but the difference here is insignificant.
The estimated total mean costs over the 6-month follow-up period were £777 (SD £2176) in the
intervention group and £679 (SD £1860) in the control group. Participants’ average cost relies heavily on
their wider health resource use over the past 6 months. The cost difference between the two groups was
£98 (95% CI –£26 to £222). After adjusting for baseline resource use, the adjusted cost difference was
£92 (95% CI –£32 to £216). The 95% CIs indicate that the total cost differences were not statistically
significant between the two treatment groups.
TABLE 26 Average cost by category and treatment allocation (prices in £ in 2012–13)
Resource category
Group (£), mean cost (SD)
Differencea (£) (95% CI)Intervention (n= 2635) Control (n= 1748)
Intervention cost 54 (12) 0.90 (1) 53 (52 to 53)
SSS attendance cost 11 (34) 5 (23) 6 (4 to 8)
Non-pharmacological cessation aids 44 (32) 40 (26) 4 (2 to 6)
Pharmacological cessation aids 61 (49) 50 (32) 10 (8 to 13)
Wider health-care resource-use cost 608 (2175) 583 (1860) 25 (–99 to 149)
Total cost 777 (2176) 679 (1860) 98 (–26 to 222)
Adjusted total costb 760 (2039) 669 (2059) 92 (–32 to 216)
a Difference= costs for intervention group – costs for control group.
b Adjusted for baseline cost.
TABLE 25 Intervention costs by allocated treatment (prices in £ in 2012–13)
Intervention component
Group
Intervention Control
Screening £0.30/participant £0.30/participant
Baseline questionnaire £32/participant N/A
Tailored letter £13/participant N/A
Generic letter N/A £0.60/participant
Taster sessions
Training manual £0.10/session £0.10/session
Providing taster sessions £26/session £26/session
N/A, not applicable.
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Outcomes: utility and quality-adjusted life-years
The primary health economic outcome was QALY gains over 6 months, estimated using the EQ-5D.
Mean EQ-5D scores in each intervention group at both baseline and the 6-month follow-up are reported
in Table 27. At baseline, the estimated between-group difference (intervention – control) in EQ-5D score
was –0.004. The results show that mean EQ-5D scores were improved over the study period for both trial
arms. The estimated between-group difference (intervention – control) in EQ-5D score was 0.004 (95% CI
–0.015 to 0.030) at 6-month follow-up. This indicates that compared with the control group, the mean
EQ-5D score was lower in the intervention group at baseline, whereas after 6 months the mean EQ-5D
score was higher in the intervention group.
Based on the EQ-5D scores, at both the baseline and the 6-month follow-up, QALYs were calculated and
reported in Table 27. The number of unadjusted average QALYs per participant over the 6 months was
0.0001 (95% CI –0.008 to 0.009), that is, they were higher in the intervention group than in the control
group. After adjustment for baseline utility scores, the results demonstrate that QALY gains were slightly
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FIGURE 15 Cost difference between two intervention groups.
TABLE 27 EQ-5D scores and QALYs by treatment and by time
Outcome
Group, mean (SD)
Differencea (95% CI)Intervention (n= 2635) Control (n= 1748)
Baseline EQ-5D scores 0.751 (0.304) 0.755 (0.292) –0.004 (–0.022 to 0.014)
6-month follow-up EQ-5D scores 0.771 (0.311) 0.76 (0.312) 0.004 (–0.015 to 0.030)
QALY 0.381 (0.141) 0.380 (0.136) 0.0001 (–0.009 to 0.009)
Adjusted QALYb 0.382 (0.046) 0.3802 (0.046) 0.0015 (–0.001 to 0.004)
a Difference= utility or QALY for intervention group – utility or QALY for control group.
b Adjusted for baseline EQ-5D scores.
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higher in the intervention group compared with the control group (the difference in QALYs was 0.002,
95% CI –0.001 to 0.004). However, the QALY differences between treatment groups were not
statistically significant.
Cost-effectiveness analysis and uncertainty
We conducted three sets of cost-effectiveness analyses using three outcome measures in this study. The
results are reported as incremental cost per outcome of interest, cost per additional attendee to the SSS,
cost per additional quitter and cost per QALY. The results of the analyses are presented in Tables 28–30.
First, after participants received the invitation letter and taster session, 458 (17.4%) smokers in the
treatment group and 158 (9.0%) smokers in the control group attended the SSS (see Table 28). The
average costs incurred in the intervention group and control group were £54 and £0.90, respectively,
resulting in an ICER of £627 per additional attendee to the SSS. The ICER indicates that, when comparing
the tailored letter and taster sessions with the generic letter, a cost of £627 was incurred to enable one
more smoker to take up the SSS.
TABLE 29 Cost per additional quitter (multiple imputation analysis)
Smoking outcome
Group, n quitter (%) Differencea
Intervention
(N= 2635)
Control
(N= 1748) OR (95% CI)
ICER2 (cost per additional
quitter), £ (95% CI)
24-hour point prevalent
abstinence (self-reported)
445 (16.9) 201 (11.5) 1.57 (1.31 to 1.88) 1700 (–602 to 4001)
7-day point prevalent
abstinence (validated)
236 (9.0) 97 (5.6) 1.68 (1.32 to 2.15) 2689 (–952 to 6329)
7-day point prevalent
abstinence (self-reported)
424 (16.1) 187 (10.7) 1.61 (1.34 to 1.94) 1699 (–601 to 3998)
1-month prolonged
abstinence (self-reported)
357 (13.6) 151 (8.6) 1.67 (1.36 to 2.04) 1866 (–660 to 4392)
3-month prolonged
abstinence (validated)
150 (5.7) 60 (3.4) 1.70 (1.25 to 2.31) 4053 (–1435 to 9541)
3-month prolonged
abstinence (self-reported)
240 (9.1) 103 (5.9) 1.61 (1.26 to 2.04) 2849 (–1008 to 6706)
a Difference= costs for intervention group – costs for control group.
TABLE 28 Cost per additional attendee to the SSS (multiple imputation analysis)
Outcome
Group
Intervention (N= 2635) Control (N= 1748)
Intervention cost, mean (SD) £54 (£12) £0.90 (£1)
Cost differencea (95% CI) £53 (£52 to £53)
Attendance at SSS, n (%) 458 (17.4) 158 (9.0)
OR (95% CI) 2.12 (1.75 to 2.57); p< 0.001
ICER1 (cost per additional person attend SSS) (95% CI) £627 (£620 to £634)
a Difference= costs for intervention group – costs for control group.
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Second, combining differential costs of the treatment groups with the differential quit rates at the
6-month follow-up, the ICERs are listed in Table 29. The main quit rate used in this trial was biochemical
validation of 7-day abstinence; the corresponding ICER was £2689 (95% CI –£952 to £6329) per
additional quitter. This means that if the decision-makers were willing to pay more up to £2689 for an
additional quitter, the tailored letter and taster session would be the preferred option; otherwise, usual
care should be adopted. ICERs using other periods of abstinence measures (from 24-hour self-reported
point prevalence to 3-month-validated prolonged abstinence) are also reported in Table 29. The cost per
additional quitter ranges from £1699 to £4053 using the multiple imputation data set.
Third, we compared the effectiveness of the two interventions using QALYs as health outcome measures
(see Table 30). It was found that the intervention was associated not only with a slight gain in QALYs
following adjustment for baseline EQ-5D, but also with higher costs than the control condition. This
generates an ICER of £59,401 (95% CI –£604,833 to £644,486) per QALY gained.
However, the differences in both QALYs and costs are not statistically significant, indicating that there may
be some uncertainty surrounding the ICERs. We employed the non-parametric bootstrapping method to
investigate the uncertainty over mean differences. A scatterplot of the 5000 bootstrapped incremental
mean costs and mean QALYs pairs is presented on the CEP (Figure 16). The horizontal axis divides the
plane according to incremental cost (positive above, negative below) and the vertical axis divides the plane
according to incremental effect (positive to the right, negative to the left).99 The axes divide the plane into
four quadrants through the origin; in the south-east quadrant, the intervention group is less costly and
more effective than the standard letter and the intervention is considered more cost-effective. In the
north-west quadrant, the opposite is true and the control is more cost-effective, whereas in the north-east
and south-west quadrants, the decision depends on the maximum willingness-to-pay threshold. The slope
of the two lines in Figure 16 shows the NICE range of decision-making thresholds: £20,000–30,000 per
additional QALY gained. The proportion of the scatterpoints that fall to the south and east of the
willingness-to-pay threshold line is the probability that the intervention is more cost-effective than the
standard letter. Using the results of the bootstrapped replicates, we also generated a CEAC (Figure 17),
which provides a plot of probabilities that the intervention is being cost-effective (y-axis) against all
potential values of willingness-to-pay thresholds (x-axis).
In Figure 16, the majority of the plots in the CEP fall in the north-east quadrant, indicating that the
intervention is likely to be more effective, but also more expensive, than the control. The CEAC (see
Figure 17) illustrates that, when using the NICE decision-making threshold range of £20,000–30,000 per
QALY gained, the tailored letter and taster session has a 20–27% probability of being considered
TABLE 30 Cost per additional QALY (multiple imputation analysis)
Outcome
Group
Differencea (95% CI)Intervention (n= 2635) Control (n= 1748)
Total cost,b mean (SD) £777 (2176) £679 (1860) £98 (–£26 to £222)
QALY,b mean (SD) 0.381 (0.141) 0.380 (0.136) 0.0001 (–0.009 to 0.008)
ICER (cost per QALY gained) (95% CI)b £862,629 (–£742,154 to £1,159,241)
Adjusted total cost,c mean (SD) £760 (£2039) £669 (£2059) £92 (–£32 to £216)
Adjusted QALY,c mean (SD) 0.382 (0.046) 0.380 (0.046) 0.002 (–0.001 to 0.004)
ICER (cost per QALY gained) (95% CI)c £59,401 (–£604,833 to £644,486)
a Difference= cost or utility for intervention group – cost or utility for control group.
b No adjustment.
c Adjusted for baseline cost and EQ-5D scores.
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cost-effective at 6 months. Only at higher willingness-to-pay thresholds (>£59,401 per QALY) does the
intervention becomes more likely to be cost-effective than the control.
Sensitivity analysis (complete-case analysis)
In order to explore the potential impact of missing data on estimated treatment effects and costs, a
sensitivity analysis was conducted based on the complete cases. In this trial, completed costs and outcome
data at the same time were available for 2775 participants (63% of all participants), 1667 in the
intervention group and 1108 in the control group. The number and percentage of missing data with
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FIGURE 17 Cost-effectiveness acceptability curve (multiple imputation analysis).
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FIGURE 16 Cost-effectiveness plane (multiple imputation analysis).
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regard to each cost component are summarised in Table 31. Table 31 also shows the mean costs of the
complete cases by treatment groups and resource categories. Tables 32–34 list the results of the CEA
using 2775 complete cases.
To make it easier to compare the primary analysis and sensitivity analysis, Table 35 summarises the main
results of the two analyses. When excluding participants with incomplete data, there is little change in
the results. The results show that, for both treatment groups, the average costs were slightly higher in the
complete cases, and the gains in effectiveness increased slightly too. The ICERs of the complete-case analyses
were estimated at £498 (95% CI £491 to £504) per additional attendee to the SSS, £2552 (95% CI –£1199
to £6303) per additional quitter and £49,842 (95% CI –£425,064 to £536,813) per QALY gained when
comparing the intervention with the control group.
TABLE 31 Average cost by category and treatment allocation (complete-case analysis)
Resource category
Group
Difference,b
(£) (95% CI)
Intervention Control
Missing,
n (%)
Average cost
(£),a mean (SD)
(n= 1667)
Missing,
n (%)
Average cost
(£),a mean (SD)
(n= 1108)
Intervention cost 0 (0) 55 (13) 0 (0) 0.90 (2) 54 (53 to 55)
SSS attendance cost 0 (0) 13 (36) 0 (0) 5 (24) 8 (5 to 10)
Non-pharmacological cessation
aids
902 (34) 22 (47) 585 (33) 17 (39) 5 (1 to 8)
Pharmacological cessation aids 752 (29) 30 (70) 467 (27) 16 (47) 14 (10 to 19)
Wider health-care resource-use
cost
903 (34) 727 (2481) 586 (34) 685.42 (2265) 42 (–140 to 224)
Total cost 968 (37) 846 (2484) 640 (37) 724 (2268) 122 (–60 to 305)
Adjusted total cost 968 (37) 851 (2455) 640 (37) 724 (2465) 127 (–60 to 314)
a Participants who had both the completed cost and outcome data at the same time.
b Difference= costs for intervention group – costs for control group.
TABLE 32 Cost per additional attendee to the SSS (complete-case analysis)
Complete casesa
Group
Intervention (N= 1667) Control (N= 1108)
Intervention cost, mean (SD) £55 (£13) £0.90 (£2)
Differenceb (95% CI) £54 (£53 to £55)
Attendance at SSS, n (%) 334 (20.04) 102 (9.21)
OR (95% CI) 2.47 (1.94 to 3.16); p< 0.001
ICER1 (cost per additional attendee to the SSS) (95% CI) £498 (£491 to £504)
a Participants who had both the completed cost and outcome data at the same time.
b Difference= costs for intervention group – costs for control group.
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TABLE 33 Cost per additional quitter (complete-case analysis)
Complete casesa
Group
Differenceb (95% CI)
Intervention
(N= 1667)
Control
(N= 1108)
Adjusted total cost, mean (SD) £851 (£2455) £724 (£2465) £127 (£60 to £314)
Smoking outcome Quitter, n (%) Quitter, n (%) OR (95% CI)
ICER2 (cost per
additional quitter),
£ (95% CI)
24-hour point prevalent abstinence
(self-reported)
383 (22.98) 168 (15.16) 1.67 (1.36 to 2.05) 1629 (–765 to 4022)
7-day point prevalent abstinence
(validated)
214 (12.84) 87 (7.85) 1.73 (1.32 to 2.27) 2552 (–1199 to 6303)
7-day point prevalent abstinence
(self-reported)
365 (21.90) 157 (14.17) 1.70 (1.38 to 2.10) 1647 (–773 to 4067)
1-month prolonged abstinence
(self-reported)
303 (18.18) 126 (11.37) 1.73 (1.37 to 2.18) 1870 (–878 to 4618)
3-month prolonged abstinence
(validated)
135 (8.10) 51 (4.60) 1.83 (1.30 to 2.60) 3640 (–1710 to 8990)
3-month prolonged abstinence
(self-reported)
204 (12.24) 82 (7.40) 1.74 (1.33 to 2.31) 2631 (–1236 to 6497)
a Participants who had both the completed cost and outcome data at the same time.
b Difference= costs for intervention group – costs for control group.
TABLE 34 Cost per additional QALY (complete-case analysis)
Complete casesa
Group
Differenceb (95% CI)Intervention (n= 1667) Control (n= 1108)
Total cost,c mean (SD) £846 (£2484) £724 (£2268) £122 (–£60 to £305)
Adjusted total cost,d mean (SD) £851 (£2455) £724 (£2465) £127 (£60 to £314)
Baseline EQ-5D scores, mean (SD) 0.7569 (0.3054) 0.763 (0.2962) –0.0061
6-month follow-up EQ-5D scores,
mean (SD)
0.7751 (0.3108) 0.7677 (0.3112) 0.0073 (–0.0163 to 0.0310)
QALY,c mean (SD) 0.383 (0.1437) 0.3827 (0.1422) 0.0003 (–0.0106 to 0.0112)
ICER,c mean (95% CI) £407,933 (–£418,734 to £591,198)
Adjusted QALY,d mean (SD) 0.3841 (0.0524) 0.3815 (0.0526) 0.0026 (0.04365 to 0.0553)
ICER,d mean (95% CI) £49,842 (–£425,064 to £536,813)
a Participants who had both the completed cost and outcome data at the same time.
b Difference= cost or utility for intervention group – cost or utility for control group.
c No adjustment.
d Adjusted for baseline cost and EQ-5D scores.
DOI: 10.3310/hta21030 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 3
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Gilbert et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
81
Similar to the multiple imputation analysis, we re-ran the bootstrapping approach to generate the CEP
(Figure 18) and CEAC (Figure 19). The probability that the intervention would be considered more
cost-effective than the control at different decision thresholds was 24% at £20,000 and 34% at £30,000
per QALY gained. The results of the complete-case analysis have been shown to be consistent with the
results of the multiple imputation analysis at the end of the 6-month follow-up.
TABLE 35 Summary of cost-effectiveness results from the multiple imputation analysis vs. complete-case analysis
Outcome
Analysis
Multiple imputation Complete case
Intervention
(N= 2635)
Control
(N= 1748)
Intervention
(N= 1667)
Control
(N= 1108)
Intervention cost, mean (SD) £54 (£12) £0.90 (£1) £55 (£13) £0.90 (£2)
Attendance at SSS, n (%) 458 (17.4) 158 (9.0) 334 (20.04) 102 (9.21)
ICER1 (cost per additional attendee to the
SSS) (95% CI)
£627 (£620 to £634) £498 (£490 to £504)
Adjusted total cost, mean (SD) £760 (£2039) £669 (£2059) £851.03 (£2455) £724 (£2465)
Cost difference (95% CI) £92 (–£32 to £216) £127 (–£60 to £314)
7-day point prevalent abstinence, n (%)
(validated)
236 (8.96) 97 (5.55) 214 (12.84) 87 (7.85)
ICER2 (cost per additional quitter) (95% CI) £2689 (–£952 to £6329) £2552 (–£1199 to £6303)
Adjusted QALY, mean (SD) 0.382 (0.046) 0.38 (0.046) 0.384 (0.052) 0.382 (0.05)
QALY difference (95% CI) 0.0015 (–0.001 to 0.004) 0.003 (–0.044 to 0.055)
ICER3 (cost per QALY gained) (95% CI) £59,401 (–£604,833 to £644,486) £49,842 (–£425,064 to £536,813)
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FIGURE 18 Cost-effectiveness plane (complete-case analysis).
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Sensitivity analysis (intervention components)
The intervention designed in this trial consists of more than one component. We broke down the costs
and effects of each component to explore the most cost-effective part of the intervention in terms of
increasing the SSS attendance. The 4383 participants were divided into three groups according to the
treatment they received: 1748 received the standard generic letter, 1896 received a personal tailored letter
and 739 participants attended taster sessions after they received the tailored letter.
Table 36 reveals the results of the CEA comparing the three groups for the three outcomes. When there
are more than two strategies involved in an incremental CEA, ICERs were calculated following three steps.
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FIGURE 19 Cost-effectiveness acceptability curve (complete-case analysis).
TABLE 36 Breakdown of the intervention components
Intervention received
Number of
participants
Mean intervention cost
(£) (SD) Attended SSS, n (%) ICER1 (£)
Generic letter only 1748 0.87 (1) 158 (9.0) –
Tailored letter only 1896 46 (0) 120 (6.3) Dominated
Tailored letter plus taster session 739 73 (0) 338 (45.7) 196
Intervention received
Number of
participants
Adjusted mean total
cost at 6 months (£) (SD)
Validated 7-day point
prevalent abstinence,
n (%) ICER2 (£)
Generic letter only 1748 669 (2059) 97 (5.6) –
Tailored letter plus taster session 739 669 (1430) 137 (18.5) 6
Tailored letter only 1896 796 (2105) 99 (5.2) Dominated
Intervention received
Number of
participants
Adjusted mean total
cost at 6 months (£) (SD)
Adjusted QALY at
6 months (SD) ICER3 (£)
Generic letter only 1748 669 (2059) 0.380 (0.046) –
Tailored letter plus taster session 739 669 (1430) 0.383 (0.031) 300
Tailored letter only 1896 796 (2105) 0.381 (0.046) 63,400
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First, the alternatives were ranked from the cheapest to the most expensive choice. Second, strategies
that were more costly, but also less effective than any previous strategy, were excluded from the ICER
calculation (known as dominance). Third, and finally, the ICERs were recalculated for the remaining
strategies, from the least to most expensive.
The first part of the results shows that smokers who received only the personal tailored letter but did not
attend the taster session were least likely (6.3%) to take up the SSS, with an average cost of £46 per
participant (see Table 36). Therefore, the tailored letter was dominated by the standard generic letter,
which only cost £0.87 per person, with 9.0% of these attending the SSS. The results indicate that about
half (45.7%) of smokers who received the taster session followed by a tailored letter attended the SSS.
The ICER of comparing the tailored letter plus the taster session to generic letter was estimated as £196
per additional attendee to the SSS.
Similarly, using validated 7-day abstinence as an outcome, the tailored letter was dominated by the
tailored letter plus taster session, as it is more costly and less effective (see Table 36). Comparing the
tailored letter plus taster session with the generic letter, the ICER was as low as £6 per additional quitter.
When the QALY was used as the outcome measure, the ICER was estimated at £300 per QALY gained
comparing tailored letter plus taster session with the generic letter. When comparing the tailored letter
alone with the tailored letter plus taster session, the ICER was £63,400 per QALY gained. Given the NICE
decision-making thresholds range of £20,000–30,000 per QALY gained, interventions below the lower
threshold will be acceptable as a cost-effective intervention, and interventions that are above the upper
threshold will be rejected. Therefore, the tailored letter plus taster session is considered as the optimal
strategy among the three alternatives in the sensitivity analysis.
Long-term costs and outcomes predictions
The CEA extrapolated to the lifetime time horizon used QALYs as the effectiveness/outcome measure.
The lifetime accumulative QALY gains by gender and age group are summarised in Table 37. QALYs were
reported by participants’ smoking status, which includes ex-occasional smokers (who have only smoked
once or twice), ex-regular smokers (who used to smoke sometimes but have now quit), light smokers
TABLE 37 Cumulative lifetime QALY gains by gender and age group
Smoking status Lifetime QALY gain (years)
Male 16–24 years 25–34 years 35–44 years 45–54 years 55–64 years 65–74 years 75–79 years
Ex-occasional smoker 65.603 46.986 37.555 28.379 19.675 11.574 3.706
Ex-regular smoker 64.914 46.461 37.155 28.097 19.501 11.481 3.679
Light smoker 64.196 46.010 36.744 27.742 19.216 11.299 3.615
Moderate smoker 63.341 45.433 36.267 27.368 18.946 11.131 3.556
Heavy smoker 61.915 44.463 35.492 26.764 18.505 10.858 3.463
Female 16–24 years 25–34 years 35–44 years 45–54 years 55–64 years 65–74 years 75–83 years
Ex-occasional smoker 49.664 45.974 36.868 27.877 19.284 11.354 3.540
Ex-regular smoker 49.002 45.369 36.381 27.509 19.030 11.203 3.494
Light smoker 48.622 44.997 36.059 27.245 18.827 11.079 3.448
Moderate smoker 48.006 44.425 35.590 26.874 18.557 10.909 3.389
Heavy smoker 46.874 43.377 34.747 26.225 18.095 10.629 3.293
HEALTH ECONOMICS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
84
(who smoke fewer than 10 cigarettes a day), moderate smokers (who smoke between 10–19 cigarettes a
day) and heavy smokers (who smoke 20 or more cigarettes a day). The long-term analysis used a lifetime
horizon, effectively covering all participants’ remaining lifetime between the age they entered the trial until
the time they reach the national average life expectancy at birth. It is reported that the average life
expectancy at birth was 81 years (79 years for males and 83 years for females) in 2013 in the UK.112
Table 38 reports the accumulative lifetime QALY gains after discounting. In this study, QALYs and costs
were both discounted at 3.5% per year. Overall lifetime health costs due to smoking-related diseases for
both smokers and ex-smokers were derived from the published economic model and are reported in
Table 39.
TABLE 38 Discounted cumulative lifetime QALY gains by gender and age group
Smoking status Discounted lifetime QALY gain (years)
Male 16–24 years 25–34 years 35–44 years 45–54 years 55–64 years 65–74 years 75–79 years
Ex-occasional smoker 22.421 20.530 18.032 14.924 11.165 6.370 3.347
Ex-regular smoker 22.137 20.287 17.832 14.776 11.067 6.320 3.322
Light smoker 21.992 20.117 17.648 14.589 10.903 6.218 3.264
Moderate smoker 21.732 19.874 17.424 14.394 10.749 6.124 3.211
Heavy smoker 21.274 19.463 17.060 14.078 10.497 5.971 3.127
Female 16–24 years 25–34 years 35–44 years 45–54 years 55–64 years 65–74 years 75–83 years
Ex-occasional smoker 22.201 20.558 18.379 15.590 12.267 8.062 5.385
Ex-regular smoker 21.901 20.288 18.136 15.385 12.105 7.956 5.315
Light smoker 21.762 20.132 17.980 15.234 11.973 7.863 5.246
Moderate smoker 21.497 19.885 17.749 15.026 11.797 7.737 5.156
Heavy smoker 20.997 19.423 17.332 14.661 11.499 7.531 5.010
TABLE 39 Lifetime health-care costs due to myocardial infarction, stroke, lung cancer, COPD and other causes
of death
Smoking status
Gender
Men Women
Current smokers
Before discounting £22,386 £17,559
Discounted £7029 £4792
Ex-smokers
Before discounting £18,044 £14,076
Discounted £5023 £3360
Difference between smokers and ex-smokers
Before discounting £4342 £3482
Discounted £2006 £1432
Source: Ali et al.52
DOI: 10.3310/hta21030 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 3
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Gilbert et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
85
Participants in the trial were simultaneously assigned different lifetime costs and QALYs in accordance with
their smoking status and characteristics. The lifetime costs and QALYs were adjusted by the 6-month costs
and QALYs reported in the previous within-trial analysis, and the average lifetime costs and QALYs of each
intervention before and after discounting are presented in Table 40. Participants who received the tailored
intervention were expected to have a health-care cost savings of £210 (before discounting) and £74
(after discounting) over their lifetime compared with those who received usual care. Meanwhile, they also
have higher lifetime QALY gains of 0.470 (before discounting) and 0.196 (after discounting) than people in
the usual-care group. The results suggest that over the participants’ lifetime, tailored letters and taster
sessions generate more QALY gains with less cost; in other words, the intervention is more cost-effective
than the control condition.
The long-term CEA results are also summarised in Table 40, indicating a lifetime horizon ICER of –£447
(95% CI –£4368 to £3646) per QALY and discounted ICER of –£376 (95% CI –£3881 to £3207) per QALY.
Figures 20 and 21 present CEACs for long-term cost-effectiveness. The first CEAC (see Figure 20), using results
before discounting, illustrates that the probability of the tailored letter and taster session being cost-effective
TABLE 40 Long-term cost-effectiveness results
Outcome
Before discounting Discounted
Intervention
group (n= 2635)
Control group
(n= 1748)
Intervention
group (n= 2635)
Control group
(n= 1748)
Lifetime cost, mean (SD) £19,390 (£2776) £19,601 (£2787) £5775 (£1109) £5848 (£1114)
Cost difference (intervention – control)
(95% CI)
–£210 (–£432 to £11) –£74 (–£162 to £15)
Lifetime QALY gains, mean (SD) 27.009 (11.894) 26.539 (11.943) 13.974 (4.424) 13.778 (4.442)
QALY difference
(intervention – control) (95% CI)
0.470 (–0.478 to 1.419) 0.196 (–0.157 to 0.549)
ICER (cost per QALY gained) (95% CI) –£447 (–£4368 to £3646) –£376 (–£3881 to £3207)
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FIGURE 20 Lifetime CEAC (before discounting).
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was between 83.4% and 83.5% at a willingness-to-pay threshold range of £20,000–30,000 per QALY gained.
Figure 21 shows the discounted CEAC, which indicates that the probability of the intervention being
cost-effective compared with generic letter was 86.1% at £20,000 per QALY and 86.0% at £30,000 per QALY.
Summary/conclusion
This economic evaluation assessed the cost-effectiveness of the personal tailored risk information and
taster sessions compared with the standard generic letter advertising the SSS.
The mean intervention cost was £54 (SD £12) per participant in the intervention group and £0.90 (SD £2)
per participant in the control group. Taking into consideration the wider health resource use, smokers who
received the intervention had non-significantly higher total mean costs over the 6-month follow-up period
(mean cost difference £98, 95% CI –£26 to £222). After adjusting for baseline resource use, the adjusted
cost difference was £92 (95% CI –£32 to £216).
The clinical outcomes used in the economic evaluation were reported in Chapter 3, that is, the uptake of
SSS and quit rates. It is recommended by NICE that cost-effectiveness be expressed in terms of cost
per QALY. In this study, there was a non-significant trend towards improved QALYs associated with the
intervention (unadjusted mean QALY difference of 0.0001, 95% CI –0.008 to 0.009). After adjustment for
baseline utility, the difference in adjusted QALYs was 0.002 (95% CI –0.001 to 0.004).
The base-case within-trial CEA was based on a multiple-imputed data set in which all the missing values
were imputed using a multiple imputation method. The ICER associated with the intervention was
estimated at £627 per additional attendee to the SSS, £2689 for an additional quitter and £59,401
per QALY gained. The CEAC illustrates that, when using the NICE decision-making threshold range of
£20,000–30,000 per QALY gained, the tailored letter and taster session has a 20–27% probability of being
considered cost-effective at 6 months. Only at higher willingness-to-pay thresholds (> £59,401 per QALY)
does the intervention become more likely to be cost-effective compared with the control.
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Complete-case analysis was conducted as part of the sensitivity analysis to explore the impact of missing
data. The results show that for both trial arms, mean costs and effectiveness were higher in the complete
cases. The ICERs of the complete-case analyses were estimated at £498 (95% CI £491 to £504) per
additional attendee to the SSSs, £2552 (95% CI –£1199 to £6303) per additional quitter and £49,842
(95% CI –£425,064 to £536,813) per QALY gained when comparing the intervention with the control
group. The probability that the intervention would be considered more cost-effective than the control was
24–34% at the £20,000–30,000 per QALY threshold. The complete-case results appeared to be robust
compared with analyses including imputed data.
This study uses a multicomponent intervention and, hence, the costs and effects of each intervention
element were explored in the sensitivity analysis. Participants who received a tailored letter but did not
attend any taster session were found to have the lowest rates of SSS attendance and smoking cessation,
and were associated with higher costs than those who received only the generic letter. When comparing
the participants who received both tailored letter and taster session with participants who received the
generic letter, the ICER was estimated as £196 per additional attendee to the SSS, £6 per additional
quitter and £300 per QALY gained. Considering that the majority of the cost (£46 out of £72) incurred in
the intervention group was for sending tailored letters, these results may suggest ways in which the
intervention in this trial can be improved. For example, cheaper alternatives such as e-mails can be used to
replace the traditional postal questionnaire to reduce the cost of the intervention.
It may take several years before the health benefits of smoking cessation interventions start to have an
impact. In this study, we extrapolated the lifetime cost-effectiveness of the two trial interventions in
addition to the within-trial analyses. The total discounted lifetime health-care cost was lower in the
intervention group at £5775 than in the control group at £5848, with a cost saving of £74 (95% CI
–£15 to £163). However, the intervention group had higher lifetime QALY gains than the control group
(difference in adjusted QALYs of 0.196, 95% CI –0.157 to 0.549). This gives a lifetime horizon discounted
ICER of –£376 (95% CI –£3881 to £3207) per QALY. The probability of the intervention being more
cost-effective compared with the standard generic letter was 86.1% at £20,000 per QALY and 86.0% at
£30,000 per QALY.
In conclusion, the economic evaluation of the Start2quit trial has provided evidence showing that the
personal tailored information and taster sessions results in better clinical outcomes. However, the ICERs
for the intervention compared with the standard generic letter are high and suggest that it is unlikely to be
a cost-effective option in the short term; however, quitting smoking yields far greater health-care cost
savings and health benefits over the long term through the reduced risk of smoking-related diseases.
The long-term results indicate that over a lifetime horizon, the tailored letter and taster sessions is more
effective and less costly than the generic letter, and has a probability of being more cost-effective > 86%
using the £20,000–30,000 per QALY gained decision-making threshold.
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Chapter 6 Discussion
Main outcome and effectiveness
The aim of the Start2quit study was to assess the effectiveness of a complex intervention designed to increase
attendance at the SSSs in England. Attendance at the first session of a 6-week SSS course was significantly
higher in the intervention group than in the control group, increasing by 8.4%. This intervention, utilising
computer-tailoring to deliver personal risk information together with an invitation to attend a no-commitment
‘taster’ session designed to offer information about the SSS, more than doubled attendance at the SSS
compared with the control group, which received a standard generic invitation to contact the service
(OR 2.12). Furthermore, participants in the intervention group were more than twice as likely to attend all
appointments and complete the 6-week SSS course as control participants (OR 2.24). Results also showed
a significantly higher rate of validated 7-day point prevalent abstinence at the 6-month follow-up in the
intervention group, an absolute increase of 3.4% over the control group. Abstinence rates were consistently
higher for all periods of abstinence at the 6-month follow-up, both point prevalent and prolonged. This
finding is important as it demonstrates that the intervention also translated to increased quit rates.
These results compare favourably with previous research of Murray et al.29 and of Lichtenstein and Hollis,27
on which the Start2quit study had built. Both of these previous studies had attempted to combine a
proactive approach with informing smokers about local services. Murray et al.29 reported a 7.7% absolute
increase in smokers using the SSS over a control group, and Lichtenstein and Hollis27 found a striking
improvement in attendance at both the first session and the last session of a cessation programme.
Murray et al.29 had also found an increase of 1.8% in 7-day-validated quit rate, although this was only in a
post hoc evaluation of a subgroup of smokers requesting help, not in the whole sample between the
intervention and the control groups.
The intervention was found to be more effective for some groups of smokers than for others. Although
the effect of the intervention on attendance at the SSS was significant for both males and females, it was
more pronounced for males, and this differential effect was also observed for 7-day point prevalent
abstinence at the 6-month follow-up. There was also a significant difference in attendance by level of
social deprivation. However, this appears to be a result of lower attendance in the control group by
smokers in mid-levels of social deprivation rather than the intervention having a greater effect on this
group. There was no significant difference in abstinence by social deprivation, and neither attendance nor
abstinence differed by age category.
The intervention was further enhanced by the addition of a repeated personal letter and invitation sent
3 months after the original, to all participants who failed to attend a taster session after the first invitation.
The pattern of attendance over the 6 months suggested that there was little effect on attendance at the
SSS of sending these repeat reminders to smokers. There was also little difference in attendance due to
seasonal variations.
Recruitment, retention and generalisability of the trial findings
The strategy of proactive recruitment approach using mass mailing aimed to recruit a more representative
sample of smokers and to reach smokers who would otherwise, using more traditional reactive recruitment
methods, not be aware of the research or of the SSS.
Although 19.6% of those invited replied to the invitation, many of these replied to say that they were
non-smokers and others declined to participate but wished to update their GP records. The response rate
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of 4.1% from smokers willing to take part is lower than in some studies using this recruitment method.
For example, Murray et al.29 reported a response rate of 31% from 24 practices located in one area of
Nottingham. Our lower response could be due to a more intensive intervention or longer assessment
questionnaire. In addition, differences in the definition of consent and stricter criteria for inclusion reduced
the possibility of being eligible for the research. The local nature of the research in Nottingham may also
have encouraged participation, whereas the Start2quit study, as a national one, was more remote and could
have deterred some smokers from taking part. In addition, records are not always accurate, and inaccuracies
in recording and in the practice search could also have led to the lower response rate. The exact number of
non-smokers wrongly recorded is not known, as some responded to update their current smoking status
on the GP records, but it is possible that the others did not do so. Nevertheless, the requirement to screen
and record smoking status does allow for the identification of smokers and patients with chronic diseases.
In comparison with the more traditional reactive approach to recruitment, where researchers advertise and
wait for response, the size and the representativeness of the sample is high.26,113,114
An additional advantage of the proactive recruitment method is the ability to target at-risk groups,
and a priority of the SSS is to help disadvantaged people and to deliver cessation services to poorer
communities.8 Therefore, practices in areas of high deprivation were preferentially selected, with the result
that over half of the practices were located in areas of high deprivation. Unfortunately, although this
meant that about half were sampled from areas of higher deprivation, this was to the detriment of
achieving a higher response rate, as people living in deprived areas, in general, had lower response rates.
The total response and recruitment varied greatly between areas and between practices within an area.
Location of the practice is a major influence on the recruitment rate to trials of smoking cessation.115
Response rates in some areas of < 2% may be explained by very high deprivation, large ethnic populations,
a younger population or practice characteristics, such as a larger list size.
Validation of attendance at the SSS was obtained for each participant from the relevant SSSs. Thus, 100%
follow-up was obtained for the primary outcome. Completion of the follow-up, either by interview or by
questionnaire, was obtained from 76.9% of the sample, a high proportion in comparison with some
smoking studies. For example, Murray et al.29 obtained a 48% follow-up rate. However, validation of
self-reported abstinence was low. Although most participants claiming abstinence agreed to send a saliva
sample, samples were received from only two-thirds of those reporting abstinence, and sent for analysis.
Reasons for not returning the sample could include a return to smoking; therefore, our assumption that all
those who were not validated had not quit was a cautious one, and our results reflect the most conservative
estimate. There is no reason to assume any differential in return, or validation, between the groups.
A strength of this study was the collection of anonymised data of those invited but who did not agree to
take part in the study, in order to explore the external validity of the sample. This allowed us to establish
that, although the sample was significantly older than the average smoker in all areas, the differences in
gender and deprivation were small, and we can consider the sample to have reasonable external validity.
Interpretation, acceptance and feasibility
The intervention used in this study employed a two-pronged approach consisting of the use of computer-
tailoring technology to send personal risk information in a letter inviting smokers to attend a taster session.
This session offered smokers the opportunity to learn more about the services before committing to and
signing up to a 6-week course.
The inclusion of individual risk information in the personal invitation to a taster session was justified by
evidence, both empirical and theoretical, that fear messages, when accompanied by a cue to action, will
increase the likelihood of following the recommended behaviour.16,36,37 Analysis of the perception of the
personal letter suggested that the letter was well accepted. Participants who received the personal letter
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perceived it as more positive than how control group participants perceived the generic letter. They were
more likely than recipients of the generic letter to read and discuss the letter with others, they felt that it
was more personally relevant to them, and reported that they felt more confident and determined towards
quitting. It is important to establish the correct balance between anxiety and reassurance,16 there is a risk
that this direct personal approach could induce too much fear or create hostility. Our concern was that our
communication would upset participants and, thus, prompt a maladaptive response. In fact, very few
respondents reported perceiving the letter as antagonistic or depressing, and < 10% of recipients reported
feeling anxious because of the letter. It could be argued that insufficient concern was induced; however,
the immediate offer of support was intended to reassure recipients and reports of anxiety could be offset
by this offer. The low anxiety could indicate that the balance of risk information with awareness of the
availability of support was appropriate.
Reports from participants who took up the offer of attendance at a taster session were also positive, and
the taster sessions were seen as helpful and encouraging. Ratings immediately following the taster session
were higher than those at the 6-month follow-up, and reported intention to sign up at both times was
higher than the actual attendance. Although this retrospective or recall bias can represent a threat to the
internal validity of studies using self-reported data, in this case it illustrates the tendency of participants to
report past events from the perspective of the present situation. In the case of smokers, their recollection
of the event could be affected by their behaviour since the taster session, that is, their success or otherwise
in attempting to stop smoking. The recollection of the smokers who did not quit, or who did not attend
the SSS, would account for the lower ratings at the follow-up. Nevertheless, comments from attendees
suggested that the taster sessions were reassuring and built the intended awareness and comfort with
the services.
A limitation of the study is that it is not possible to disentangle these two parts of the intervention.
The Global Dialogue for Effective Stop Smoking Campaigns44 particularly recommended the use of a
combination of ‘why quit’ and ‘how to quit’ messages, hard-hitting messages about the consequences of
tobacco use paired with a supportive and positive message emphasising quitting resources, and giving
smokers hope that they can succeed. Indeed, when participants were asked whether attending the taster
session or receiving the letter was more important in their decision to attend the SSS, most said both
equally contributed to their decision. Although many cited health concerns as a reason for attending, the
letter coming at the right time to prompt them to make an appointment was also cited. However, despite
many participants reporting that both the letter and the taster session prompted attendance at the SSS,
few attended the SSS without first attending the taster session. Thus, it is likely that once prompted to
attend an introductory no-commitment session, the sessions did help smokers to feel empowered and
hopeful about quitting, and encouraged them to accept the support offered by the SSS, implying that
both parts of the intervention together are needed to prompt uptake of the service. Although we can
speculate that both the personal letter and risk information prompted attendance at the taster session,
it is not known how much attendance would have occurred if smokers had received a standard generic
invitation to a taster session.
That the intervention also translated to increased quit rates is an important outcome of this study. Of the
two previous studies on which this study built, Lichtenstein and Hollis27 did not follow up to discover if
attendance led to an increased quit rate, and Murray et al.29 failed to show a difference between point
prevalent abstinence rates, either validated or self-reported, between the intervention and control groups,
at the 6-month follow-up.
Concern has been expressed that, although proactive recruitment is effective and it is possible to raise
awareness of services and encourage use of treatment services, smokers recruited proactively may be
less likely than self-referred patients to quit.116 Although traditionally smokers with an intention to quit
smoking in the next 2 weeks are targeted by the SSS for attendance, studies have shown that smokers
stating no plans to quit can be engaged in quitting activity117,118 and that some smokers do quit without
entering a preparation stage.41,119 Thus, we deliberately used wider criteria for enrolment in this study, and
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included those whose intention to quit was more distant, or who were not planning to quit but expressed
an interest in receiving help. Despite recruiting a high proportion (42.5%) of participants who intended
to quit in the next 6 months (but not in the next 30 days), the proportion of validated 7-day abstinent
who had received a personal risk letter and had attended the SSS was comparable with estimates of
longer-term abstinence in recipients of treatment from the SSS.6
Tzelepis et al.,24 in a study of telephone counselling among cold-called smokers, found that the proportion
achieving prolonged abstinence was lower than corresponding rates in treatment seekers, and that
proactive recruitment to a quitline was more effective in smokers who are intending to quit in the next
30 days. However, Tzelepis et al. also pointed out that if counselling were offered only to smokers ready to
quit, a large proportion of proactively recruited smokers would miss out on getting effective support.120
Borland et al.121 recently demonstrated the superiority in longer-term outcome of structured planning
over unstructured, more spontaneous quit attempts. Balmford and Borland88 have also suggested that
treatments do not only help during a quit attempt and help to prevent relapse, but can encourage and
increase motivation to quit. Thus, recruiting smokers who might have more distal plans to quit may be
beneficial in increasing readiness to quit and in planning and preparing to quit, and might result in more
successful attempts and long-term abstinence than if these smokers are left to make abrupt unplanned
attempts on their own.
What was clear in these results was that attendance at the SSS greatly impacted on quit rates. Participants
in both the intervention and control groups who attended the SSS were more likely to achieve 7-day
abstinence at the follow-up than those who did not. It is difficult to compare these figures with official SSS
figures, as different abstinence periods and definitions of abstinence are used. It does, however, support
the efficacy of the SSS in increasing the success of quit attempts over unsupported attempts, and endorses
the notion that smokers who take advantage of stop smoking programmes have a greater chance of
stopping smoking and remaining abstinent than those who try to quit on their own. Nevertheless, the quit
rate of around 5% in those who did not attend (in both treatment groups) is higher than one would
expect in spontaneous quit rates,122,123 suggesting that a prompt of any kind through mass mailing can
have a positive effect.
In addition, it was found that abstinence was substantially higher in participants who received the
intervention and attended the SSS than in control group participants who had attended but received only
the generic letter. One interpretation of this higher quit rate in SSS attendees in the intervention group is
that the additional components of the intervention, both the personal risk letter and the introductory
session, played some part in increasing motivation. This motivation was then augmented by the support
given by the SSS advisors, resulting in a higher abstinence rate. Again, over half of the respondents
reported that both the personal letter and the taster session were equally important in their decision to
quit. However, it was not possible to validate these claims in the current analysis and further research is
necessary to disentangle the effects of each of the components of this intervention.
Although the efficacy of the SSS in increasing the success of quit attempts was evident, some variation was
found in both attendance and in 7-day validated abstinence between SSSs. At the best-performing SSS, the
rate of attendance was 28.3% in the intervention group, and overall 7-day abstinence, combining both
groups, was 13.4%. There is known to be wide variation in outcomes between SSSs.123–125 Abstinence rates
can vary significantly depending on which practitioner and type of practitioner was seen, and it is known
that some types of intervention (group or one-to-one) are more effective than others.126,127 Abstinence rates
can also be affected by other factors, such as the dependence and deprivation level of the population
served,128 and it is likely that these factors were at least partly responsible for the variation in abstinence
rates seen in this study. However, differences in organisation and service characteristics could be a more
central influence on attendance following the taster session. Advisors were trained to standardise taster
sessions according to a protocol, and the analysis of adherence to the protocol showed that the delivery
of the intervention did not influence subsequent attendance. Thus, local service characteristics and
organisational factors are likely candidates that could account for the variation in the number of participants
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attending the first session of a SSS course. The organisation of the SSSs could have played a part in terms of
how soon the clients were seen, how many different locations and times were offered and, importantly,
how responsive the services were to smokers wanting to accept the offer of treatment when they indicated
their intention to sign up to a course. It is reasonable to assume that those SSSs that were able to offer
appointments at the time of the taster session were more successful in recruiting smokers to their service,
as motivation can quickly wane if immediate action is not taken. Unfortunately, this information was not
available from the SSSs, so it is not possible to confirm this supposition.
During the recruitment period for this study, SSSs were going through a significant change in
commissioning. The tendering out of previously in-house services led to some SSSs being run by private
and voluntary sector companies. We do not know how this might have positively or negatively influenced
our findings. The most likely effect was that those SSSs that were least confident and organised in the
changeover would decline to participate and this would reduce the generalisation of our results.
Our analysis showed that the intervention was more effective for some subgroups of smokers. Whereas
typically more women than men attend and set a quit date with the services,18 more men than women
were encouraged by this intervention to attend. In addition, slightly more men than women achieved
abstinence, and this corresponds to the success rate of giving up smoking reported by the SSS, which is
higher among men than among women (52% of men compared with 50% of women), although in this
study the differential was a result of fewer men in the control group achieving abstinence. This suggests
that the trend for greater attendance by women could be reversed by using these measures to encourage
men to use the support and, thus, reduce the number of unaided and unsuccessful attempts made by men
to quit smoking.
Traditionally, smokers in employment classified as ‘routine and manual occupations’, as classified by a
methodology adapted for use in NHS Smoking Cessation Services,96 have the highest number of people
setting a quit date and successfully quitting, accounting for about one-quarter. In our study, attendance at
the SSS in the intervention group was similar for all levels of deprivation but lower in the control group for
participants in areas of medium deprivation. This, again, suggests that a group who would not normally
seek help were encouraged to do so by this intervention. However, even though attendance was as high
in smokers from areas of higher deprivation, abstinence rates tended to be lower overall in these smokers,
with no differential effect. Murray et al.29 also reported a linear trend where the desire to talk with an
advisor increased with the amount of deprivation, and the low abstinence rates in these smokers in areas
of high deprivation suggests that this expressed need for help does not translate to an increase in
abstinence in those who need it most. Unacceptable smoking-related health inequalities persist, and one
of the aims of this study was to target more deprived smokers and encourage them to get help. The
problem may be one of keeping these smokers in the programmes, and addressing the particular problems
faced by them, rather than encouraging them to attend in the first place.
This leads to a consideration of the factor analysis of barriers to attendance at the SSS. This exploration
suggested that one of the main reasons for non-attendance is work and time constraints, also endorsed by
answers to open questions in which many said that they were too busy and had other commitments to
attend the SSS or the taster session, or that that the sessions were held at inconvenient times or locations.
These constraints can apply through all social strata, and to both men and women. The people from areas
of lower deprivation might genuinely work longer hours and have less time, whereas the more highly
deprived might not have the support for childcare and transportation, and are not able to get to clinics.
Our exploratory factor analysis also showed that a disbelief in the efficacy of programmes was evident,
confirming an issue that is prevalent in the literature across the globe. This lack of faith in programmes of
support, together with pressure from work or lack of support, particularly in lower socioeconomic smokers,
can combine to deter attendance, and calls for interventions designed to change beliefs to increase the
initiation of evidence-based treatment.85 Reassurance of the effectiveness of the programmes of support
and of the empathy of advisors, in the form of introductory sessions, in addition to the provision of clinics
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that are easily and immediately accessed at convenient times, could help to overcome these barriers and
increase uptake.
Cost-effectiveness
To our knowledge, Start2quit is the first large randomised controlled trial that has assessed the cost-
effectiveness of a complex intervention designed to increase attendance at the SSS in the UK. The CEA
was conducted to establish the value for money of the personal risk information and taster sessions
compared with the standard generic letter. The mean intervention cost was high at £54 per participant,
whereas the corresponding average cost in the control group was only £0.90 per participant. The
within-trial CEA generated ICERs of £627 per additional attendee to the SSSs and £2689 for an additional
quitter. This means, if the decision-makers are willing to pay more than £627 for an additional service user
or £2689 for an additional quitter, the tailored letter and taster session would be the preferred option,
otherwise usual care should be adopted.
When using QALY as a standard health outcome measurement, the short-term ICER was estimated
at £59,401 per additional QALY gained. When using the NICE decision-making threshold range of
£20,000–30,000 per QALY gained, the tailored letter and taster session has a 20–27% probability of being
considered cost-effective at 6 months. Only at higher willingness-to-pay thresholds (> £59,401 per QALY),
does the intervention become more likely to be cost-effective compared with the control.
However, it is important to consider that quitting smoking yields far greater health-care cost savings and
health benefits over the long term through the reduced risk of smoking-related diseases. The long-term
benefits from the smoking control interventions may take several years before starting to have an impact.
After taking into account the lifetime cost savings and health benefits from stopping smoking, the
long-term results indicate that the intervention is more effective and less costly than the generic letter.
Over a lifetime horizon, the intervention has a probability of being more cost-effective using the
£20,000–30,000 per QALY gained decision-making threshold range.
Participants who received the tailored letter but did not attend any taster session were found to have the
lowest rates of SSS attendance and smoking cessation, and when costs and effects of each intervention
element were explored in a sensitivity analysis, it was found that these participants were associated with
higher costs than those who received solely the generic letter. When comparing the participants who
received both the tailored letter and taster session with participants who received the generic letter, the
ICER was estimated as £195 per additional attendee to the SSS, £66 per additional quitter and £300 per
QALY gained. The results indicate that providing participants with both a tailored letter and taster session
improved the cost-effectiveness, compared with using the tailored letter alone. Therefore, further research
should aim to increase attendance of taster sessions.
Postage accounted for a high proportion of the cost in the intervention group, and adaptations could be
introduced that could, while retaining the personal nature of the letter, reduce the amount of assessment
necessary. If assessment could be achieved through cheaper alternatives, such as e-mails used to replace
the traditional postal questionnaire, it might be possible to attain the same results at lower cost. In
addition, the tailored letter did not include information promoting the local availability of the service, and
adding a SSS advertising component to the tailored letter might increase uptake of the service without
attendance at a taster session.
Strengths and limitations
This trial has demonstrated several methodological strengths. This is the first and largest study to examine
the effect of using introductory taster sessions to encourage people to attend a smoking cessation service.
We recruited 4383 people from 18 regions across England. The collection of anonymised data of those
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invited but who did not agree to take part in the study allowed us establish that the representativeness of
the sample was acceptable.
Another major strength of the study was that for the main outcome we were able to collect complete
data from SSS records. Although we were reliant on the accuracy of reporting from the SSSs, this
represents a significant improvement on the self-report outcome reported by Murray et al.,29 which relied
on self-reporting and, in addition, had a low follow-up completion rate of 48%. We demonstrated a
discrepancy between recalled attendance and validated attendance. Thus, our study represents a much
more accurate outcome, not affected by poor recall or misunderstanding of what constituted attendance
at the SSS, and not over-reported because of the social desirability response bias of the intervention group,
which would involve wanting to report higher attendance.
A further important strength was that smoking outcome data were collected, allowing us to define the
ultimate efficacy in terms of abstinence, rather than only at the attendance point. Although abstinence
could be estimated based on quit rates within SSSs, different definitions of abstinence have been used,
which do not allow comparison with other smoking cessation studies. Furthermore, it allowed us to show
that smokers recruited proactively to the SSS can have outcomes as successful as self-referred clients.
By randomising at the level of participant rather than by practice, there was a slight risk of contamination
by communication between patients at the same practice allocated to different intervention groups. We
built into the trial safeguards against contamination by ensuring that only one person from the same
household received a screening questionnaire and by monitoring attendance at the taster sessions, to
ensure that anyone attending who had not received an invitation was recorded and checked against
participants in the control group. We also kept a record of attendance at the taster sessions and measured
the amount of contamination at follow-up by asking participants who had not attended a taster session
whether or not they personally knew or had spoken to anyone else who had been invited or attended to a
taster session. The results suggested that few control participants had access to information from the taster
sessions and, thus, there was no contamination bias.
Finally, an assessment of the fidelity of the delivery of taster sessions to the protocol was embedded into
the trial. In general, adherence to the protocol was high, although variable. But adherence to the protocol
was not related to the main outcome of attendance at the SSS or to abstinence from smoking. The first
part of the intervention consisting of the personal risk letter was tailored to the individual’s personal
characteristics by computer and, therefore, the format was standard for all participants, and all advisors
had received standardised training to deliver the taster sessions. Thus, we can be sure that the outcome is
a result of the intervention and not a result of other non-specified variables.
There were also some limitations to the study, in addition to the difficulty of dismantling the two
components of the intervention, which has been already discussed.
Although the recruited SSSs were spread across England, were located in both high and low areas of
deprivation and represented both large and small organisations, we did include only a sample of areas.
Eighteen of the 151 SSSs were included, and these participating SSSs may not necessarily be representative
of all SSSs in England. It is likely that those agreeing to participate were the more organised and
enterprising ones. That is not to say, however, that the less organised SSSs would be less successful in
encouraging uptake were they to introduce these procedures and offer introductory sessions to encourage
attendance. Recruitment took place at a time when SSSs were undergoing changes in commissioning and
we do not know how this affected the decision to take part or not.
In addition, although our proactive recruitment strategy was a strength of the study, the recruitment rate
was low, at 4%. As a result, we recruited only a small proportion of smokers in each area. Comparison of
some demographics confirmed that the sample was reasonably representative of smokers in terms of
gender and deprivation, but we failed to recruit sufficient younger smokers. It is important to attract this
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population as attendance at the SSS at present tends to be concentrated in older age groups. There was
a large difference in response from different SSS areas. Although we aimed to target areas with a high
number of ethnic minorities, the response rate in these areas was particularly low and, thus, in areas with
a very low response rate the generalisability of the results may be reduced.
We had initially hypothesised that the intervention’s effectiveness might differ by socioeconomic group and
analysis of the interaction between the intervention and deprivation was prespecified. Before any analysis
began, we extended our planned investigation to investigate interactions of intervention with age group
and gender also. These were the only prespecified analyses of interactions.
Observational data were used for the primary outcome rather than subjective self-reported data. However,
the collection of these outcome data depended on accurate recording and submission by local SSS
collaborators, and on the collaborators being blind to group assignment. There may have been some cases
in which loss of blinding occurred, and SSS advisors knew to which group the client had been assigned,
leading to bias in treatment.
Finally, assumptions were made for the long-term CEA. To maintain consistency with the Markov model
we adopted to generate lifetime cost savings from the interventions, participants’ smoking status was
assumed to stay unchanged after the trial period. Specifically, we assumed that those participants who
managed to quit at the end of the trial will stay abstinent from smoking for the rest of their life, and
smokers who have not given up will carry on smoking until they die. However, in real life, many quitters
may relapse to smoking again and some smokers may quit smoking without any aid at some point.
Therefore, further research with longer follow-up periods or models that allow for smoking relapse and
spontaneous abstinence are recommended.
DISCUSSION
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Chapter 7 Conclusions
Main conclusion
The Start2quit trial built on previous work by Murray et al.29 and added to the evidence that a proactive
approach can be successful in reaching more smokers and informing them of the SSSs and, consequently,
increase uptake of the service. We introduced a more intensive intervention to deliver personalised risk
information and provide a no-commitment introductory session designed to inform smokers about the
service and what it offers. The results showed that reaching out to smokers with more individualised
personal invitations can more than double attendance at the SSS. We also demonstrated that the
increased attendance translated into increased quit rates. The acceptability of both parts of the
intervention was established.
Although the results of the within-trial CEA indicate that the personal risk information and taster sessions
is less likely to be a cost-effective option in short term than the generic letter, the long-term predictions
suggest that over a lifetime horizon the intervention is more effective and less costly than the generic
letter. Some adaptation, such as using e-mail to replace the traditional postal questionnaire, might reduce
the postage costs without reducing the impact and, thus, could increase the viability of the strategy as a
means to increase uptake of the SSSs.
Recommendations for research
The complexity and interaction between the two components of this intervention make it difficult to
identify how the components work and to determine which component is the most essential. The first
priority for future research following on from this study would be to dismantle the components of the
intervention in a factorial study to assess their separate effects, and to identify the mechanisms of action.
Other recommendations for future research include:
l Further investigation into the long-term abstinence of smokers proactively recruited compared with
those who self-refer, to determine whether or not the quit rates persist into longer-term abstinence of
≥ 12 months.
l More exploration of the barriers to seeking help and to attendance at support services could suggest
changes to the format, content and timing of the introductory session. Although this research has
suggested the value of an introduction of some kind to the service, attendance at these sessions could
still be higher, and subsequent attendance at the SSSs could also be improved. Different formats of
introductory session might be attractive to different smokers, and qualitative research might suggest
ways to increase attendance, for example an open invitation to family and friends to allow more
widespread promotion of the service, and possibly engage with more members of a community.
l Qualitative work to break down the components of the personal risk letter and to investigate, for
example, which type of smoker is likely to be prompted by the contents to attend (i.e. what works and
for whom?).
l Despite the proactive recruitment strategy, response to the initial questionnaire was relatively low.
Experimentation with reactive and opportunistic recruitment could suggest ways in which initial
recruitment to the research could be improved.
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Implications for health care
Until 2011 the number of smokers accessing the SSSs had been increasing. However, recent data have
shown a significant decrease in the past few years.18 This trend is regrettable, as services offer smokers a
significantly higher chance of stopping smoking than trying to quit without support.
The evidence suggests that a programme of proactive recruitment can be effective in raising awareness of
the SSS and personal invitations, with or without additional risk information, may also offer the services an
opportunity to promote the service in the form of introductory sessions to emphasise its approachability
and empathy.
The cost of this intervention in its entirety may be a problem for some providers. The use of computer
programs is expensive and increases the cost for each additional quitter. Adaptations to the intervention
could be introduced, with the potential to retain the impact on attendance. Health professionals are
currently encouraged to routinely refer smokers to local SSSs, but the provision of very brief advice in the
form of ‘ask, advise, act’ is insufficient and many referrals are not followed up by the patient, or by the
health-care professional. A more proactive approach of ‘ask, advise, contact’, in which smokers are
contacted proactively by the service on receipt of their contact information, can reduce patient barriers to
receiving treatment, and also has high potential to increase uptake.128
The results of the adherence to the delivery of the intervention would suggest that the protocol for the
taster session is appropriate. Adaptations to suit the local features and attributes could be implemented,
with mechanisms to ensure that interested clients are offered early and convenient appointments with
the service.
In the short term, the personal risk information and taster session is an expensive intervention compared
with the generic letter. However, over a lifetime horizon, the intervention has an 86% probability of being
more cost-effective than the generic letter. Successful implementation of the intervention is likely to yield
greater health-care cost savings and health benefits over the long term through the reduced risk of
smoking-related diseases. These results suggest that use of personal risk information and taster session
rather than generic letters has potential long-term costs and health benefits.
Intellectual property and adoption of positive elements of the
approach in the NHS
This approach is one that could be adopted by commissioners, who may in the future request cessation
services to run introductory taster sessions with no obligation for patients to sign up. If such taster sessions
are available, tailored letters to patients who are smokers may be used to prompt their attendance at
taster sessions.
There is a possibility that the intellectual property generated around the tailored letter generation could be
licensed out. However, the software we have used in the study is cumbersome to use and requires manual
input, and is therefore unlikely to suitable to transfer into practice as it is. There may be letter-generating
modules in general practice computer patient record systems, although there are multiple providers of such
systems and, therefore, adaption or custom plug-in software would need to be developed for each.
CONCLUSIONS
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Appendix 1 Changes to protocol
The following changes to the protocol were made during the course of the research.
12 January 2011
l To establish external validity of our results, anonymised average data will be collected from practices
on patients who are invited to participate in the study but do not respond, in order to compare them
with the responders on certain variables. At the end of recruitment in each practice, the names of all
participants who have responded will be removed from the original list. For those remaining, the
names will be removed, along with any other identifying data (i.e. address and NHS number), leaving
gender, date of birth and postcode. The date of birth will be converted to age, and the postcode will
be converted to a deprivation score (IMD via GeoConvert), and then removed from the spreadsheet.
This spreadsheet, containing three variables – gender, age and IMD score – with no identifier, will
then be taken to UCL and used to calculate means for these variables for each practice, and will be
compared with these variables in responders. This will enable us to identify differences between those
who have responded and those who have not, in order to establish whether or not our sample is
generalisable to the rest of the practice population.
25 July 2011
l If a smoker is not eligible to take part in the study we will send an ‘Ineligible’ letter to these individuals,
indicating that they are unable to be included in the study. Furthermore, some smokers may return
their questionnaires outside the timeframe for processing, in which case we will send these individuals
a ‘Late Responder’ letter. Both letters will be sent from the surgery and will advertise the local NHS SSS
and advise the smoker to contact the service for more information or to speak to an advisor.
10 August 2011
l Participants will be asked to fill out a taster session evaluation form at the end of each session. The
purpose of this evaluation form is to provide an ongoing assessment of participants’ perceptions of the
taster session.
l With participant consent, each taster session will be audio-recorded to ensure standardisation of
delivery of taster sessions throughout the trial.
7 December 2011
l All self-reported attendance will be validated by records of attendance. All participants will be asked if
they attended a taster session; those answering negatively will be asked if they know or have spoken
to anyone who attended a taster session.
l Participants claiming 7-day abstinence will be asked to provide a saliva sample to biochemically validate
7-day point prevalent smoking cessation at this 6-month follow-up. Those who agree will be sent a
saliva sample kit which they will be required to complete themselves and return by post. They will also
be asked to complete a consent form and a short questionnaire to confirm their current smoking status
and NRT usage. By way of compensation for participants’ time and to maximise kit return, a £5 Marks
and Spencer voucher will be included with each postal kit.
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9 May 2012
l Advisors will be required to complete a Stop Smoking Advisor Personal Details Form. The information
provided will ensure that ‘therapist effects’ are accounted for in the fidelity analysis.
l To maximise retention of participants at the 6-month follow-up (70% retention obtained in pilot phase),
additional procedures will be utilised to obtain follow-up data.
¢ Interviewers will make a maximum of 10 attempts (based on experience in current and previous
studies) to contact a participant by telephone at varying times of day and on different days. If a call
to a participant is answered, interviewers will aim to complete the full follow-up telephone interview.
However, if a participant does not fully complete or does not wish to complete this telephone
follow-up interview, the interviewer will attempt to ask the participant four basic questions most
relevant to the outcome measures. If a participant is unable to be contacted, a paper version of the
follow-up questionnaire will be sent by post. This paper questionnaire will also be sent to participants
who are unable to complete the telephone interview but are willing to fill in a paper questionnaire.
¢ If, after 10 attempts on different days and times, the interviewers have been unable to speak to a
participant in person, they will attempt to leave a message, either with another person or on an
answer phone/voicemail. At this time, participants will also be sent a text message, prompting a
response back to the mobile phone from which it was sent. This message will state, ‘six months
ago you agreed to complete a follow-up phone interview for UCL smoking study Start2quit. Please
text/call to let us know when we can contact you’. If a participant replies, they will be given a date
and time convenient to them to complete the telephone interview. If no response is received after
3 days, the participant will be sent the same message a second time. If no response is received
after a further 3 days, the participant will be sent a postal questionnaire.
l All participants who report not attending the SSS will be asked to complete a further postal
questionnaire. The 40-item TBQ has been validated on a US population and will be used to assess in
more depth reasons and barriers to the use of the NHS SSS. We will validate this instrument on this
UK population.
l If saliva samples are not returned within 7 days, participants will be contacted by a research interviewer
who will remind them to return their kit. Interviewers will make a maximum of 10 attempts to contact
the participant at varying times of day on different days, as before, ensuring that the correct postal
address is held for the participant. After 10 unsuccessful attempts to contact the participant, they will
be sent a text message stating ‘Don’t forget to send your UCL smoking study saliva sample back to
receive your additional £5 M&S’. If the interviewer is successful in contacting the participant but their
sample is not returned within 7 days, the participant will be sent the same text message reminding
them to return their kit. On the return of a saliva sample kit, the participant will be sent an additional
£5 Marks and Spencers voucher thanking them for returning their kit.
16 October 2012
l If the TBQ is not returned within 2 weeks, a reminder will be sent to prompt the participant to return
the questionnaire.
12 November 2013
l Additional funding granted: £631,263
l Additional time granted: 12 months
l In response to an invitation from the HTA programme, for projects successfully recruiting participants,
to fund additional work which will build on and extend the studies.
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Reasons for additional funding
The Start2quit study, assessing the effectiveness on attendance at the NHS services of proactive
recruitment by a brief personal tailored letter and invitation to a taster session, is currently recruiting
successfully. To maximise the utility of the study, the following additional work will build on and enhance
its value.
1. It is important to know whether or not this intervention also translates to increased quit rates, and if
the quit rates in people attending as a result of this intervention differ from the usual quit rates in NHS
services. As well as powering the trial for the original primary outcome (the proportion of people
entering the SSS over a period of 6 months), we will now also power the trial for the secondary
outcome of 7-day point prevalent abstinence at the 6-month follow-up, validated by salivary
cotinine analysis.
Assuming quit rates of 4% versus 2.2% in the intervention and control groups (mimicking the findings
of Murray et al.29), an 80% increase in the sample size is required, to 1793 in the control group and
2707 in the intervention group (assuming the same therapist effect as the original protocol), giving a
total of 4500. A sample of this size would give 85.4% power to detect a difference of 1.8% at the 5%
significance level. The same sample size would have 95% power to detect the difference between quit
rates of 4.4% and 2.2% (doubling of quit rate).
Based on present recruitment figures, we estimate that with an additional eight SSSs (48 GP practices)
we will recruit another 2060 participants, meeting the requirement of the power calculation.
2. Identification of barriers to attendance and the reasons for non-attendance in this sample, following an
explicit invitation (either with risk information and taster session invitation or without), will help to
develop strategies to overcome the barriers, and to allocate resources to encourage attendance, and
thus increase the potential to recruit the optimum number of smokers to the services.
We are currently assessing barriers to attendance at the NHS services using an open question. For the
remainder of the study we will use the TBQ, a 40-item measure of reasons for not entering smoking
cessation programmes49 that has been recently validated on a low socioeconomic status population in
the USA. This questionnaire will allow us to assess different aspects of smoker’s decisions to attend a
group or therapy session and highlight any misconceptions or lack of awareness of the service offered.
It will also allow us to explore any associations with demographic and dependence factors, as well as
validating the questionnaire on a UK population. Participants who report not attending the services will
be sent the questionnaire by post.
The TBQ will be mailed to approximately 3500 participants who report not attending the SSS and who
agree to complete an additional questionnaire.
3. Taster sessions are being recorded to ensure fidelity to the protocol. Assessing this fidelity can help to
address factors that might have impacted on subsequent attendance and quit rates. Extra time for a full
analysis of these tapes, using thematic analysis, will allow the exploration of differences in style and
delivery of the intervention and their impact on subsequent attendance.
Full analysis of the audio-recording of the taster sessions, using thematic analysis, will be carried out to
address factors that might have impacted on subsequent attendance and quit rates.
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Introduction
Background
The NHS SSSs are effective in helping people to quit smoking,129 and, although 74% of current smokers in
2007 reported that they wanted to quit, only a tiny proportion (< 5%)130–132 made use of the free service
provided by the NHS. A wide range of factors, such as lack of availability and accessibility, perceived
inappropriateness of the service, a perception that help is not necessary, or a sense of a lack of empathy
from health professionals, as well as a lack of readiness to quit, will bar smokers from seeking help.
Although recruitment methods to cessation services generally employ a reactive approach, in which
smokers are expected to seek out and approach the service,20 evidence suggests that if smokers are
proactively and personally invited to use the services, the resultant use will be higher than standard referral
by health professionals, or open advertising.27 The development of computer-tailored self-help materials,
intended to meet the needs of one specific person, based on characteristics unique to that person,30 offers
a method for further personalising communications to patients and has the potential to engage with and
recruit a larger proportion of the smoking population in a relatively inexpensive way. In addition, previous
research29 has shown that inviting smokers to attend a no-commitment introductory session designed to
offer information about what attendance at the service would involve, together with a strong referral
message to the service, can increase attendance.
Thus, the Start2quit intervention is employing a two-pronged approach to encourage people to attend the
SSSs, that consists of using computer-tailoring technology to send personal risk information to smokers,
and an invitation to a taster session to allow them to find out more about the service before committing
and signing up to a 6 week course.
Principal research question
We hypothesise that smokers, identified from general practice records, sent brief personal tailored letters
based on characteristics available in their primary care medical records and on a short screening
questionnaire, and invited to a ‘Come and Try it’ taster session designed to inform them about the SSSs,
are more likely to attend the services than those who receive a standard generic letter advertising
the service.
Primary objective
To assess the relative effectiveness on attendance at the SSSs, of proactive recruitment by a brief personal
letter, tailored to individual characteristics available in medical records, and invitation to a taster session to
provide information about the SSSs, over a standard generic letter advertising the service.
Design and procedure
Start2quit is a randomised controlled trial of a two-component intervention conducted in two stages. First,
a pilot trial to be carried out in 12 practices covered by two SSSs was scheduled to run from June 2010 to
December 2011. Procedure to the full trial in a further 48 practices covered by eight SSSs is dependent
on the success of the pilot in terms of recruitment, the rate of attendance at the taster session, and the
uptake of SSSs. The methodology of the pilot phase is essentially the same as the full trial to enable
combination of the data from both phases for analysis. However, lessons learnt on recruitment strategies
from the pilot phase will be applied to the main trial.
The target group is smokers motivated to quit who have not attended the SSSs in the last 12 months.
We will also target smokers in areas of high deprivation and ethnic minorities, where smoking prevalence
is high.
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Procedure
All smokers aged ≥ 16 years are identified from their medical records in participating practices. After
screening by GPs to exclude anyone deemed to be unsuitable, all remaining persons on the list are sent a
screening questionnaire with a cover letter from their GP, a participant information leaflet describing the
research, and a consent form to participate in the trial. Participants are asked to provide consent for the
release of relevant data from their attendance at the SSSs to the researchers, used to validate attendance
and quit rates. Participants have the opportunity to decline to participate but to return the questionnaire
with Section A only completed to update their smoking status in their records.
All current smokers willing to participate and returning the signed consent form, aged ≥ 16 years, able to
read English, motivated to quit and have not attended the SSSs in the previous 12 months are eligible
to participate. Exclusion criteria are minimal because the aim is to recruit all smokers into the SSSs.
Interventions
The control group receive a standard generic letter sent from the surgery advertising the SSS and asking
the smoker to contact the service to make an appointment to see an advisor.
The intervention group receive a brief motivational letter offering personalised risk information and help to
improve their condition by quitting smoking, sent from the GP. This contains information specific to the
patient, including an invitation and an appointment to attend a ‘Come and Try it’ taster session run by
advisors from the local SSS to find out more about the services. Each SSS runs between 4 and 12 taster
sessions, and attendees are encouraged to sign up to a group or one-to-one session at the end of the
taster session. Participants who fail to attend will receive a further invitation 3 months later to encourage
attendance.
Pilot phase
Objectives
The aims of the pilot phase of the study were:
1. to assess the feasibility of the procedure in terms of:
i. searching medical records and mailing screening questionnaires
ii. the randomisation and generation of the tailored letters
iii. delivery of the intervention.
2. to ascertain recruitment rates
3. to assess the uptake of the taster sessions and subsequent attendance at the SSSs.
The criteria for judging the success of the pilot phase and proceeding to full trial is based on:
1. achieving a 7% response rate (i.e. a mean of 42 participants per practice giving consent and agreeing
to randomisation) in the first 12 practices
2. a preliminary analysis that suggests that the difference in uptake of SSSs between the intervention and
control groups is greater than zero.
Successful achievement of recruitment, the rate of uptake in attendance at the taster session, and the
uptake of SSSs in the intervention group will allow progression to the main trial in a further eight areas
that are representative of the SSS.
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Planned recruitment
We planned to recruit practices and participants through the PCRN, in two areas selected for the pilot
phase. Practices generally identify 13% to 22% of their patients as smokers,55 depending on the
characteristics of the patient population, and the accuracy and completeness of the records. Based on the
response rate from previous and ongoing studies29,56 we estimated a response rate of 7% from smokers
motivated to quit, from two mailings. By selecting six practices in each of the two SSSs with a list size of
> 4000, we aimed to secure 504 participants to the pilot phase of the randomised controlled trial.
Progress
The pilot phase for Start2quit was carried out between September 2010 and December 2011.
Research and development approval
The two original SSSs selected for the pilot phase of Start2quit were Camden and Berkshire East. Although
provisional approval was gained from Berkshire East Primary Care Trust (PCT), the SSS manager made a
late decision to withdraw from the trial. With the help of the CLRN lead in the Thames Valley (Dot
Powers), we were able to recruit Oxfordshire SSS as the second area for the pilot phase. Research and
development approval was granted by our lead NHS site, Camden PCT, on 16 December 2010, followed
by site-specific approval for Oxfordshire PCT on 21 January 2011.
1. Assessing the feasibility of the procedure in terms of:
Searching medical records and mailing screening questionnaires During the pilot phase, procedures
for searching medical records and mailing screening questionnaires for the recruitment of participants
were implemented. A search strategy for identifying current smokers aged over 16 years on computerised
records at GP practices was created and used by practice staff. Although there were small differences in the
codes that practices use to record patients’ smoking status, our search strategy was effective in identifying
potential participants for this project. Using computer programs written specifically for Start2quit, invite
letters were generated in practices and sent with screening questionnaires to smokers identified in the initial
search. One such program was designed to successfully remove duplicate addresses, ensuring that only one
smoker per address was invited to the study. Sending invite letters and questionnaires with pre-addressed
Freepost envelopes ensured that responses were returned to the practices without charge to the participants.
The mailing of the invites was performed by trained practice staff aided by members of the research team
and instruction manuals (Practice Manual and Research Manual).
The randomisation and generation of the tailored letters The subsequent randomisation of fully
consenting, eligible participants was performed independently by a computer program designed during the
pilot phase. This program also generated the intervention and control letters. Data from questionnaires
and medical records of consented participants were collated and entered on to an Excel spreadsheet.
Using this spreadsheet, the computer program was able to randomly assign each participant to the control
or intervention group and then generate the personal tailored risk letters and taster session invitation cards
for participants in the intervention group, and control letters for participants in the control group. This
program was run effectively by trained research staff visiting the practices. Some minor amendments to the
intervention and control letters were required because of differences in the organisation of SSSs, but these
changes did not hamper the progress of the pilot phase. As a result of lessons learnt during the pilot
phase of Start2quit, minor amendments have been made to all computer programs used in the study.
Many of these changes have made the programs more ‘user-friendly’ and have reduced process time.
Delivery of the intervention Procedures for the delivery of taster sessions to participants in the
intervention group were also created during the pilot phase of Start2quit. In collaboration with advisors
from the SSSs, a protocol for running taster sessions and an Advisor Training Manual were prepared to
ensure standardisation of the delivery of the sessions. Advisors, trained by the research team to run taster
sessions, ran these sessions between March and July 2011 in Camden and Oxfordshire SSSs. In total, four
taster sessions were run by Camden SSS and 10 sessions were run by Oxfordshire SSS (five sessions in
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Oxford and five sessions in Banbury). In each area, participants were invited to one of three initial taster
sessions. If they failed to attend, they were then invited to another taster session held 3 months later.
Depending on participant numbers in each area, either one or two more sessions at this 3-month time
point were required. Throughout the pilot phase, a number of documents required for the effective
running of taster sessions were found to be required. These included an audio-recording consent form,
evaluation form and an advisor details form.
2. Ascertain recruitment rates
The rate of participant recruitment to the trial throughout the pilot phase was determined and is presented
in the Results section of this report.
3. Assessment of the uptake of the taster sessions and subsequent attendance at the
Stop Smoking Services
The number of participants who were randomised to the intervention arm and, subsequently, attended a
taster session was recorded throughout the pilot phase and is presented in the Results section of
this report.
The primary outcome of attendance at the SSSs for Start2quit is ascertained from records at the SSS. SSS
records are updated quarterly and, therefore, not all participant data are available at present. Data from
Oxfordshire SSS will be available in March 2012. Therefore, we will use participant self-reported
attendance as a proxy measure for the primary outcome for the pilot analysis described in this report.
Self-reported attendance was collected by research telephone interviewers, independent from the service
providers and research team, via follow-up interviews with participants 6 months after the date of
randomisation. A computer program, which guides the telephone interviewers through this process was
developed and used during the pilot phase. A Telephone Interviewer Manual was designed to ensure
standardisation of the delivery of the interviews. These follow-up interviews were conducted between
September 2011 and December 2011 for all participants in Camden and Oxfordshire.
Participant self-reported attendance at the SSSs was obtained from the 6-month follow-up interviews,
which contained the following questions relevant to this outcome measure:
1. Have you tried to make an appointment with the SSS (this includes making an appointment with a
practice nurse or health-care assistant at your surgery for stop smoking advice)?
2. Were you successful in making an appointment with the SSS?
3. How many times in the last 6 months have you attended any appointments with the SSS (this includes
making an appointment with a practice nurse or health-care assistant at your surgery for stop
smoking advice)?
If the participants answered ‘yes’ to the first two questions, and reported at least one appointment in
responding to question 3, then they were classified as having attended with the SSS. All others were
classified as not having attended. Analysis followed the intention-to-treat principle. Those lost to follow-up
were assumed to have not attended the SSS.
Descriptive analysis was carried out. For each treatment group the proportion of participants who attended
out of all participants in that group was calculated. These proportions are presented for all participants and
for each SSS separately.
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Results
Recruitment
Practices
In collaboration with the PCRN in each area, we recruited seven GP practices, three in Camden and four
in Oxfordshire, between December 2010 and February 2011. Although we originally intended to recruit
12 practices, the total number of smokers approached to take part in the study over the seven practices
(7792) was greater than the original target (7200 smokers).
The two SSSs that participated in the pilot phase (Camden and Oxfordshire) both have areas of high deprivation
and above-average ethnic diversity.133–135 IMD 2007 average scores were used to assess the deprivation scores
for each area involved in the pilot phase of the trial. These scores provide a population-weighted average of the
combined IMD scores for the particular neighbourhoods (called lower-layer super output areas) in a particular
district. Data from Camden (IMD 2007) indicate that the borough is within the 20% most deprived areas on
five of the six key measures.133 Oxfordshire also covers some areas where deprived and ethnic minorities form a
high proportion of the population. The non-white population is 26.8% in Camden, and the proportion born
outside the UK and Eire is 33.6%.134 In Oxfordshire, it has been reported that 19.6% of the population is
non-white.135
The study aimed to target areas within Camden and Oxfordshire that were relatively deprived, within the
limitations of co-ordinating sites for ‘taster’ sessions, GP practices declining to participate and time
constraints. We were successful in recruiting a representative selection of practices including some in
deprived areas (e.g. practice 5 was located in an area within the 20% most deprived areas in England, and
within the 10% most deprived area in England in the areas of education, skills and training and crime).136
Participants
Figure 22 shows a flow diagram of recruitment progress through the pilot phase of the trial.
Although 11,202 smokers were initially identified, screening questionnaires with cover letters were mailed
to 8548 smokers. This decrease was largely due to the necessity of selecting only one smoker per address.
In addition, some patients identified as smokers were found to be ineligible after the mailing had taken
place (n = 756; incorrectly coded, wrong address, deceased or ineligible due to answers in the questionnaire;
see Table 41 for figures) and were therefore deleted from the denominator, leaving a total of 7792 eligible
smokers who were mailed a questionnaire and invited to participate in the study. Reminder invitation
letters were sent out to non-responders (n = 7342).
The total number returning the questionnaire was 1127 (14.5%). Of these, 552 (7.1%) completed
section A only to update their practice records and were not willing to participate. A total of 575 (7.3%)
gave consent and agreed to randomisation, and 149 of these were not eligible to participate, leaving 426
(5.5%) enrolled in the study (Table 41). To account for therapist effects, the sample size in the intervention
group was inflated by 1.51 and eligible participants were randomised to the intervention or control group
at a ratio of 3 : 2 within each practice. Thus, 259 participants were randomised to the intervention and
167 to the control group. The overall number in each group conformed closely to the randomisation ratio.
The response rate varied greatly between GP practices (ranging from 2.7% to 9.4%) and between the two
SSSs (Camden, mean 3.2%; Oxfordshire, mean 6.8%; Figure 23).
Attendance at taster sessions
In the pilot phase, taster sessions were run by Camden and Oxfordshire SSSs. As mentioned earlier,
participants were invited to one of three initial taster sessions. If they failed to attend, they were then
invited to another taster session 3 months later. A total of four taster sessions were held in Camden and a
total of 10 sessions were held in Oxfordshire, split evenly between the two areas in which GP practices
were recruited from in Oxfordshire (Oxford and Banbury).
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General practices recruited
Total smokers
(n = 11,202)
Total sent reminders
(n = 7342)
Not replied
(n = 6665)
Total returns
(n = 1127)
Total enrolled in study 
and randomised
(n = 426)
Refused (section A only)
(n = 552)
Lost to follow-upa
(n = 72)
Interviews to be
 completed
(n = 1)
Lost to follow-upa
(n = 52)
Returned questionnaire 
but not eligible
(n = 149)
(smoke pipes/cigars,
 have attended NHS SSS
 in previous 12 months, 
not seriously thinking 
of quitting within the 
next 6 months, not thinking 
of quitting if help was
 offered at convenient 
time and place)
Total sent questionnaires with cover letter from GP (after exclusions)
(n = 7792)
Randomised to control group
(n = 167)
Randomised to intervention group
(n = 259)
Total 6-month interviews completed
(n = 115)
Total 6-month interviews completed
(n = 186)
FIGURE 22 Flow diagram of the progress of the pilot phase of the Start2quit trial. a, This figure relates to the
proxy measure (self-reported attendance at the SSSs) for the primary outcome of the pilot phase, which was
obtained through follow-up telephone interview. We expect to collect primary outcome data of attendance at the
SSSs for 100% of participants from records held at each SSS involved in the study. We have assurance from the
Oxfordshire SSS that these data will be available to us in March 2012.
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Attendance rates at the three initial taster sessions were broadly consistent (Figure 24). However, it is
important to note that there was relatively low attendance at the taster sessions held 3 months later. In
total, 87 out of 259 participants randomised to the intervention group (33.6%) attended a taster session.
Follow-up response rate
The completion rate for the follow-up interviews was 70.7%. The response was equivalent in the
intervention and control groups (71.8% vs. 68.9%). Self-reported attendance at the SSSs obtained from
these interviews will be used as the proxy measure of the primary outcome in the pilot phase.
Attendance at the Stop Smoking Services
Self-report data confirm that the uptake of attendance at the SSSs was greater in the intervention group
(70/259; 27%) than in the control group (21/167; 12.6%). Table 42 shows the differences in attendance
at the SSSs between the intervention and control groups. These figures assume that those who were lost
to follow-up did not attend the SSSs.
0
1 2 3 4
Practice
5 6 7
1
2
3
4
5
R
es
p
o
n
se
 r
at
e 
(%
)
6
7
8
9
10
Camden practices
Oxfordshire practices
FIGURE 23 Response rates for practices in the pilot phase.
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FIGURE 24 Taster session attendance rates.
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Discussion
This report and analysis has set out to demonstrate that the aims of the pilot phase of the study have been met.
The first aim of assessing the feasibility of the procedure in terms of searching medical records and mailing
screening questionnaires, generating the tailored letters, and randomising participants and delivering the
intervention has been met. These procedures have been carried out successfully. Minor revisions to the
programs and procedures will ensure their smooth running in the main trial. Manuals have been produced
documenting all procedures to ensure the standardisation of all procedures in the main trial.
Variation in the delivery of services in different areas has meant that we have had to introduce a little more
flexibility in the personnel delivering the taster sessions, and in the procedure for signing up smokers to
attend the services, and allow more flexibility to fit in with the existing service delivery. Minor revisions to
the procedure have been made to account for these variations.
The second aim was to ascertain recruitment rates. The proportion of people giving consent and agreeing
to randomisation was 7.3%, meeting the target of 7%. However, not all of those willing to participate
satisfied the inclusion criteria and thus the proportion eligible to participate was 5.5%, although this varied
greatly between the two SSSs and between GP practices. While in Camden, one practice fell far short of
the target at 2.7% enrolment, the highest enrolment from a practice in Oxfordshire was well over, at
9.4%. The low response rate observed in Camden is in accordance with previous studies115 that have
shown London-based primary care recruitment rates to be lower than those outside London. Thus, taking
the recruitment from Oxfordshire alone as an estimate, an enrolment rate of approximately 7% for the
main trial is achievable in areas that are outside the London area. This is highly relevant as all future
recruitment centres will take place outside London.
The third aim was to assess the uptake of the taster sessions and subsequent attendance at the SSSs,
on which the criteria for judging the success of the pilot phase and proceeding to full trial is based.
Attendance at taster sessions of 33.6% was considered acceptable, and service managers were pleased
with the result, expressing the opinion that smokers went along who would not have otherwise
considered using the SSSs. The uptake of the SSSs in the intervention group was more than twice that of
the control group in Camden, and substantially higher than the control group in Oxfordshire. Therefore,
the criterion of a greater than zero difference for attendance at the SSS between the intervention and
control groups has been satisfied.
Some problems with the NHS Permission Process have been encountered by the project during the pilot
phase, leading to delays in obtaining ethics approval letters, and in gaining approval for Service Support
Costs from the comprehensive local research network (CLRN). In addition, we suffered a major setback
when Berkshire East dropped out of the pilot phase at a late stage, leaving us short of one study site, less
than 2 months before the start of recruitment for the pilot phase. Thanks to the CLRN lead in Thames
Valley, we were able to promptly engage with Oxfordshire SSS, and have subsequently been able to meet
the project milestones.
TABLE 42 Differences in attendance at SSSs between the intervention and control groups
Intervention, f (%) Control, f (%)
All participants (n = 426) 70/259 (27.0) 21/167 (12.6)
Camden (n= 93) 14/60 (23.3) 1/33 (3.0)
Oxfordshire (n= 333) 56/199 (28.1) 20/134 (14.9)
f, frequency.
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Conclusion and future timetable
We have met the criteria of a 7% response rate for those giving consent and agreeing to randomisation.
The number enrolled in the trial fell slightly below this, but this was mainly because of low recruitment in
Camden. We are now focusing on a representative selection of SSSs across England, outside London,
and are confident that we can meet the target for main trial.
We have also demonstrated in our preliminary analysis that the difference in uptake of SSSs between the
intervention and control groups is greater than zero. Although the numbers taking part in this phase are
low, and cannot be generalised, we believe that the results shown here warrant the continuation of this
trial to evaluate the intervention across a representative selection of SSSs across England.
The SSSs in Medway, Eastern and Costal Kent, Essex and Lincolnshire have already agreed to participate
in the trial. We believe that with a timely start to the main trial in these areas we will be able to meet
recruitment targets and proceed to a satisfactory conclusion of the trial. The timetable shows how we plan
to meet the project milestones and to reach our target for recruitment (Figures 25 and 26).
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FIGURE 25 Actual recruitment vs. target recruitment for Start2quit.
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Appendix 3 Recruitment materials
Invitation letter
PRACTICE HEADED PAPER 
 
Date 
 
Dear  
I would like to invite you to take part in the Start2quit study, a research project to 
try out a new way of providing help and advice to smokers who want to stop.  We 
are carrying out the research with University College London (UCL) and the 
University of Cambridge.   
 
Please read the enclosed information leaflet carefully.  It is important that you 
understand why the research is being done and what it will involve.  Discuss it 
with others if you wish.  If there is anything that is not clear, or if you would like 
more information, please contact Leanne Gardner at UCL Research Department 
of Primary Care and Population Health on ***** etxn: *****.  Take time to decide if 
you want to take part.  Your decision will not affect the medical care you receive 
from the practice in any way. 
 
When you have read the information, if you are willing to take part, please 
complete the enclosed questionnaire, and return it in the Freepost envelope 
provided.  No stamp is required.  Please ensure that you also sign the consent 
form on the questionnaire.  Your answers will be totally confidential and seen only 
by researchers at UCL.   
 
We are also currently checking the information that we have on our practice 
records on whether or not you smoke.  When you complete and return the 
enclosed questionnaire your medical records will be updated.  If, after reading the 
information, you do not wish to take part in the research, please complete the 
questionnaire and return it to us, indicating clearly on the questionnaire that you 
do not wish to participate any further in the research, so that we can use the 
information just to update your records.  You need only complete and return 
Section A of the questionnaire for this purpose. 
 
Thank you for your help. 
Yours sincerely 
 
Lead General Practitioner 
DOI: 10.3310/hta21030 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 3
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Gilbert et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
127
Patient information sheet
 
 
 
 
 
 
 
 
A Primary Care Study to Increase 
 Use of Smoking Cessation Services  
 
 
Information Sheet 
 
 
in collaboration with  
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What is the purpose of the study? 
 
We are always trying to find out more about smokers and how to help them.  Most 
smokers say they want to quit but only a small proportion seek help.  It is important 
that we find out from smokers themselves what will help them, so that we can offer 
the support they need.  We want to find out how smokers react to different types of 
intervention.  We need to know what effect this has, and your opinions of it. 
 
Why me? 
 
We can only do this by getting the help of people who smoke.  Your general 
practice has offered to take part, and you have been selected because your GP 
records show that you are a smoker. 
 
Do I have to take part? 
 
Your contribution is important, but it is up to you to decide whether to take part or 
not.  If you decide to take part, you can still drop out at any time without giving a 
reason.  Your decision will not affect the care you receive at your general practice. 
 
What do I have to do first? 
 
If you are willing to help, all you need to do is: 
• Complete and sign the consent statement, initialling all the boxes. 
• Complete the questionnaire.  The questionnaire has three purposes. The 
information under section A is to update your medical records.  The remaining 
questions are to provide the researchers firstly with information about smokers 
needs generally and secondly with more information about you personally so that 
they can assess what information to send you.  This is discussed further in the next 
section. 
• Return both to the surgery in the envelope provided.  You do not need a stamp. 
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What will happen next? 
 
You will be sent some information about services in your area, and may be invited 
to attend a stop smoking session.  You may also receive a letter containing 
personal risk information based on your answers in the questionnaire, and on your 
health records.  Whether you receive this extra information will be decided at 
random, rather like tossing a coin. You will receive a telephone call in 6 months 
time to complete a final questionnaire including quality of life questions.  You may 
be asked to provide a saliva sample to confirm your smoking status. 
  
What are the benefits of taking part? 
 
The information you give will help us to think about the kinds of support we offer 
and learn more about different types of smokers.  There is no guarantee that the 
information you receive will help, but you may find that you learn more about 
yourself by answering the questions.   
 
What if something goes wrong? 
 
We think that it is unlikely that anything could go wrong in this study.  However, if 
you have any concerns about the research, you can contact the Lead Researcher, 
Dr Hazel Gilbert at UCL on *****.   
If you wish to complain about any aspect of the way you have been approached or 
treated during the course of this study, the normal NHS complaints mechanism is 
available to you.  You can find out how to do this by following this link: 
http://www.nhs.uk/choiceintheNHS/Rightsandpledges/complaints 
If you feel the questions or the personalised letter upset you, or if you are worried 
about smoking, you could discuss it with your practice nurse or GP, or we can refer 
you to a smoking cessation counsellor.  
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What happens to the information I give? 
 
All of the information you give is protected by the Data Protection Act, and will be kept strictly 
confidential.  It will be stored and analysed on a secure and password protected computer.  It 
will not be kept with any details that might identify you personally, and will not be passed on to 
anyone else.  Any report resulting from the research will give only group information. 
 
Who is responsible for this research? 
 
The study is being co-ordinated by researchers at University College London, University of 
Cambridge, and by Stop Smoking Advisors from the NHS.  The research is funded by a grant 
from the National Institute for Health Research Health Technology Assessment programme.  
All research in the NHS is looked at by an independent group of people, called a Research 
Ethics Committee, to protect your interests.  This study has been given a favourable opinion by 
the London-Surrey Borders Research Ethics Committee.  It has also received approval from 
the local NHS Trust. 
 
 
If you have any questions about this research, please contact:: 
.......................................................................................................................... 
 
Trial Manager: Leanne Gardner 
 
 
 
 
 
 
 
 
 
 
 
Version 2 25/03/2010  
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Consent form
 
Please place your initials in the box (e.g.AC) and sign below.  
 
1. I agree to participate in the Start2Quit study    
 
2. I confirm that I have read the Information Sheet  
(version 2 dated 25/03/2010).      
 
3. I understand that I am free to drop out at any time  
without giving a reason, and that my medical care  
will not be affected.       
 
4. I understand that my GP practice will be informed of  
my participation but the details I give are completely  
confidential and will not be passed on to anyone  
outside the research team.      
 
5. I understand that relevant sections of my medical  
notes and data collected during the study, may be  
looked at by individuals from UCL, from regulatory  
authorities or from the NHS Trust , where it is relevant  
to my taking part in the research.  I give permission  
for these individuals to have access to my records.   
 
6. I understand that information from my medical records  
and from my answers in the questionnaire may be  
used to send me information about quitting.  
 
7. I understand that relevant data from my attendance at 
 the NHS services will be released to the researchers. 
 
 
Signature      Date  
 
OR 
 
I am willing to complete Section A but do not wish to 
 participate further in this research.  
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Late response letter
 
PRACTICE HEADED PAPER 
 
 
 
Dear 
 
Thank you for completing the questionnaire and agreeing to participate in the Start2quit project.  
This trial is open to current cigarette/rollup smokers who want to quit in the near future and have 
not recently used the NHS Stop Smoking Services.  Unfortunately you do not fit these criteria 
and we are unable to include you in the trial. 
 
But the NHS Stop Smoking Services is still freely available to offer information, advice and 
support to all smokers interested in giving up. The service also offers advice on the use of 
medications such as Nicotine Replacement Therapy and Champix.  For more information or to 
speak to a specialist advisor please call the ___________ Stop Smoking Service on 
___________.   
 
Once again thank you for your response. 
 
Yours sincerely 
 
 
 
GP signature 
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Standard ineligible letter
 
PRACTICE HEADED PAPER 
 
 
 
Dear  
 
 
 
Thank you for completing the questionnaire and agreeing to participate in the Start2quit project. 
The trial was running in your area from the beginning of (month) to the end of (month and year). 
Unfortunately we received your questionnaire outside of this time frame and as such we are 
unable to include you in the trial. 
 
But the NHS Stop Smoking Services is still freely available to offer information, advice and 
support to all smokers interested in giving up.  The service also offers advice on the use of 
medications such as Nicotine Replacement Therapy and Champix.  For more information or to 
speak to a specialist advisor please call the ____________ Stop Smoking Service on_______.   
 
Once again thank you for your response. 
 
 
 
Yours sincerely 
 
 
 
Lead General Practitioner signature 
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Appendix 4 Questionnaires and data
collection forms
Baseline smoking questionnaire
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Case report form
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Stop smoking advisor details questionnaire
 
 
Stop Smoking Advisor Details Form 
 
Please provide the following information for statistical purposes of Start2quit trial 
Age:  18-24               25-34                  35-44                 45-54                  55 or older             
Gender:       Male                            Female 
Highest Qualification:   GCSE/CSE/O Level 
                                     A Level 
                                     Degree or Equivalent 
                                     Postgraduate degree  
Qualifications relevant to Stop Smoking advisor training (e.g. NCSCT Certification): 
 
 
Date of Level 2 training: 
Employer: 
Job Title: 
Number of smoking cessation patients that you have seen the last 6 months:  
1-5                      6-10                      11-20                     21-30                   31 or over 
Thank you 
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Taster session evaluation form
 
  Taster Session- Evaluation Form Date: ___________ 
 
We'd like to know what you think of the ‘Come and try it’ taster session.  
 
Please answer the following items on a scale of agreement from 1 to 5, where 1= not at all and 5= 
extremely. Please circle your answer. 
             Not at all .. Extremely 
 
1. This taster session contained a lot of  
     new information: 
 
2. The information provided at this taster session 
    was easy to understand: 
   
3. The information provided at this taster session  
    was interesting: 
 
4. The information provided at this taster session 
    was useful:   
 
5. As a result of attending this taster session,  
     I feel more confident about quitting: 
 
6.  As a result of attending this taster session, 
     I am more determined to quit. 
 
7. What did you think of the taster session overall? Please write your comments below:  
 
 
 
 
 
 
 
 
8. If this is the second taster session to which you were invited, what were your reasons for not attending 
the first? 
 
 
 
 
 
 
 
 
9. Would you like to make a follow up appointment with the NHS Stop Smoking Services? Please 
circle one below: 
Yes  No  
 
Name:      _____________________________    
 
Day time phone number:   _____________________________    
PLEASE HAND COMPLETED FORM TO AN ADVISOR 
 
1 2 3 4 5 
1 5 4 3 2 
1 2 5 4 3 
1 2 3 5 4 
1 5 4 3 2 
1 2 3 4 5 
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Follow-up questionnaires
Telephone interview
Start2Quit: Follow up Questionnaire 
 
Opening statements 
 
• These questions are about the last six months since you enrolled in this research.  We 
want to know about how your smoking has changed and any help that you have had in 
trying to quit. We also want to know what you think of the information you were sent. 
• Don’t worry whether you are smoking now or not, for the purposes of the research your 
feedback is very important and valuable to us. We need information from both smokers 
and ex-smokers. 
• Some of the questions may be similar to ones you have been asked before, but we would 
like to know how you feel now, at this point in time. 
• The information you give and the views you express are completely confidential and will 
be identified only by a number. 
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Opening Section 
 
    Complete Opening 
section then go to:  
1   Do you currently smoke cigarettes or rollups: Every day  Section B Q1 
  Most days  Section B Q2 
  Occasionally  Section B Q2 
  Not at all  Section A 
     
2 In the last 6 months have you tried to make an 
appointment with the NHS Stop Smoking 
Service (this includes making an appointment 
with a Practice Nurse or Health Care Assistant 
at your surgery for stop smoking advice)?  
   
  Yes  Go to Q3 
  No  Go to Q6 
     
3 Were you successful in making an 
appointment with the Stop Smoking Service? 
 
   
  Yes  Go to Q4 
  No  Go to Section A or B 
     
4 How many times in the last 6 months have you 
attended any appointments with the Stop 
Smoking Service (this includes making an 
appointment with a Practice Nurse or Health 
Care Assistant at your surgery for stop 
smoking advice)? 
   
    Go to Q5 
     
5   Answering on a scale from 1 to 5, where 1= not at all and 5= 
extremely, how helpful was attending the Stop Smoking Service to you 
in quitting/attempting to quit smoking?  
(Interviewer to choose correct version according to previous answer) 
 
 
 1 2 3 4 5 not answered  Go to Section A or B 
 
6 Can you tell me your reasons for not trying to make an appointment with the Stop Smoking Service?  
 
 
6a We are interested in why people do not attend clinics to help them to stop smoking, and would like to send you 
a short questionnaire by post to assess your reasons for not wanting to attend the Stop Smoking Service.  
 
 Is that OK? Yes  Go to Q6b 
  No  Go to section A or B 
 
6b Can I check that your address has not changed in the last 6 months since you were enrolled in this research?  
Check postcode against the one on the paper list.  If different take new address. 
Go to Section A or B 
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SECTION A  
For people who have quit smoking 
 
1 How long ago did you quit smoking? days   
 (program will categorise) weeks   
  months   
     
2 When did you last smoke a cigarette/rollup? In the last 24 hrs   
 (to be categorised by interviewer) 1-6 days ago   
  7-13 days ago   
  2-4 weeks ago   
  1-3 months ago   
  4-6 months ago   
  Longer than 6 
months ago 
  
  Not answered   
     
3a Have you smoked any cigarettes/rollups since  Yes  Go to Q3b 
 you quit? No  Go to Q4 
  Not answered  Q4 
     
     
3b How many cigarettes/rollups have you smoked 
since you quit? 
   
Go to Q4 
     
4 Have you smoked a cigarette/rollup at all in the  Yes  Go to Q5 
 last 7days, even as little as a puff? No  Go to Q7 
  Not answered  Q7 
     
     
5 Have you smoked a cigarettes/rollup at all in  Yes  Go to Q6 
 the last 24 hours, even as little as a puff? No  Go to Q6 
  Not answered  Q7 
     
     
6 How much did you smoke in the last 7 days/ 
24 hours?  
Only a puff or two   
  One cigarette 
 
  
  More than one 
cigarette on one 
day 
  
  One or more than 
one cigarette on 
more than one 
day 
  
Not answered   
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Please answer the following questions on a scale of agreement from 1 to 5, where 1= not at all and 5= extremely. 
(repeat instruction where necessary) 
 
7 How determined are you to stay quit?  
  
1 2 3 4 5 not answered  
 
 
8 How confident are you that you will be able to stay quit?  
  
1 2 3 4 5 not answered  
 
 
9 How difficult is it to resist your strongest temptations to smoke?  
  
1 2 3 4 5 not answered  
 
 
10 How confident are you that you can enjoy life more than when you were 
a smoker? 
 
  
1 2 3 4 5 not answered  
 
 
 
 
Still answering on a scale of 1-5, can you rate the extent to which you agree with the following items about how you 
see yourself: 
 
11a Smoking is part of who I am  
  
1 2 3 4 5 not answered  
 
 
11b I am able to see myself as a non-smoker 
 
 
  
1 2 3 4 5 not answered  
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SECTION B 
For people who are still smoking 
 
1 (If Opening Section Q1= ‘every day’)    
 How many cigarettes/rollups, on average, do you smoke 
a day? 
  Go to Q3 
     
2 (If Opening Section Q1=‘most days’ or ‘occasionally’)    
A How many days in one week, on average, do you 
smoke? 
   
     
B How many cigarettes/rollups, on average, do you smoke 
per day on the days that you smoke? 
   
     
     
3 In the last 6 months have you made any 
attempts to quit smoking? 
Yes  Go to Q4 
  No 
 
 Go to Q5 
     
4. How many quit attempts have you made?  
 
   
     
5a In the last 6 months have you gone without a 
cigarette for 24 hours or more? 
Yes  Go to Q5b 
  No 
 
 Go to Q6 
  Not answered  Q5b 
     
5b In the last 6 months have you gone without a 
cigarette for 7 days or more? 
Yes  Go to Q5c 
  No 
 
 Go to Q6 
  Not answered  Q5c 
     
5c In the last 6 months what is the longest period 
you have gone without a cigarette? 
7-13 days   
  2-4 weeks 
 
  
  Longer than 1 
month 
  
  Not answered   
     
6 Are you seriously thinking of quitting (again): 
(read out options) 
Within the next 2 
weeks 
 Go to Q7 
  Within the next 30 
days 
 Go to Q7 
  Within the next 6 
months 
 Go to Q7 
  Not within the 
next 6 months 
 Go to Q8 
     
7 Have you set a quit date? Yes  Go to Q9 
  No  Go to Q9 
  Not answered  Q9 
     
     
8 If you are not planning to quit, is it because:  it is too difficult 
  
  
  you want to 
smoke  
  
  Both   
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  Not answered   
 
Please answer the following questions on a scale of agreement from 1 to 5, where 1= not at all and 5= extremely. 
 
9 How much do you want to quit?  
  
1 2 3 4 5 not answered  
 
 
10 How determined are you to quit for good? 
 
 
  
1 2 3 4 5 not answered  
 
 
11 How confident are you that you can quit for good? 
 
 
  
1 2 3 4 5 not answered  
 
 
 
 
Still answering on a scale of 1-5, can you rate the extent to which you agree with the following items about how you 
see yourself: 
 
12a Smoking is part of who I am  
  
1 2 3 4 5 not answered  
 
 
12b I am able to see myself as a non-smoker  
  
1 2 3 4 5 not answered  
 
 
 
 
 
       GO TO SECTION C 
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SECTION C 
Now I’m going to ask you some questions about products and services that you might have used in the past six months 
to help you to stop smoking. 
 
Q1. In the last six months how many times have you: (if none insert zero) 
a Sought help or advice to quit smoking from your GP?  
 
   
b Sought help or advice to quit smoking from a pharmacist?  
 
   
c Rung up the NHS Smoking Helpline service for advice or 
support? 
   
d Rung up any other smoking helpline e.g. Quitline for advice 
or support?  
   
e Used an Internet site for help or support?  
 
   
f Been given a prescription for Nicotine Replacement Therapy 
products  
   
g Been given a prescription for Zyban?  
 
   
h Been given a prescription for Champix?  
 
   
     
2a 
 
In the last six months, have you used Nicotine 
Replacement Therapy products to help  
Yes  Go to Q2b 
 you to quit smoking? No 
 
 Go to Q3a 
  Not answered  If Section C Q1g>=1 
proceed to Q3a 
    Else 
If Section C Q1h>=1 
proceed to Q4a 
Else 
proceed to Q5 
     
2b For how long did you use Nicotine Replacement 
Therapy on prescription? 
Days   
  OR  
weeks 
  
     
2c For how long did you use Nicotine Replacement 
Therapy purchased over the counter?   
days    
  OR  
weeks 
  
     
2d Are you currently using Nicotine Replacement 
Therapy? 
Yes   
  No   
  Not answered   
     
3a (If  Section C Q1g= 1 or more)    
 In the last six months, have you used Zyban to 
help you to quit smoking? 
Yes  Go to Q3b 
  No 
 
 Go to Q4a 
  Not answered  If Section C Q1h>=1 
proceed to Q4a 
    Else 
proceed to Q5 
3b For how long did you use it? Days   
  OR weeks   
     
     
4a (If  Section C Q1h= 1 or more)    
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 In the last six months, have you used Champix 
to help you to quit smoking? 
Yes  Go to Q4b 
  No 
 
 Go to Q5 
  Not answered   
     
4b For how long did you use it? Days   
  OR weeks   
     
5 In the past six months how much to the nearest  Nothing   
 pound have you spent purchasing additional products  £1- £10   
 to help you stop smoking excluding Nicotine 
Replacement Therapy on prescription? 
£11- £20   
  £21- £30   
  £31- £40   
  £41- £50   
  £51- £100   
  Over £100   
  Not 
answered 
  
 
6 In the last six months: (repeat for each question) 
 (if none insert zero)   
 
a How many times have you visited a hospital A & E dept as a 
patient? 
   
b How many times have you visited hospital as an outpatient? 
 
   
c How many nights have you stayed in hospital as a patient? 
 
   
d How many times have you visited hospital for a day case, 
where you have attended hospital for a procedure but have 
not stayed overnight? 
   
e How many times have you visited your GP? 
 
   
f How many prescriptions have you received (excluding 
prescriptions to help you stop smoking)? 
   
 
 
      GO TO SECTION D 
APPENDIX 4
NIHR Journals Library www.journalslibrary.nihr.ac.uk
152
SECTION D 
 
We would now like your views about the information you received. 
 
 Six months ago you were sent a letter from 
your GP about the NHS Stop Smoking 
Service.  
   
1 Do you remember receiving this letter? Yes  Go to Q2 
  No  Go to Section E 
     
2 Have you read this letter? Yes  Go to Q3 
  No  Go to Section E 
     
3 Have you discussed this letter with others? Yes   
  No   
  Not answered   
     
 
 
Answering on a scale from 1 to 5, where 1= not at all and 5= extremely, how much do you agree with the following? 
 
4 The letter was easy to read.  
  
1 2 3 4 5 not answered 
 
 
5 The letter was easy to understand.  
  
1 2 3 4 5 not answered  
 
 
6 The letter was written especially for me.   
  
1 2 3 4 5 not answered  
 
 
7 The letter contained a lot of new information.  
  
1 2 3 4 5 not answered  
 
 
8 The advice in the letter was interesting.  
  
1 2 3 4 5 not answered  
 
 
9 The advice in the letter was useful.  
  
1 2 3 4 5 not answered  
 
 
10 As a result of the letter I felt more confident about quitting.  
  
1 2 3 4 5 not answered  
 
 
11 As a result of the letter I felt more determined to quit.  
  
1 2 3 4 5 not answered  
 
 
12 This letter made me feel angry.  
  
1 2 3 4 5 not answered  
 
 
13 This letter made me feel anxious.  
  
1 2 3 4 5 not answered  
 
 
14 This letter made me feel depressed.  
  
1 2 3 4 5 not answered  
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15 This letter made me feel optimistic.  
  
1 2 3 4 5 not answered  
 
 
16 I liked the tone of this letter.  
  
1 2 3 4 5 not answered  
 
 
17 I liked the appearance of this letter.  
  
1 2 3 4 5 not answered  
 
 
   
 
18 (if Opening Section Q3 = yes)     
 Did you make the appointment with the Stop 
Smoking Service as a result of receiving this 
letter or was it something else? 
Yes  Go to Q19 
  Something else 
  
 Go to Q18a 
  Not answered   
 
18a (Probe for what else) 
 
 
 
19 (If Opening Section Q1 = not at all)     
 Have you quit smoking as a result of receiving  Yes   
 this letter? No   
  Not answered   
     
20 (If Section B Q3 = yes)    
 Have you tried to quit smoking as a result of  Yes   
 receiving this letter? No   
  Not answered   
     
21  (If Opening Section Q1 = Every day, Most 
days or Occasionally  
and  
Section B Q3 = no  
and  
Section B Q6 = within next 2 weeks, next 30 
days or next 6 months)  
   
 Do you intend to quit smoking as a result of  Yes   
 receiving this letter? No   
  Not answered   
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SECTION E 
 
 
1 Do you remember receiving an invitation from 
your GP to attend a ‘Come and Try it’ taster  
Yes  Go to Q2 
 session to introduce you to the Stop Smoking 
Service? 
No  Go to Q18 
     
2 Did you attend a ‘Come and Try it’ taster  Yes  Go to Q3 
 session? No  Go to Q17 
 
 
Q3. What made you decide to attend a ‘Come and Try it’ taster session? 
 
 
 
 
Answering on a scale from 1 to 5, where 1= not at all and 5= extremely, how much do you agree with the following? 
 
4 The taster session contained a lot of new information.  
  
1 2 3 4 5 not answered  
 
 
5 The information provided at the taster session was easy to understand.  
  
1 2 3 4 5 not answered  
 
 
6 The information provided at the taster session was interesting.  
  
1 2 3 4 5 not answered  
 
 
7 The information provided at the taster session was useful.  
  
1 2 3 4 5 not answered  
 
 
8 As a result of attending this taster session, I felt more inclined to make 
an appointment with the Stop Smoking Service. 
 
  
1 2 3 4 5 not answered  
 
 
9 As a result of attending the taster session I felt more confident about 
quitting. 
 
  
1 2 3 4 5 not answered  
 
 
10 As a result of attending the taster session I felt more determined to quit.  
  
1 2 3 4 5 not answered  
 
 
 
 
 
 
11 (If Opening Section Q3 = yes)     
 Did you make the appointment with the Stop Yes  Go to Q12 
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Smoking Service as a result of attending   
 this ‘Come and Try it’ taster session or was it 
something else? 
Something else  Go to Q11a 
  Not answered   
 
Q11a Probe for what else 
 
 
12 (If Opening Section Q1 = not at all)     
 Have you quit smoking as a result of attending the taster  Yes  Go to Q15 
 session? No  Go to Q15 
  Not 
answered 
 Q15 
     
13 (If Section B Q3 = yes)     
 Have you tried to quit smoking as a result of attending 
the  
Yes  Go to Q15 
 taster session? No  Go to Q15 
  Not 
answered 
 Q15 
     
14 (if Opening Section Q1 = Every day, Most days or 
Occasionally  
and  
Section B Q3 = no  
and  
Section B Q6 = within next 2 weeks, next 30 days or next 
6 months)   
   
 Do you intend to quit smoking as a result of attending the  Yes  Go to Q15 
 taster session? No  Go to Q15 
  Not 
answered 
 Q15 
     
15 (If Opening Section Q3 = yes)     
 Which of the following statements best describes your 
decision to attend the NHS Stop Smoking Service  
   
 a. attending the taster session was more important 
in my decision than receiving a letter from my 
GP 
   
 b. receiving the letter from my GP was more 
important in my decision than attending the 
taster session 
   
 c. attending the taster session and receiving the 
letter from my GP were both equally important in 
my decision 
   
  Not 
answered 
  
     
16 (If Opening Section Q1 = not at all) or (If Section B Q3 = 
yes) 
   
 Which of the following statements best describes your 
decision to quit smoking / attempt to quit smoking 
   
 a. attending the taster session was more important 
in my decision than receiving a letter from my 
GP  
   
 b. receiving the letter from my GP was more 
important in my decision than attending the 
taster session  
   
APPENDIX 4
NIHR Journals Library www.journalslibrary.nihr.ac.uk
156
 c. attending the taster session and receiving the 
letter from my GP were both equally important in 
my decision 
   
  Not 
answered 
 Go to Section F 
 
 
 
17 (Ask if Section E Q2 = no) 
17a. Can you tell me your reasons for not attending the ‘Come and Try it’ taster session?  
 
 
 
 
17b Would you have attended if you had received a  Yes   
 reminder by text or telephone? No   
  Maybe   
  Not 
answered 
  
     
18 Ask only if Section E Q1 = no    
 Do you know or have you spoken to anyone who has  Yes   
 attended a ‘Come and Try it’ taster sessions? No   
  Not 
answered 
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SECTION F 
We would now like to ask you some questions about your health and well being. 
 
Q1.  Can you tell me for each topic which statement best describes your health today? 
 
a) I have no problems walking about    
 I have some problems walking about    
 I am confined to bed    
  Not 
answered 
  
     
b) I have no problems with self-care    
 I have some problems washing and dressing myself    
 I am unable to wash or dress myself    
  Not 
answered 
  
     
c) I have no problems with performing my usual activities 
e.g. work, study, housework, leisure activities 
   
 I have some problems performing my usual activities    
 I am unable to perform my usual activities    
  Not 
answered 
  
     
d) I have no pain or discomfort    
 I have moderate pain or discomfort    
 I have extreme pain or discomfort    
  Not 
answered 
  
     
e) I am not anxious or depressed    
 I am moderately anxious or depressed    
 I am extremely anxious or depressed    
  Not 
answered 
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FINAL QUESTIONS 
 
1 (If Opening Section Q1 = not at all) 
For the purposes of the research, we are collecting saliva samples from ex-smokers which will allow us to confirm your 
smoking status.   We’d like to send you a kit for you to provide a sample and post back to us. Full instructions will be 
included, the postage will be paid, and we will send you a Marks & Spencer voucher to compensate for your time.   
 
 Would that be OK? Yes  Go to Q2 
  no  Go to Q3 
 
2  
Can I check that your address has not changed in the last 6 months since you were enrolled in this research?  
Check postcode against the one on the paper list.  If different take new address. 
 
 
3 
Can you give me your reasons for not wanting to provide a sample? 
 
 
 
4 Finally, are you satisfied with the way this research was  Yes   
 conducted? No   
  Not 
answered 
  
 
  
Do you have any other comments? 
 
 
 
Thank you for your time and for participating in this research. Your answers are completely confidential. The 
information you have given will be identified only by a number. 
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Postal questionnaire
 
 
 
 
 
 
 
 
Follow-up Questionnaire 
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Thank you for your time and for taking part in this research.  These questions are about the last six months since you 
enrolled in this research.  We want to know about how your smoking has changed and any help that you have had in 
trying to quit. 
 
Don’t worry whether you are smoking now or not, for the purposes of the research your feedback is very important and 
valuable to us. We need information from both smokers and ex-smokers.  Some of the questions may be similar to 
ones you have been asked before, but we would like to know how you feel now, at this point in time. 
 
 
Your name is not on this questionnaire.  All the information you give is completely confidential. This means 
that your answers will be treated as private and you will not be identified by the answers you give. The 
information you provide will be kept separate from your personal details 
 
 
Please complete the questionnaire and return it to the research team in the FREEPOST envelope provided.  
No stamp is needed.  Please check that you have answered all the questions before posting the questionnaire. 
 
 
 
 
 
 
 
 
Please complete the following questions by placing an ‘x’ in the appropriate 
box. Please read the notes carefully after each answer so you know which 
question to go to next. 
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Opening Section 
 
 
      
1) Today’s date     
  day month year  
      
2) In the last 6 months, have you tried to make an appointment with 
the NHS Stop Smoking Service (this includes making an 
appointment with a Practice Nurse or Health Care Assistant at 
your surgery for stop smoking advice)?  
 
Yes  
 
Go to Q3 
No  
 
Go to Q6 
   
3) Were you successful in making an appointment with the Stop 
Smoking Service? 
Yes  
 Go to Q4 
  No  
 
Go to Q7 
     
4) How many times in the last 6 months have you attended any 
appointments with the Stop Smoking Service (this includes 
making an appointment with a Practice Nurse or Health Care 
Assistant at your surgery for stop smoking advice)? 
  Go to Q5 
 
 
  
Not at all        A little        Moderately      Very much    Extremely 
5) How helpful was attending the Stop Smoking Service to you 
in quitting or attempting to quit smoking? 
 
 
Go to Q7 
  
 
  
6) Please write down your reasons for not trying to make an 
appointment with the Stop Smoking Service? 
   
     
   
   
   
   
   
                      Please turn over  ► 
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Answer this question then go to the Section and Question 
indicated 
 
 
 
 
 
     
7)  Do you currently smoke 
cigarettes or rollups: 
 
Everyday  Go to Section B Q1 
   
Most days  Go to Section B Q2 
   
Occasionally   Go to Section B Q2 
   
Not at all  Go to Section A Q1 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  ID 
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Section A:  Complete this section if you do not currently 
smoke 
   
1) How long ago did you quit smoking? Days   
  or    Weeks   
  or   Months   
     
2) When did you last smoke a cigarette/rollup? 
In the last 24 hours 
  
  
1-6 days ago 
  
  
7-13 days ago 
  
  
2-4 weeks ago 
  
  
1-3 months ago 
  
  
4-6 months ago 
  
  
Longer than 6 months ago 
  
   
3) a Have you smoked any cigarettes/rollups since you 
quit? 
Yes  
Go to Q3b 
 No  
Go to Q4 
     
3) b How many cigarettes/rollups have you smoked 
since you quit? 
  
Go to Q4 
    
 
4) Have you smoked a cigarette/rollup at all in the 
last 7days, even as little as a puff? 
 
Yes  
Go to Q5 
 No  
Go to Q7 
    
 
5) Have you smoked a cigarette/rollup at all in the 
last 24 hours, even as little as a  
Yes  Go to Q6 
 puff? No  Go to Q6 
     
 Please turn over  ► 
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Section A:  Continued 
 
 
  
 
  
6) How much did you smoke in the last 7 days/ 24 
hours?  
 
Only a puff or two 
 
 
 
  
One cigarette 
 
 
 
  
More than one  
cigarette on one day 
 
 
  
One or more than one cigarette  
on more than one day 
 
Go to Q7 
    
 
  Not at all        A little        Moderately      Very much    Extremely 
7) How determined are you to stay quit?  
8) How confident are you that you will be able to stay quit? 
 
 
9) How difficult is it to resist your strongest temptations to 
smoke? 
 
 
10) How confident are you that you can enjoy life more than 
when you were a smoker? 
 
 
11) How much do you agree with the following statements 
about how you see yourself: 
 
 
a ‘Smoking is part of “who I am” ’ 
 
 
b ‘I am able to see myself as a non-smoker’  
   
 
Please go to Section C 
 
 
 
 
 
 
 
 
 
 ID 
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Section B: Complete this section if you currently smoke 
cigarettes or rollups, even occasionally 
 
    
 
1) How many cigarettes/rollups, on average, do you smoke a day?   
Go to Q3 
    
 
2) a How many days in one week, on average, do you smoke?   
 
    
 
    b How many cigarettes/rollups, on average, do you smoke per day 
on the days that you smoke? 
  
Go to Q3 
   
 
3) In the last 6 months have you made any attempts to quit 
smoking? Yes 
 
Go to Q4 
 
No 
 
Go to Q5 
  
 
 
 
4) How many quit attempts have you made?  
 
 
 Go to Q5 
  
 
 
 
5) a In the last 6 months have you gone without a cigarette for 24 
hours or more? Yes 
 
Go to Q5b 
  
No 
 
Go to Q6 
  
 
 
 
    b In the last 6 months have you gone without a cigarette for 7 
days or more? Yes 
 
Go to Q5c 
  
No 
 
Go to Q6 
  
 
 
 
    c In the last 6 months what is the longest period you have gone 
without a cigarette? 7-13 days 
 
 
  
2-4 weeks 
 
 
  Longer than 1 
month 
 
Go to Q6 
    
 
 
 
                                               Please turn over  ► 
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Section B: Continued 
 
     
6) Are you seriously thinking of quitting (again): 
Within the next 2 
weeks 
 
Go to Q7 
 
Within the next 30 
days 
 
Go to Q7 
 
Within the next 6 
months 
 
Go to Q7 
  
Not within the next 6 
months 
 
Go to Q8 
  
 
 
 
7)  Have you set a quit date? 
Yes 
 
Go to Q9 
  
No 
 
Go to Q9  
  
 
 
 
8) If you are not planning to quit, is it because: 
It is too difficult 
 
 
  
You want to smoke 
 
 
  
Both 
 
Go to Q9 
  
 
 
 
  
Not at all        A little        Moderately      Very much    Extremely 
9) How much do you want to quit?  
10) How determined are you to quit for good?  
11) How confident are you that you can quit for good? 
 
 
12) How much do you agree with the following statements 
about how you see yourself: 
 
 
a  ‘Smoking is part of “who I am” ’ 
 
 
b ‘I am able to see myself as a non-smoker’ 
 
 
   
Please go to Section C 
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Section C: Complete this section whether you smoke now or 
not 
     
1) a In the last 6 months how many times have you been given a 
prescription for Zyban?  
   
  
    b In the last 6 months how many times have you been given a 
prescription for Champix? 
   
     
2) a In the last 6 months, have you used Nicotine Replacement 
Therapy (NRT) products to help you to  
Yes  
Go to Q2b 
 quit smoking? No  
Go to Q3 
     
    b For how long did you use Nicotine Replacement Therapy 
(NRT) on prescription? 
Days   
  or    Weeks   
     
     c For how long did you use Nicotine Replacement Therapy 
(NRT) purchased over the counter? 
 
Days   
or    Weeks   
     
    d Are you currently using Nicotine Replacement Therapy 
(NRT)? 
Yes   
 No   
     
 For the purposes of the research, we are collecting saliva samples from ex-smokers which will allow us 
to confirm their smoking status. If you have quit smoking, we’d like to send you a kit for you to 
provide a sample and post back to us. Full instructions will be included, the postage will be paid, and 
we will send you a Marks & Spencer voucher to compensate for your time. 
   
3) Would you be willing to receive this kit? 
 Yes, please send me a kit 
  
  
No, do not send me a kit 
  
  
No, I am still smoking 
  
     
Please go to Section F 
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SECTION F:  These questions are about your health and well 
being. Complete this section whether you smoke now or not. 
Please put a cross in the box that best describes your health today 
 
     
1) I have no problems walking about    
 I have some problems walking about    
 I am confined to bed    
     
2) I have no problems with self-care    
 I have some problems washing and dressing myself    
 I am unable to wash or dress myself    
     
3) I have no problems with performing my usual activities  
e.g. work, study, housework, leisure activities 
   
 I have some problems performing my usual activities    
 I am unable to perform my usual activities    
     
4) I have no pain or discomfort    
 I have moderate pain or discomfort    
 I have extreme pain or discomfort    
     
5) I am not anxious or depressed    
 I am moderately anxious or depressed    
 I am extremely anxious or depressed    
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Basic questions
Basic Questions  
Ask everyone who does not complete the telephone interview 
 
Q1.  Do you currently smoke cigarettes or rollups?  
Yes 
No 
 
Q2.  When did you last smoke a cigarette or roll-up? 
In the last 24 hours 
1 to 6 days ago 
7 to 13 days ago 
1 to 3 months ago 
4 to 6 months ago 
Longer than 6 months  
 
Q3.  Have you attended any appointments with the NHS Stop Smoking Service (this includes making 
an appointment with a Practice Nurse or Health Care Assistant at your surgery for stop smoking 
advice) in the last six months?  
Yes 
No 
 
 
Q4. If yes, how many have you attended? 
 
ID  
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Stop Smoking Service validation form
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Treatment Barriers Questionnaire
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Appendix 5 Intervention materials
Personal tailored risk intervention letter
Example 1 
 
PRACTICE LETTERHEAD 
 
 
 
 
 
 
 
Personal Health Risk Report and Taster Session 
Invitation 
 
 
Dear  
You recently filled in a questionnaire for the s t a r t 2 q u i t project.  This letter is based 
on your answers in the questionnaire and your medical records.  It is written for 
you personally and gives you advice about smoking.  We are also inviting you to a 
Taster Session to help you to become smokefree and improve your health. 
 
Your personal risk 
 
Based on your smoking habits and your personal health, your current risk of 
developing further serious illnesses and suffering an early death is very high 
compared to a non-smoker or ex-smoker of your age. 
 
Your records show that you also have diabetes and already have heart disease.  
Even by smoking 15 cigarettes a day you are seriously increasing your risk of high 
blood pressure and kidney disease.  By going smokefree now, you can prevent 
further decline. 
 
Take control and change your life 
 
Stopping smoking is the single most important thing that you can do to improve 
your health and quality of life.  The good news is that if you quit now, at 45, you 
have greater chance of preventing any further complications and can halve your 
additional risk of contracting other diseases.  By stopping smoking you will slow 
the progress of your existing conditions and live with better health for longer.  
We recommend that you consider quitting without delay.  It could well be the best 
thing that you will ever do for yourself. 
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Don‛t do it alone 
 
You might think it is hard to stop but you don‛t have to do it alone.  Help and 
support is available.  The NHS Stop Smoking Service offers free personal support 
to help you to quit.  Even though you previously have not quit for more than 24 
hours, joining a stop smoking group or getting one-to-one support will increase 
your chances of becoming smokefree.  You will also feel less alone and gain the 
support of other people who are quitting. 
 
A place is reserved for you 
 
So that you can find out more about the Stop Smoking Service, we are inviting you 
to a ‘Come and Try it‛ session at Kentish Town Health Centre on Monday 21st 
February 2011 at 2.15pm.  Please bring the Invitation Card enclosed with you.  If 
you cannot attend this session, please contact Leanne Gardner on *****.  We can 
offer you an alternative time or an immediate appointment with an advisor. 
With very best wishes 
 
 
Lead General Practitioner 
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Example 2 
 
 
PRACTICE LETTERHEAD 
 
 
 
 
 
 
Personal Health Risk Report and Taster Session 
Invitation 
 
 
Dear  
You recently filled in a questionnaire for the s t a r t 2 q u i t project.  This letter is based 
on your answers in the questionnaire and your medical records.  It is written for 
you personally and gives you advice about smoking.  We are also inviting you to a 
Taster Session to help you to become smokefree and improve your health. 
 
Your personal risk 
 
Based on your smoking habits and your personal health, your current risk of 
developing a serious illness and suffering an early death is very high compared to a 
non-smoker or ex-smoker of your age. 
 
You may think that you are not affected by smoking, but smokers are more likely 
to get all kinds of cancer, heart conditions and lung disease.  Even by smoking 12 
cigarettes per day you are seriously increasing your risk of developing one of 
these major diseases and dying sooner than you need to. Your records show that 
you are also pregnant and smoking during pregnancy also harms your baby, and can 
lead to complications and miscarriage. 
 
Take control and change your life 
 
The good news is that if you quit now, at 45, you can halve your additional risk of 
contracting these diseases, or of suffering any other conditions such as a stroke 
and osteoporosis.  You will also drastically reduce the increased risks to your 
unborn child.  By going smokefree now, even though you do not yet have any 
symptoms, you are more likely to live longer, and we recommend that you consider 
quitting without delay.  It could well be the best thing that you will ever do for 
yourself. 
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Don‛t do it alone 
 
You might think it is hard to stop but you don‛t have to do it alone.  Help and 
support is available.  The NHS Stop Smoking Service offers free personal support 
to help you to quit.  Even though you previously have not quit for more than 24 
hours, joining a stop smoking group or getting one-to-one support will increase 
your chances of becoming smokefree.  You will also feel less alone and gain the 
support of other people who are quitting. 
 
A place is reserved for you 
 
So that you can find out more about the Stop Smoking Service, we are inviting you 
to a ‘Come and Try it‛ session at Islington Town Hall on Tuesday 22nd February 
2011, at 6.15pm.  Please bring the Invitation Card enclosed with you.  If you cannot 
attend this session, please contact Leanne Gardner on *****.  We can offer you an 
alternative time or an immediate appointment with an advisor. 
With very best wishes 
 
 
Lead General Practitioner 
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Example 3 
 
 
 
PRACTICE LETTERHEAD 
 
 
 
 
 
 
Personal Health Risk Report and Taster Session 
Invitation 
 
Dear  
You recently filled in a questionnaire for the s t a r t 2 q u i t project.  This letter is based 
on your answers in the questionnaire and your medical records.  It is written for 
you personally and gives you advice about smoking.  We are also inviting you to a 
Taster Session to help you to become smokefree and improve your health. 
 
Your personal risk 
 
Based on your smoking habits and your personal health, your current risk of 
developing further serious illnesses and suffering an early death is extremely high 
compared to a non-smoker or ex-smoker of your age. 
 
Your records show that you already have heart disease and high blood pressure.  
By smoking 30 cigarettes a day you are damaging your heart even more, as well as 
seriously increasing your risk of heart attack or of developing any kind of cancer 
and lung disease.  By going smokefree now, you can prevent further decline. 
 
Take control and change your life 
 
Stopping smoking is the single most important thing that you can do to improve 
your health and quality of life.  The good news is that if you quit now, at 44, you 
have greater chance of preventing any further complications and can halve your 
additional risk of contracting other diseases.  If you give up smoking now you will 
slow the progress of your conditions.  We recommend that you consider quitting 
without delay.  It could well be the best thing that you will ever do for yourself. 
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Don‛t do it alone 
You might think it is hard to stop but you don‛t have to do it alone.  Help and 
support is available.  The NHS Stop Smoking Service offers free personal support 
to help you to quit.  You have previously quit for a few days, and joining a stop 
smoking group or getting one-to-one support will increase your chances of staying 
quit and becoming smokefree.  You will also feel less alone and gain the support of 
other people who are quitting. 
 
A place is reserved for you 
 
So that you can find out more about the Stop Smoking Service, we are inviting you 
to a ‘Come and Try it‛ session at Kentish Town Health centre, on Monday 21st 
February 2011 at 2.15pm.  Please bring the Invitation Card enclosed with you.  If 
you cannot attend this session, please contact Leanne Gardner on *****.  We can 
offer you an alternative time or an immediate appointment with an advisor. 
 
With very best wishes 
 
 
 
Lead General Practitioner 
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Taster session invitation
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Generic control letter
Practice headed paper 
 
 
 
 
 
Dear 
 
You are being sent this letter as part of your participation in the Start 2quit project. 
 
I recommend that you consider stopping smoking, and invite you to contact the Stop Smoking 
Services to arrange to see an advisor.   
 
The service is available free to offer information, advice and support to all smokers interested in 
giving up, and also offers advice on the use of medications such as Nicotine Replacement 
Therapy and Champix.   
 
You can arrange to join a group, or get individual advice in a one-to-one session, to help you 
stop smoking and stay stopped.  For more information or to speak to a specialist advisor please 
call the <name of Local> Stop Smoking Service on <Local SSS telephone number>. 
 
 
Yours sincerely 
 
 
 
GP signature 
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Appendix 6 Taster session training manual
and protocol
Advisor Training for  
Taster Sessions 
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Start quit is a randomised controlled trial aiming to increase the number of people 
attending the specialist NHS Stop Smoking Services.   
 
Funding 
This research is funded by the Health Technology Assessment programme (HTA) which 
is part of the National Institute for Health Research (NIHR). This body provides funding 
to independent research investigating the effectiveness of different healthcare 
treatments in the NHS. It identifies the most important questions that the NHS needs to 
answer and commissions the most important research. 
 
Background 
As smoking cessation advisors, you will be aware that NHS Stop Smoking Services 
(SSS) are effective in helping people to quit smoking but are significantly under used. 
Previous research in this area has identified a number of key reasons why smokers 
may not be inclined to utilise NHS SSS. These include: a perception that help is not 
necessary or available, a desire to quit independently and a sense of a lack of empathy 
from health professionals. Other studies have also suggested that many smokers are 
not aware of, or have insufficient knowledge of the NHS SSS which are available to 
them.  
 
Current guidance suggests that health professionals should provide brief advice to 
smokers and refer them to the NHS SSS. However, in reality, the percentage of 
smokers receiving such advice is low and those who do receive advice are often left to 
follow up their referral and contact the NHS SSS to make their own appointment.  
 
Research has emerged to address the problems in smokers’ knowledge of smoking 
cessation services and in the perceived accessibility of these services. Lichtenstein and 
colleagues (1992) proactively recruited and referred smokers by providing all smokers 
with detailed information on the structure of a smoking cessation session. Of the 
participants who received this information, 11.3% attended a first session of a  
 
Introduction  
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smoking cessation programme compared to only 0.006% of participants in the control 
group who received brief advice only. Similar findings have been reported by other 
researchers. This suggests that if smokers are proactively and personally invited to use 
the services, the resultant use will be higher than standard referral by health 
professionals or by open advertising. 
 
Individually computer-tailored self-help materials intended to meet the needs of one 
specific person, have also emerged as an important avenue for research in behaviour 
change. These materials involve an assessment of an individual’s health related 
behaviour and the use of a computer program to select the correct communication 
content for each individual based on their assessment. This information can be 
formatted into a letter and advice encouraging the individual to improve or maintain their 
health related behaviour is also included. A key strength of these methods in smoking 
cessation is that they have the potential to engage with a large proportion of the 
smoking population on a personal level, in a relatively inexpensive way. Evidence 
suggests that computer tailored interventions can improve health-related behaviours. 
 
The current study combines research on computer-tailored feedback and proactive 
recruitment with the provision of detailed information on NHS SSS. Further detail is 
provided in the next section. 
 
Start quit 
As part of this study current smokers will be identified from GP records and sent a 
smoking questionnaire. Those who return this questionnaire and give full consent will be 
randomly assigned to the control or intervention group. Those in the intervention group 
will be sent computer generated letters containing personal tailored risk information 
based on both their answers to the questionnaire and on information in their medical 
records. An invitation to a ‘Come and Try it’ taster session will be also be enclosed.  
The aim of these taster sessions will be to introduce smokers to the NHS SSS and to 
encourage those who attend to sign up for a 6 week group or one-to-one NHS SSS 
course.  
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Those in the control group will be sent a generic letter advertising the NHS SSS, asking 
the smoker to contact the service to make an appointment to see an advisor. 
 
Smokers who are willing to participate in the study but are ineligible will be sent an 
ineligible letter. 
 
The primary objective of this study will be to assess whether those receiving a letter 
containing personal tailored risk information and an invitation to a taster session are 
more likely to attend NHS SSS than participants who only receive a generic letter 
advertising NHS SSS. Secondary objectives of this study include an assessment of the 
effectiveness of the intervention in increasing cigarette abstinence, determining the 
predictors of attendance at both the taster sessions and the NHS SSS and exploring the 
effectiveness of the intervention by socio-economic status and social deprivation. 
 
Start quit will involve the recruitment of participants from 12 GP practices across 2 
NHS SSS areas (Camden and Oxfordshire) in the pilot phase, and a further 48 
practices in 8 different NHS SSS areas, representative of the NHS SSS, across 
England, in the main trial. With an estimated response rate of 7% based on previous 
research, we aim to recruit 2520 participants in total across the intervention and control 
groups. This figure will be broken down to 504 participants in the pilot phase and 2016 
in the main trial. 
 
Practical implications 
If the results of this trial find that participants in the intervention group were more likely 
to attend NHS SSS it is possible that these methods could be introduced as standard 
practice in GP surgeries across the country. As computer generated letters containing 
personal tailored risk information are relatively inexpensive, this is a potentially cost 
effective method of increasing uptake of the NHS SSS. Even a modest success rate in 
this aim could make a valuable contribution to public health by lowering smoking 
prevalence. 
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Regulatory approvals and trial conduct 
Start quit has received ethical approval from the South West London REC 4 
(reference number 10/H0806/20). This trial also adheres to the principles of Good 
Clinical Practice and in accordance with these principles, the rights, safety and well-
being of trial participants are protected and the results of the trial will be credible and 
accurate. Confidentiality will be maintained at all times and participants will have the 
option of withdrawing from the study at any time. 
 
Randomised controlled trials  
The randomised controlled trial (RCT) is considered the most reliable method to 
determine whether or not an intervention is effective. The strength of this type of study 
lies in the equal chance of participants being randomly allocated to either the 
intervention group which receives the intervention being investigated, or the control 
group which does not receive the intervention. This methodology eliminates the chance 
of participants being assigned to a particular group based on any specific factor which 
could influence the outcome of the study. These participants are then followed up at a 
later date to assess whether there are any differences in outcome between the two 
groups.  
 
A crucial element of the RCT is that those within each group are exposed to the same 
intervention. Only when this is the case can accurate comparisons be made between 
the control and intervention groups. As such, in this study, it is essential that the taster 
sessions are standardised and that all participants in the intervention group who attend 
different sessions have as similar an experience to each other as possible. In this way 
the researchers can ascertain whether or not these taster sessions are truly effective in 
increasing the uptake of NHS SSS, increasing quit attempts and reducing cigarette 
consumption. In addition, standardisation of taster sessions is important to ensure that 
any difference between those who attend the taster sessions can be attributable to each 
individual rather than differences in the presentation of the taster session that they 
attended.  
Research Methodology  
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Role of advisor and RCT standards 
 
Taster session presentation  
In this study there will be a number of different advisors facilitating taster sessions 
across England. Due to the nature of these taster sessions it is possible that there will 
be some degree of variation across sessions due to participant contribution, the style of 
the advisor etc. However, it is essential that advisors adhere to the taster session 
protocol. The same information should be communicated in the same manner at each 
taster session. This principle of standardisation ensures that all intervention group 
participants respond to the same research stimulus. This will make any assessment of 
the effectiveness of these sessions much more reliable.  
 
As part of our efforts to ensure standardisation, we aim to audio record each of the 
taster sessions. This will be used only in the analysis of the results of the study and is 
not intended to be a method of evaluating advisors.  Thus before the start of each taster 
session attendees will be asked to sign an audio recording consent form (Appendix 1). 
 
Recording attendance 
In addition, it is crucial that the advisor ensures every attendee signs the attendance 
sheet (Appendix 2) at the beginning of each taster session. Advisors will also be asked 
to gather details from any person who attends the session whose details are not on the 
attendance form. This is particularly important if an individual is attending with a 
friend/family member who has been invited to the taster session. Accurate gathering of 
this information is essential in allowing the researchers to keep track of the group 
(control or intervention) to which each attendee is allocated, at each taster session. For 
example, in the unlikely event of a member of the intervention group attending a taster 
session with a friend/neighbour/family member who is in the control group it is essential 
for the researchers to have a record of this. Without this level of accuracy and attention 
to detail, the results of the study could be compromised. 
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Encouraging sign up to NHS SSS 
 
Finally, it is important that the advisor encourages as many taster session attendees as 
possible to sign up for a full NHS SSS course. In the event that an attendee does not 
want to sign up, it is important that they be given the contact details of the NHS SSS in 
their area in case they change their mind in the future. 
 
At the end of each taster session the attendees are asked to fill out an evaluation form. 
These forms should be retained by the advisors as a record of attendee contact details 
in the event of it not being possible to organise an NHS SSS appointment immediately. 
All of these forms should be returned to the research team when the advisor has 
finished with them. 
 
For statistical purposes we also require each advisor running taster sessions to 
complete a Stop Smoking Advisor Details form. 
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The purpose of these taster sessions is to inform attendees about the NHS Stop 
Smoking Services and to encourage them to sign up for an NHS stop smoking 
course. It is not intended to replicate the first session of an NHS Stop Smoking 
course.  
 
During this session you will: 
 Inform the attendees about the NHS Stop Smoking Services in general. 
 Discuss ways to remain smokefree including behavioural strategies and smoking 
cessation medication. 
 Explain and conduct carbon monoxide (CO) monitoring. 
 Provide practical information about the NHS Stop Smoking Services in your area. 
 Show the Start quit DVD. 
 Distribute evaluation and consent forms, and collect when completed.  
 
This session should aim to enhance motivation and boost self confidence of 
participants. 
 
Advisors delivering this session should: 
 Emphasise the benefits of the NHS Stop Smoking Services 
 Build a rapport with participants 
 Elicit client views 
 Provide reassurance 
 
 
 
 
 
 
 
 
Taster Sessions: Protocol  
Information outlined in boxes:  Point of interaction 
Italics:       Information to be conveyed directly to attendees 
Regular text:      Instructions for advisor 
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1. Introduction  
Upon arrival attendees should be welcomed and asked to sign the attendance sheet 
(Appendix 2). A note should be made of anyone in attendance who is not recorded 
on the attendance sheet (include name, age and address). 
 
Ask attendees to sign the audio recording consent form (Appendix 1). Emphasise the 
fact that the session will be audio recorded only to ensure that all taster sessions are 
delivered in as similar a manner as possible by each Stop Smoking advisor. All audio 
recordings will be anonymous, stored securely on a UCL computer for 5 years and 
only accessed by the Start quit research team. The tapes will be analysed to ensure 
that the taster sessions are standardised. 
 
If any of the attendees decline to consent, do not record the session. 
 
Ask attendees to switch their phones off. 
 
Congratulate attendees on coming to the session (for two reasons): 
a) “Quitting smoking is the most important thing you can do for your health, in both 
the short and long term.” 
 Short term benefits: Breathing improves, more energy 
 Long term benefits: Reduction in risk of developing lung disease, 
emphysema, cancer. 
 General:  
 No longer put others at risk from second hand smoke  
 Reduction in health anxiety which many people experience when 
smoking  
 More money to spend on other things  
 Clothes and home won’t smell of cigarettes.  
 
 b) “The fact that you have come here this evening suggests that you are motivated 
to stop smoking, and this is a very important step in the process of quitting.”  
Advisor introduces him/herself and describes his/her background/expertise.  
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2. The Services 
General: 
 
“The NHS Stop Smoking Services are based on well researched evidence and 
attending an NHS SS course has been proven to be the best way to help people to 
quit smoking.” 
 
“People who take advantage of these free services and sign up to a course are four 
times more likely to stop and stay stopped than if those who try to quit on their own.” 
 
Explain that the NHS SSS support smokers to stop smoking completely and not to cut 
down. 
 Evidence also indicates complete abstinence is more likely to result in 
remaining quit in the long-term. 
 
 
Structure: 
 
“Courses last for (insert number of sessions). These courses may be run by a 
Specialist Stop Smoking Advisor or by a fully trained Practice Nurse.” 
 
“The first session is spent helping you to prepare for stopping smoking which is very 
important. We will discuss with you the reasons why you want to stop smoking and 
also the reasons why you don’t want to quit smoking” 
 
 
 
 
 
 
 
 
“How many of you enjoy smoking?” 
Encourage attendees to share their opinions. 
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 “A lot of people like smoking so to quit they have to give up something that they 
enjoy. This is difficult however in the first session you will be helped to weigh up the 
pros and cons of stopping smoking which is the best way to make a strong decision 
to quit.”  
 
 “One thing we won’t do is tell you to stop smoking. The important thing is that we 
help you to decide that giving up smoking is something that you want to do.” 
 
“We will also encourage you to set a quit date during your first few sessions. This is a 
really good idea as it gives you something to aim for, something to prepare for.”  
 
“There will be a minimum of weekly sessions for at least 4 weeks following the Quit 
Date.”  
 
“The remaining sessions are used to support you as you get used to your new life as 
a healthy non-smoker.”  
 
Emphasise that weekly contact is extremely important.  
 
Explain that stopping smoking with the NHS SSS involves a rule of not smoking a 
single puff after their Quit Date because cutting down gradually is not an effective 
approach to quitting smoking.  
 
“However it is important to mention that we understand if you slip up and have a 
cigarette after you’ve quit. Don’t think that you can’t come back to the services. You 
can come back and we will help you work out why you had the cigarette and work out 
strategies for avoiding further slips in the future.”  
 
Identify reasons for wanting and not wanting to stop smoking.  
 
 
 
 
“Would any of you like to give a summary of why you are 
considering giving up smoking?” 
Encourage attendees to take part in this discussion. 
DOI: 10.3310/hta21030 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 3
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Gilbert et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
197
3. Ways to remain smokefree: 
 
Strategies: 
 
“A key aspect of an NHS Stop Smoking course is helping you to develop strategies 
to avoid smoking.” 
 
“Smoking is a very habitual addiction and throughout the day there are many trigger 
points that remind people that they want to smoke. These trigger points are different 
for every smoker, they can range from having a cup of coffee, waiting at a bus stop 
to getting up in the morning.”  
 
“It is very important that you develop strategies to break the association between 
these trigger points and smoking and we can help you achieve this.” 
 
Stop Smoking Medication: 
 
“Another important part of quitting smoking is the use of medication.” 
 
“When you have a cigarette you are taking in nicotine which makes you feel good. If 
you are deprived of this nicotine you may experience withdrawal symptoms.” 
 
 
 
 
If no withdrawal symptoms are suggested by the group, the advisor should mention 
some common symptoms. 
 
 “These symptoms can include anxiety, feeling stressed or angry, lower 
concentration and increased appetite or weight gain.  However it is important to 
know that not everyone will experience these withdrawal symptoms.” 
 
“Can anyone tell me some common withdrawal symptoms?” 
Encourage attendees to take part. 
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 “The good news is that there is medication available which can reduce cravings 
while a person gets used to not smoking.” 
 
 “Nicotine replacement therapy is one such type of medication. NRT is available in 
various forms and it works by replacing the nicotine you get in cigarettes with 
nicotine in a clean controlled form. It is important to remember that nicotine is not the 
harmful part of cigarettes, it’s just the part that causes the addiction.” 
 
“There are various types of NRT available including; lozenges, patches, gum and 
inhalators. There is one to suit everyone which is important because if you find the 
one that suits you, you will be more inclined to use it regularly. You can find out 
more about NRT at an NHS Stop Smoking Service course.” 
 
 “Advisors can help you decide which form of NRT would be most appropriate for 
you.” 
 
“Other medications are also available including Zyban which has been on the market 
for about ten years, and Champix which is a newer medication. These treatments 
can help reduce the desire to smoke. You can also get more information and advice 
on using these medications by attending an NHS Stop Smoking Service course.” 
 
Ensure that client has a realistic expectation of what medication use can add to a quit 
attempt.  
 
Behavioural support: 
  
“An important function of the NHS SSS is to give support to help you to change your 
behaviour.”  
 
Emphasise that medication is not a miracle cure, and that smokers will also need to 
change their behaviour. Stop Smoking advisors will provide support during this process 
of change. That is the reason why weekly contact is extremely important for the full 
duration of the course, including the final visit.  
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4. Practical information 
 
Give information regarding the NHS Stop Smoking Sessions in your area. 
 
 “Each group session lasts approximately (insert length of sessions) and can 
have up to  (insert approximate maximum number of attendees) attendees” 
 
 “Each one-to-one session lasts approximately (insert length of session)” 
 
 “Both types of courses last for (insert number of sessions)” 
 
 “In this area, sessions are offered in (insert locations of sessions)” 
 
 “We can discuss the times and dates of these sessions in further detail with you 
at the end of this talk and we will also give you the opportunity to sign up for a 
course.” 
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5. Carbon monoxide monitoring  
 
Explain that carbon monoxide (CO) is a poisonous gas contained in cigarette smoke 
and that there is a simple test that can be carried out to determine CO levels in the 
body. 
 
“One thing that we often do during the NHS Stop Smoking Service courses, and that 
we can show you now, is measuring the level of CO in people’s expired air.”  
 
“CO is a toxic gas you inhale when you smoke. It is particularly dangerous because it 
takes the place of oxygen in your red blood cells so as a smoker you don’t get the 
oxygen supply that you need. Your blood then tries to compensate for the presence of 
CO by producing more red blood cells so your blood literally becomes thicker and this 
can impair your circulation. A lot of smokers have cold finger tips because blood can’t 
get to their peripheries.”  
 
“The good news is that as soon as you stop smoking the CO levels in your blood drop 
right down so immediately your circulation improves, and your chance of experiencing 
any health problems relating to this (such as a heart attack and stroke) are reduced.” 
 
“Measuring CO is also a great way of showing the immediate benefits of quitting 
smoking and proving that you really are doing something very positive for your health.” 
 
 
 
 
 
 
 
 
 
 
 Encourage attendees to have their CO levels measured. 
 
 “We will now measure your CO levels. Who would like to go first?”  
 
 “You will be able to compare your measurement today to a measurement 
you can have at an NHS Stop Smoking Service course after you’ve quit.” 
 
 In the case that CO measurement is low: “I realise that you haven’t smoked a 
cigarette for a day or two but if I measured your CO after smoking you would 
have a high reading”.  
DOI: 10.3310/hta21030 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 3
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Gilbert et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
201
6. DVD 
 
At this point the DVD should be shown to attendees. This DVD includes stop smoking 
sessions in progress and testimonials from previous successful attendees at an NHS 
SSS session. 
 
7. Questions 
 
Answers to attendees’ questions should be kept as succinct as possible. They should 
be reminded that further information will be available during the NHS SSS courses. 
 
8. Summary 
 
   Provide a brief recap of the main points of the taster session: 
 
“There are huge benefits to stopping smoking in both the long and short term’’. 
 
“Attending a free NHS Stop Smoking Services course makes it four times more likely 
that you will successfully stop smoking.” 
 
“These courses will help you develop strategies to avoid smoking and will also provide 
you with information regarding the medication available to make quitting smoking 
easier.” 
 
Thank attendees for attending.  
 
Remind attendees to complete the evaluation form and hand it to an advisor. 
Emphasise that immediate sign up for an NHS Stop Smoking Service course is possible 
when they give their evaluation form to an advisor.  
 
The evaluation forms should be retained by the advisor for organising NHS SSS sign up 
and following this, should be returned to the research team. 
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Participants will be contacted by telephone six months after randomisation (by an 
independent telephone interviewer) to complete a follow up questionnaire. As part of 
this questionnaire, participants will be asked about their attendance at the SSS and 
their current smoking status. Both of these aspects of the questionnaire will need to be 
externally validated with the assistance of the SSS. 
 
Postal kits to collect saliva samples to test for cotinine will be sent to all participants 
claiming abstinence at this follow up interview. Participants will be compensated for 
providing this sample with a £5 voucher. 
 
Stop Smoking Service attendance 
 
It is necessary to determine attendance of both control and intervention groups at the 
SSS in the six months following the date of randomisation. At the six month follow up 
the research team will supply the SSS with a list of all participants and their study ID 
numbers. The service records should then be searched for these names and relevant 
information recorded on each participant who has attended the SSS using the case 
report form. Once completed, these forms should be returned to the research team.  
 
 
 
 
 
 
 
 
 
 
Six month follow up 
DOI: 10.3310/hta21030 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 3
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Gilbert et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
203
 Consent form for attendees at Start2quit Stop Smoking taster sessions 
 
You have already agreed to participate in the Start2quit trial. We are now asking for 
your permission to allow us to audio record this Stop Smoking Taster session as part of 
this research study.  
Throughout the Start2quit study there will be a large number of Stop Smoking Taster 
sessions held across England. By audio recording these sessions we will make sure 
that they are delivered as similarly as possible by each Stop Smoking advisor. This will 
help make these sessions effective in encouraging more people to quit smoking. The 
audio recording of this Stop Smoking Taster session will be used only for this purpose. 
All recordings will be anonymous, stored securely on a UCL computer for 5 years and 
only accessed by the Start2quit research team. The recordings will be analysed to 
ensure that the taster sessions are standardised. 
I confirm that the proposed purpose of the tape recording has been explained to me and 
that I fully understand the proposed use of this material.  As such, I agree to this Stop 
Smoking Taster session being audio recorded for the purposes explained to me and 
detailed above. 
Name (please print) _________________________________________ 
Signature  _________________________________________ 
Date   _________________________________________ 
Address   _________________________________________  
   _________________________________________ 
    _________________________________________ 
 
Appendix 1: Audio recording consent form 
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Attendance sheet 
 
                       
 
Advisor name:__________ 
                                                                         
PCT:__________________ 
                                                                         
Place:_________________ 
                                                                         
Date:__________________ 
                                                                         
Time:_________________ 
 
 
 Taster Session      
                        
Name Signature 
  
  
  
  
  
  
 
 
 
 
 
 
Appendix 2: Attendance Sheet 
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